A Randomised Controlled Trial and Economic Evaluation of Intra-Operative Cell Salvage during Caesarean Section in Women at Risk of Haemorrhage: The SALVO Trial (cell SALVage in Obstetrics) by Roberts, Tracy et al.
 
 
University of Birmingham
A Randomised Controlled Trial and Economic
Evaluation of Intra-Operative Cell Salvage during
Caesarean Section in Women at Risk of
Haemorrhage: The SALVO Trial (cell SALVage in
Obstetrics)
Roberts, Tracy; McLoughlin, Carol; Daniels, Jane; Gao Smith, Fang; Jackson, Louise
License:
None: All rights reserved
Document Version
Peer reviewed version
Citation for published version (Harvard):
Roberts, T, McLoughlin, C, Daniels, J, Gao Smith, F & Jackson, L 2016, 'A Randomised Controlled Trial and
Economic Evaluation of Intra-Operative Cell Salvage during Caesarean Section in Women at Risk of
Haemorrhage: The SALVO Trial (cell SALVage in Obstetrics)', Health Technology Assessment.
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
Eligibility for repository: Checked on 13/4/2017
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Mar. 2020
A Randomised Controlled Trial and 1 
Economic Evaluation of Intra-Operative 2 
Cell Salvage during Caesarean Section 3 
in Women at Risk of Haemorrhage: The 4 
SALVO Trial (cell SALVage in Obstetrics) 5 
Khalid S. Khan,1* Philip Moore,2 Matthew Wilson,3 Richard Hooper,4 Shubha Allard,5 Ian 6 
Wrench,6 Tracy Roberts,7 Carol McLoughlin,7 Lee Beresford,4 James Geoghegan,2 Jane 7 
Daniels,8 Sue Catling,9 Vicki A. Clark,10 Paul Ayuk,11 Stephen Robson,12 Fang Gao-Smith,13 8 
Matthew Hogg, 14 Louise Jackson,7 Doris Lanz,1 Julie Dodds, 1 on behalf of the SALVO study 9 
group 10 
1 Women’s Health Research Unit, Barts and the London School of Medicine and Dentistry, 11 
Queen Mary University of London, UK 12 
2 Birmingham Women’s Hospital, Birmingham, UK 13 
3 School of Health and Related Research (ScHARR), University of Sheffield, UK 14 
4 Pragmatic Clinical Trials Unit, Centre for Primary Care and Public Health, Queen Mary 15 
University of London, UK  16 
5 NHS Blood and Transplant, London, UK 17 
6 Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK 18 
7 Health Economics Unit, University of Birmingham, UK 19 
8 Birmingham Clinical Trials Unit, University of Birmingham, UK 20 
9 Singleton Hospital, Swansea, UK 21 
10 Simpson Centre for Reproductive Health, Royal Infirmary, Edinburgh, UK 22 
11 Royal Victoria Infirmary, Newcastle-upon-Tyne, UK 23 
12 Institute of Cellular Medicine, University of Newcastle, UK 24 
13 Perioperative, Critical Care and Trauma Trials Group, University of Birmingham, UK 25 
14 Royal London Hospital, Barts Health NHS Trust, London, UK 26 
 
 
* Corresponding author. Professor Khalid S. Khan, Women’s Health Research Unit, Centre 27 
for Primary Care and Public Health, Barts and the London School of Medicine and Dentistry, 28 
Queen Mary University of London, Yvonne Carter Building, 58 Turner Street, London, 29 
E1 2AB, United Kingdom; k.s.khan@qmul.ac.uk  30 
Competing interests: None declared. 31 
Keywords: Cell Salvage, Caesarean Section, Obstetrics. 32 
Page 1 of 132 
Abstract 1 
Background:  Caesarean section is associated with blood loss and maternal morbidity. 2 
Excessive blood loss requires transfusion of donor (allogeneic) blood, a finite resource. Cell 3 
salvage returns blood lost during surgery to the mother. It may avoid the need for donor 4 
blood transfusion, but reliable evidence of its effects is lacking. 5 
Objectives: To determine if routine use of cell salvage during caesarean section, in mothers 6 
at risk of haemorrhage, reduces the rates of blood transfusion and postpartum maternal 7 
morbidity, and is cost-effective, in comparison to standard practice without routine salvage 8 
use. 9 
Design: Individually randomised controlled, multicentre trial with cost-effectiveness analysis. 10 
Treatment was not blinded. 11 
Setting: 26 UK obstetric units. 12 
Participants: Of 3054 women recruited between June 2013 and April 2016, we randomly 13 
assigned 3028 women at risk of haemorrhage to cell salvage or routine care. Randomisation 14 
was stratified, using random permuted blocks of variable sizes. Of these, 1672 had 15 
emergency and 1356 elective caesareans. We excluded women for whom cell salvage or 16 
donor blood transfusion was contraindicated. 17 
Interventions: Cell salvage (intervention) versus routine care without salvage (control). In 18 
the intervention group, salvage was set up in 95.6% of the women and, of these, 50.8% had 19 
salvaged blood returned. In the control group, 3.9% had salvage deployed. 20 
Main outcome measures: Primary: donor blood transfusion. Secondary: units of donor blood 21 
transfused; time to mobilisation; length of hospitalisation; mean fall in haemoglobin; 22 
fetomaternal haemorrhage measured by Kleihauer test; maternal fatigue. Analyses were 23 
adjusted for stratification factors and other factors believed to be prognostic a priori. Cost-24 
effectiveness outcomes: costs of resources and service provision taking the UK National 25 
Health Service perspective.  26 
Results: We analysed 1498 and 1492 participants in the intervention and control groups, 27 
respectively. Overall, the transfusion rate was 2.5% in the intervention group versus 3.5% in 28 
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control (adjusted odds ratio [OR] 0.65, 95% confidence interval [CI] 0.42 to 1.01, p=0.056). 1 
In a planned subgroup analysis, the transfusion rate was 3.0% in intervention versus 4.6% in 2 
control among emergency caesareans (adjusted OR 0.58, 95% CI 0.34 to 0.99), whereas it 3 
was 1.8% versus 2.2% among elective caesareans (adjusted OR 0.83, 95% CI 0.38 to 1.83) 4 
(interaction p=0.46, suggesting that the difference in effect between subgroups was not 5 
statistically significant). Secondary outcomes did not differ between groups, except 6 
fetomaternal haemorrhage was higher under salvage in Rhesus D-negative women with D-7 
positive babies (25.6% vs. 10.5% adjusted OR 5.63, 95% CI 1.43 to 22.14, p=0.013). No case 8 
of amniotic fluid embolism was observed. The additional cost of routine cell salvage during 9 
caesarean was estimated, on average, at £8,110 per donor blood transfusion avoided. 10 
Limitations: We are unable to comment on long-term antibody sensitisation effects. 11 
Conclusions: The modest evidence for an effect of routine use of cell salvage during 12 
caesarean section on rates of donor blood transfusion was associated with increased 13 
fetomaternal haemorrhage, which emphasises the need for adherence to guidance on anti-D 14 
prophylaxis. Based on the findings of this trial, cell salvage is unlikely to be considered cost-15 
effective.  16 
Future work: Research into risk of alloimmunisation among women exposed to cell salvage 17 
is needed.  18 
Study Registration: ISRCTN66118656. 19 
Funding Details: This project was funded by the NIHR Health Technology Assessment 20 
programme, project reference number 10/57/32. 21 
[526 words]  22 
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Plain English summary 1 
 
Mothers delivering by caesarean section bleed heavily at times. In this situation, unless they 2 
get a donor blood transfusion their life is put at risk. Donor blood for transfusion is a limited 3 
resource, and despite many advances, people who receive donor blood can sometimes 4 
experience adverse reactions. Blood transfusions should only be given when absolutely 5 
necessary, and alternatives should be used wherever available.  6 
Nowadays, it is possible to use cell salvage. This is a process where blood a patient loses at 7 
surgery is collected by a machine, cleaned, and returned to them. In women who have 8 
caesarean sections, this might avoid the need for donor blood, reduce the risk of 9 
complications and potentially cut costs. We conducted this study to evaluate the effects of 10 
routine use of cell salvage in caesarean section, compared to standard care where this is not 11 
routinely done.  12 
This study included over 3,000 mothers giving birth by caesarean section. Half of these were 13 
randomly selected to receive cell salvage, meaning that the cell salvage was set up to collect 14 
blood lost. Cell salvage was found to be safe. It slightly reduced the use of blood 15 
transfusions. For every 100 mothers given cell salvage, one avoided donor blood transfusion. 16 
If the blood groups of the mother and the baby were mismatched, mothers with a negative 17 
blood group needed additional treatment to avoid complications in future pregnancies. This 18 
can be easily monitored and provided as part of routine care. Based on the results of this 19 
study, cell salvage is unlikely to be considered cost-effective.  20 
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Scientific summary 1 
Background 2 
Excessive blood loss (haemorrhage) in childbirth is an important direct cause of maternal 3 
death and has a profound impact on survivors. It is responsible for the majority of emergency 4 
hysterectomies and maternal critical care admissions. Haemorrhage is more common in 5 
women undergoing a caesarean section, particularly in the presence of placental 6 
abnormalities (placenta praevia/accreta), pre-eclampsia, antepartum haemorrhage, a history 7 
of previous caesarean section(s), or emergency caesarean for any indication. Approximately 8 
166,000 caesarean sections (26% of all deliveries) are performed annually in England, around 9 
60% of which are emergency procedures. It is the most frequent major surgery conducted by 10 
the UK National Health Service. Major haemorrhage can occur without warning during 11 
caesarean section with rapid unanticipated deterioration requiring urgent response.  12 
The treatment for major haemorrhage involves donor blood transfusion when the operative 13 
loss is life threatening or when the mother has severe anaemia following arrest of the 14 
haemorrhage. Red cell concentrate is a limited resource in demand by many clinical services. 15 
The high frequency of caesarean sections has a major impact on blood transfusion services 16 
(with £7M direct cost for donor blood components alone used in the obstetric setting per 17 
year), placing a constant challenge to the delivery of high quality health care at all points of 18 
need simultaneously. There has also been a major shift to more restrictive clinical transfusion 19 
practice aligned to the principles of patient blood management, which include using 20 
transfusion alternatives where feasible and harnessing the patient’s own reserves. 21 
Accordingly, donor blood is used sparingly in the healthy obstetric population. This can 22 
result in anaemia postnatally, which is potentially associated with longer recovery, increasing 23 
hospitalisation costs and wound infection rates. 24 
Intraoperative cell salvage collects the woman’s own blood lost during caesarean, processes it 25 
and returns it to her circulation. It reduces the infectious and allergenic risks associated with 26 
donor blood transfusion. It can be used routinely for moderate blood loss, which is an 27 
expected feature of uncomplicated caesarean sections, returning all salvaged blood to 28 
minimise postoperative anaemia and its consequences, including reduction in maternal life 29 
quality. Cell salvage has been shown to reduce the amount of donor blood given in other 30 
operations from a wide spectrum of surgical disciplines, but has hitherto been considered 31 
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relatively contraindicated for use in obstetrics, as a result of theoretical concerns around the 1 
risk of contamination of salvaged blood with amniotic fluid, the potential for provoking 2 
maternal amniotic fluid embolism and the possibility of increasing exposure of the mother to 3 
fetal blood. These concerns have proven unfounded, as research has not only shown that 4 
modern equipment effectively removes amniotic fluid from the salvaged blood, but also that 5 
transfer of amniotic fluid into the maternal circulation is a common event during birth which 6 
usually does not cause any adverse effects. Cell salvage has begun to enter use in caesarean 7 
section, but opinion about its value is not yet evidence-based. 8 
Objectives 9 
The primary objective of the trial was to determine whether the routine use of cell salvage 10 
during caesarean section in women at risk of haemorrhage safely reduced the need for donor 11 
blood transfusion, in comparison to standard practice where salvage is not routinely used. In 12 
addition, we sought to assess the consistency of the effect of cell salvage across subgroups 13 
defined by indication for caesarean, and to determine the effect of cell salvage on secondary 14 
outcomes including the units of donor blood transfused, fall in perioperative haemoglobin 15 
concentration, any resulting morbidity, maternal exposure to fetal blood, as well as its cost-16 
effectiveness.  17 
Methods 18 
The SALVO study was designed as a multicentre individually randomised controlled trial 19 
(registered as ISRCTN66118656) with cost-effectiveness analysis. Following the necessary 20 
approvals (UK ethical approval number 12/NW/0513), the study was conducted in 26 21 
obstetric units across the UK, aiming to recruit 3,050 women to give 80% power to detect a 22 
2% difference in the transfusion rate (control event rate of 5%). Our sample consisted of 23 
women who were admitted to the labour ward for delivery by emergency (Category 1 to 3: 24 
with an element of maternal or fetal compromise) or elective (Category 4: no maternal or 25 
fetal compromise) caesarean section, with an identifiable increased risk of haemorrhage, who 26 
were at least 16 years of age and able to understand written and spoken English. We excluded 27 
women undergoing an elective first caesarean due to either maternal request or known breech 28 
presentation, as the risk of severe haemorrhage is very low in these groups. We also excluded 29 
women for whom either cell salvage or donor blood transfusion was contraindicated, 30 
including sickle cell disease or trait, active malignancy such as abdominal cancer, religious or 31 
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other beliefs precluding blood transfusion, or significant maternal antibodies making it 1 
difficult to find cross-matched blood compatible for transfusion.  2 
For all women undergoing elective caesarean section, information about the study was 3 
provided at least one day before the surgery, usually at the time of booking the caesarean 4 
section; written informed consent for the study was then obtained before the surgery. For 5 
women undergoing emergency caesarean section, either written informed consent was 6 
obtained before the surgery if there was sufficient time for discussion and reflection, or 7 
otherwise verbal consent was taken immediately before the surgery with written consent 8 
obtained after the operation usually on the postnatal ward. In either case, in order for consent 9 
to be properly informed, the woman either had to have a) received information antenatally 10 
before the onset of labour, and previously stated her willingness to take part in the study, or 11 
b) following a substantial amendment to the protocol, had sufficient time, and was not too 12 
distressed to receive study information after admission to the labour ward; this was deemed to 13 
be the case if the woman was comfortable with effective epidural analgesia in situ, or not yet 14 
in established first stage of labour, and had at least one hour to come to a decision after 15 
receiving the information and prior to giving verbal consent. Participating women were 16 
randomised by entry into an online system, to either caesarean section with cell salvage 17 
(intervention group), with cell saver set-up and collection of shed blood from the outset of 18 
surgery, and return of any processed blood obtained; or to caesarean section without cell 19 
salvage (control group), with transfusion of donor blood according to local guidelines.  20 
The primary outcome was the proportion of women receiving donor blood transfusion due to 21 
haemorrhage. Trial groups were compared according to this outcome on an intention-to-treat-22 
basis estimating the effect using odds ratio (OR) and 95% confidence intervals (CI). Two pre-23 
specified subgroup analyses were planned, including analysis of treatment effect by 24 
indication for caesarean section (elective or emergency) and by treatment centre. The first of 25 
these was analysed by statistically testing for an interaction between indication for caesarean 26 
section and treatment. The second was analysed by testing for a random regression 27 
coefficient for the effect of treatment at different centres, in addition to a random intercept.  28 
In order to account for women in the control group who received cell salvage due to a clinical 29 
decision, an additional sensitivity analysis was planned which would assume that all 30 
instances of return of salvaged blood in the control group would have been instances of donor 31 
blood transfusion had the cell salvage machine not been present. Analyses were adjusted for a 32 
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random effect of treatment centre and fixed effects of stratification variables and other 1 
baseline characteristics believed to be associated with the outcome measure of haemorrhage a 2 
priori. 3 
Secondary outcomes included: units of blood transfused; time to first mobilisation; length of 4 
hospital stay; pre- and postoperative serum haemoglobin, maternal exposure to fetal blood as 5 
measured by a Kleihauer test, maternal fatigue; adverse events (including transfusion 6 
reactions); resources used intra- and postoperatively; costs of staff training; and process 7 
outcomes (including volume of salvaged blood returned, and technical failure of cell 8 
salvage). 9 
A cost-effectiveness analysis was carried out from the NHS perspective based on the 10 
principal clinical outcome of the trial with the results expressed as cost to avoid donor blood 11 
transfusion. A decision tree model was used which collated all the relevant resource use, cost, 12 
and outcome data collected prospectively during the trial to compare the overall cost-13 
effectiveness of cell salvage with standard care. The resource use for both groups of the trial 14 
was estimated by evaluating the individual components of these procedures (bottom-up 15 
costing). Unit cost data were then attached to the resource use. A probabilistic sensitivity 16 
analysis was carried out to explore the effects of the inherent uncertainty in parameter 17 
estimates on model results. 18 
Results 19 
Between June 2013 and April 2016, 3054 participants requiring caesarean section from 26 20 
participating hospitals were initially recruited for randomisation. After 26 exclusions for 21 
eligibility and consent issues, 3028 participants were randomly allocated to either control 22 
(n=1511) or intervention (n=1517). Of these 3028 participants, 1672 were scheduled for 23 
emergency and 1356 for elective caesarean section. A further 35 participants had to be 24 
excluded after randomisation due to vaginal delivery or transfer to another site. We analysed 25 
data from 1492 participants in the control group and 1498 participants in the cell salvage 26 
group, after these exclusions for eligibility and loss to follow-up. Adherence to assigned 27 
intervention was 95.6% in the cell salvage group and 96.1% in the control group. Among the 28 
women treated with cell salvage in the intervention group, 50.8% had salvaged blood 29 
returned, with an average volume of 259.9ml.  30 
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Overall, the transfusion rate was 2.5% in the group assigned to cell salvage versus 3.5% in 1 
control (adjusted OR 0.65, 95% CI 0.42 to 1.01, p=0.056). In the planned subgroup analysis, 2 
the transfusion rate was 3.0% in women assigned to salvage versus 4.6% in control among 3 
emergency caesareans (adjusted OR 0.58, 95% CI 0.34 to 0.99), whereas it was 1.8% versus 4 
2.2% among elective caesareans (adjusted OR 0.83, 95% CI 0.38 to 1.83) (interaction 5 
p=0.46, suggesting that the difference in effect between subgroups was not statistically 6 
significant). In an additional, exploratory subgroup analysis, the transfusion rate was 1.9% in 7 
women assigned to salvage versus 2.9% in control among caesareans with normal 8 
placentation (adjusted OR 0.56, 95% CI 0.34 to 0.94), whereas it was 9.6% versus 8.9% 9 
among caesareans with abnormal placentation (adjusted OR 0.83, 95% CI 0.38 to 1.83) 10 
(interaction p=0.28). As a sensitivity analysis assuming that donor blood transfusion would 11 
have been required had cell salvage not been deployed in the control group showed a 12 
reduction in the proportion of participants requiring donor blood transfusion (5.6% vs. 2.5%, 13 
adjusted OR 0.39, 95% CI 0.26 to 0.59, p<0.001).  14 
There were small differences between groups for time to mobilisation (median 0.74 vs. 0.72 15 
days, adjusted hazard ratio [HR] 1.11, 95% CI 1.03 to 1.19, p=0.006) and length of hospital 16 
stay (2.131 vs. 2.126 days, adjusted HR 1.08, 95% CI 1.00 to 1.16, p=0.050). Mothers 17 
assigned to cell salvage had greater exposure to fetal blood (25.6% vs. 10.5%, adjusted OR 18 
5.63, 95% CI 1.43 to 22.14, p=0.013). There were no differences between groups in other 19 
secondary outcomes. There was no case of amniotic fluid embolism observed in any 20 
instances of cell salvage use. 21 
The results of the economic evaluation suggested that routine cell salvage is more costly than 22 
standard care with the average cost per patient estimated at £1,327 compared to £1,244. The 23 
incremental cost-effectiveness ratio (ICER) representing the average additional cost of 24 
routine cell salvage during caesarean section in women at risk of haemorrhage compared to 25 
standard care was estimated to be approximately £8,110 to avoid a donor blood transfusion. 26 
This estimate was shown to be robust in sensitivity analyses. 27 
Conclusions 28 
There was modest evidence for an effect of routine use of cell salvage during caesarean 29 
section on the need for donor blood transfusion, particularly among emergency procedures. In 30 
women with RhD-negative blood groups who gave birth to RhD-positive babies, cell salvage 31 
was associated with increased maternal exposure to fetal blood, which needs to be matched 32 
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with higher doses of anti-D if cell salvage is to be deployed during caesarean sections among 1 
RhD-negative mothers. Our finding highlights the need to adhere to guidelines on anti-D 2 
prophylaxis and the need for vigilance also with respect to the potential sensitisation to other, 3 
rarer antibodies. The health economic analysis could not demonstrate that cell salvage was 4 
more cost-effective than standard care. Recommendations for future research include: 5 
1. Investigate the impact of non-Rhesus antibody sensitisation with long-term follow-up 6 
of mothers exposed to cell salvage during caesarean section. 7 
2. Investigate the need for greater amounts of routine anti-D administration where cell 8 
salvage has been used. 9 
3. Investigate factors, e.g. swab washing or number of suckers used, that increase the 10 
likelihood of returning blood during use of cell salvage. 11 
4. Investigate the effectiveness of cell salvage in specific sub-groups e.g. placenta 12 
accreta. 13 
5. Investigate the role of cell salvage in low-middle income countries where caesarean 14 
rates are rising and blood transfusion services are not well developed. 15 
6. If new, cheaper or more efficient cell salvage technology becomes available, the 16 
conclusions of SALVO may need to be revisited. The same is true if donor blood 17 
shortages should become extreme and acute. 18 
 
Trial registration 19 
This study was prospectively registered as ISRCTN66118656. 20 
 
[2170 words.]  21 
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Chapter 1 Introduction 1 
Background and rationale 2 
Haemorrhage and caesarean section 3 
Haemorrhage (excessive blood loss) is an important direct cause of maternal death1. Life 4 
threatening blood loss is the primary indication for 95.6% of emergency hysterectomies in 5 
labour.2 Haemorrhage is the commonest cause for maternal critical care admission3-5 and 6 
places a profound health burden on the childbearing population during an important life 7 
event. Haemorrhage is more common in women who have caesarean sections,6 particularly 8 
when indicated for conditions such as placenta praevia (low lying placenta) or when an 9 
emergency caesarean section is required.7 10 
Approximately 166,000 caesarean sections are performed annually in England. Almost two 11 
thirds of these are performed as emergency procedures, and the numbers of operations have 12 
been ever increasing.8 Caesarean section currently accounts for 26.2% of deliveries (2013-14) 13 
and it is the most frequent major operation conducted by the NHS with over 400 performed 14 
per day in England alone. Major haemorrhage can occur without warning during caesarean 15 
section, and the woman’s condition can quickly deteriorate during attempts to arrest blood 16 
loss. Rates of major obstetric haemorrhage vary in the literature according to the definition 17 
used; postpartum haemorrhage occurs with a frequency of 2.93%,6 but severe PPH of 2.5l or 18 
more is much less common with a frequency of around 0.5-0.6%.9 The likelihood of 19 
haemorrhage is increased by risk factors including previous caesarean section, low-lying or 20 
morbidly adherent placenta, emergency caesarean section for any indication, antepartum 21 
haemorrhage and pre-eclampsia.6, 9 22 
Donor blood transfusion in obstetrics 23 
The treatment for major haemorrhage involves allogeneic (donor) blood transfusion when the 24 
operative loss is life threatening or when the mother has severe anaemia following arrest of 25 
the haemorrhage. Approximately 66,000 units of blood (known as Packed Red Cells) are 26 
given annually in the UK maternity setting.10 This equates to £7M per year11 without 27 
considering additional healthcare costs involved in the administration of blood or the 28 
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financial consequences of maternal acute illness. Thus any reduction in the amount of blood 1 
required for obstetrics could significantly reduce the cost of blood transfusions. 2 
Donor blood is a limited resource which needs to be used judiciously. Although national 3 
blood services are constantly improving their capacity to guarantee availability of blood for 4 
transfusion across all clinical requirements,12 it remains an expensive service to recruit and 5 
retain blood donors to minimise the risks of shortages, and new infective risks may pose risks 6 
in future. The availability of donor blood is an essential prerequisite for major procedures 7 
including joint replacement, cardiac surgery, organ transplantation, cancer care, obstetric 8 
emergencies and the management of trauma. This wide range of demands provides 9 
significant challenges to the NHS in the delivery of high quality health care to all points of 10 
need simultaneously. All NHS hospitals are required to have policies for blood shortages, 11 
including cancellation of elective surgery which may require transfusion.  12 
There is an increasing focus on Patient Blood Management (PBM), an international initiative 13 
promoting the use of transfusion alternatives including cell salvage where feasible and 14 
limiting the use of donor transfusion where avoidable.13, 14  Transfusion sparing strategies 15 
successful in other surgical populations, such as pre-donation and acute normovolaemic 16 
haemodilution, cannot be employed in caesarean section. The role of permissive anaemia and 17 
high transfusion threshold is potentially limited by maternal symptoms in the post-natal 18 
period (see below). 19 
Additionally, there are major risks associated with donor blood transfusion, including death 20 
from transfusion error, acute transfusion reaction, fatal lung injury and infection 21 
transmission.15 These risks are monitored by the UK Haemovigilance scheme Serious 22 
Hazards of Transfusion (SHOT) with feedback of results via annual reports.16 Despite 23 
improved safety mechanisms, these rates persist, although serious events are very rare, with 24 
mortality rates of 1 in 100,000.17 Nevertheless, minimising unnecessary transfusion is an 25 
important strand in promoting patient safety. 26 
Postnatal anaemia and its consequences 27 
Concerns regarding transfusion safety together with changes in clinical practice as 28 
highlighted above have led to a more overall restrictive approach to transfusion. The 29 
application of these principles to the obstetric setting with higher transfusion thresholds can 30 
result in significant postnatal maternal anaemia. 31 
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In addition to fatigue as a direct consequence, postoperative maternal anaemia has also been 1 
associated with longer hospitalisation, increased wound infection rates and delayed time to 2 
mobility.18 Anaemia prolongs hospital stay by a third, with an overall 50% higher cost per 3 
hospitalisation.19 The economic consequences of anaemia resulting from obstetric 4 
haemorrhage are therefore profound and any intervention which could reduce maternal 5 
morbidity and mortality is worthy of scrutiny.  6 
Maternal morbidity resulting from anaemia crucially affects the mother’s capacity to provide 7 
care for the newborn. An intervention to relieve maternal anaemia is therefore highly relevant 8 
for the quality of life of this young, generally healthy population and that of their offspring.  9 
Intraoperative cell salvage  10 
Intraoperative cell salvage collects the patient’s own blood lost during an operation, 11 
processes it and returns it to their circulation. This way, cell salvage allows re-transfusion of 12 
the patient's own blood that would otherwise have been wasted.  13 
Its use has been shown to reduce the amount of donor blood given in other operations: A 14 
Cochrane review and other meta-analyses of the use of cell salvage in non-obstetric settings 15 
demonstrated a significant reduction in patient exposure to donor blood.20 An HTA report put 16 
the relative risk of exposure to donor blood at 0.59 (95% CI 0.48 to 0.73) for pooled trials of 17 
cell salvage.21 However, this evidence did not include any trials examining caesarean section.  18 
Given that cell salvage may reduce the need for a standard donor blood transfusion, there 19 
should be fewer transfusion reactions and infections that may be associated with donor blood. 20 
One potential complication associated with cell salvage in the non-obstetric setting arises due 21 
to the use of leukocyte depletion filters (LDFs) during the return of salvaged blood.16, 22-25 22 
LDFs are used in the re-transfusion of salvaged blood with the aim of filtering out foreign 23 
cells such as squamous cells contained within amniotic fluid. They have been the subject of 24 
scrutiny in the medical literature: There are some reports of unexplained hypotension 25 
associated with blood return and filters have been implicated as a potential source of most 26 
anaphylactoid responses (although this remains a contentious issue, and in rare cases 27 
hypotension has been associated with cell salvage even when no LDF was used).16 Moreover, 28 
the addition of a filter may restrict the rapid re-infusion of blood in the context of massive 29 
haemorrhage, by slowing down the blood flow rate. Therefore, these filters are routinely 30 
omitted at the discretion of clinicians when rapid blood return is imperative.  31 
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Overall, cell salvage is a technology that may simultaneously reduce the need for donor blood 1 
transfusion and prevent anaemia. It could therefore avoid the serious morbidity associated 2 
with haemorrhage as well as achieve a significant reduction in costs. In recent years, cell 3 
salvage machines have been refined and have entered routine use in cardiac, orthopaedic, 4 
liver and vascular surgery where there is a risk of major haemorrhage. Their use in caesarean 5 
section has not yet been adequately examined. 6 
Cell salvage in caesarean section 7 
Moderate blood loss is a normal expectation during uncomplicated caesarean section. By 8 
salvaging this blood, it may be returned to the patient, even when donor blood transfusion 9 
would not normally be considered for the reasons already discussed. This might further serve 10 
to reduce post-natal anaemia and its associated morbidity, thus benefiting mothers who only 11 
lose a moderate amount of blood during caesarean section, and who would not normally be 12 
considered for a donor blood transfusion. 13 
The use of cell salvage in the obstetric setting had previously been considered contraindicated 14 
as a result of theoretical concerns regarding the risk of amniotic fluid embolism (AFE), a 15 
serious but extremely rare (about 1 in 20,000) complication of pregnancy and childbirth. Its 16 
pathophysiology is more similar to anaphylaxis than to embolism. AFE is usually diagnosed 17 
at autopsy when fetal squamous cells are found in the maternal lungs, but fetal cells are also 18 
found in the circulation of labouring women who do not develop the typical clinical features 19 
of AFE. Even though the term is controversial, the complications of AFE are attributed to 20 
multi-organ failure and maternal fatality. Studies examining the quality of blood that would 21 
be returned to the mother, had cell salvage been used at caesarean section, have shown that 22 
there is no safety concern with modern equipment since amniotic fluid is effectively and 23 
completely removed by cell salvage processing.26, 27 Despite concerns about AFE as a 24 
consequence of cell salvage having proven unfounded in research thus far,26, 27 and evidence 25 
that transfer of amniotic fluid into the maternal circulation is a common event which does not 26 
necessarily cause adverse effects,28-31 this issue remains of concern to clinicians. 27 
Another potential risk associated with cell salvage in the obstetric setting is sensitization to 28 
red cell antigens leading to haemolytic disease of the fetus and newborn (HDFN).32, 33 This 29 
occurs when there is an incompatibility between antigens carried on red blood cells of a 30 
woman and her infant, with the RhD antigen being one of the most important. In a D-negative 31 
woman carrying a D-positive baby, fetal red cells entering the maternal circulation may 32 
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provoke an immune response in the maternal immune system. These antibodies can then 1 
result in severe fetal and neonatal haemolytic disease in future pregnancies. All RhD-negative 2 
unsensitised women delivering a D-positive baby should be routinely offered a standard dose 3 
of anti-D immunoglobulin (at least 500IU) as prophylaxis to minimise this risk of 4 
sensitization.  5 
A test for fetomaternal haemorrhage (FMH) is recommended to quantify the volume of fetal 6 
red cells that have entered the maternal circulation and determine if additional doses of anti-D 7 
immunoglobulin are indicated. The Kleihauer test is a manual test undertaken in hospital 8 
transfusion laboratories as an initial screen to assess the volume of FMH. Since this test is 9 
associated with a high coefficient of variation, referral for more specialist testing with flow 10 
cytometry is recommended for accurate confirmation if the FMH is estimated to be ≥2ml by 11 
the Kleihauer test. 12 
The volume of fetal red cells in maternal blood following cell salvage is variable but can be 13 
relatively large. Accordingly, updated UK guidelines from the British Society of 14 
Haematology published in 201433 recommend a minimum anti-D Ig dose of 1500 IU to be 15 
administered after reinfusion of salvaged red cells. FMH testing as above should guide if any 16 
additional doses of anti-D Ig are required. Antibodies to other red cell antigens are also 17 
implicated in causing HDFN.34 These may have consequences for future pregnancies or long-18 
term blood transfusion. While there is no evidence to suggest that cell salvage increases the 19 
risk of sensitization, this topic has not been specifically addressed in studies to date,35, 36 but 20 
merits further scrutiny. 21 
The National Institute for Health and Care Excellence (NICE) currently only recommends 22 
cell salvage for obstetrics in the emergency management of massive haemorrhage in 23 
caesarean section, but has called for robust evidence from clinical trials to support its wider, 24 
routine use.37 The guideline states that the technology may be of benefit with careful patient 25 
selection, for example caesarean or vaginal delivery in cases with known placenta praevia or 26 
placenta accreta. Selective use of cell salvage in obstetrics is also recommended by obstetric 27 
and anaesthetic professional bodies.38, 39 28 
Cell salvage is beginning to enter routine use in caesarean section in some hospitals, with the 29 
aim of realising some of the benefits known from other settings. A national survey 2005-6 30 
reported that 38% of UK maternity units had access to cell salvage and 12% included it in 31 
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their major obstetric haemorrhage protocol.40 By 2011, this had increased to 49% of UK 1 
maternity units having access to cell salvage.41 However, use in this context remains 2 
unproven and is not supported by evidence for its clinical or economic effectiveness. Opinion 3 
had not yet solidified in the clinical community, and clinicians engaged in preparation for the 4 
SALVO trial showed that the need to launch a large multicentre randomised controlled trial 5 
to generate reliable, valid evidence was recognised.  6 
Cost considerations 7 
Caesarean section is a frequently performed operation and the cost per patient of 8 
consumables used in routine cell salvage is approximately the same as a single unit of blood. 9 
This must be set against the cost of blood transfusion, the care costs of prolonged hospital 10 
stay and the expense of treating adverse events associated with transfusion. Cell salvage 11 
could realise the dual economic goals of earlier hospital discharge and enhanced maternal 12 
quality of life. 13 
Existing evidence   14 
We published42 and updated35 a systematic review which identified one small controlled trial 15 
of cell salvage in caesarean section in Italy, with 34 participants in each group, which 16 
reported a significant reduction in the number of participants requiring transfusion in the cell 17 
salvage group.43 However, there were flaws in trial design and conduct, including no 18 
explanation of the randomisation method. Furthermore, the control group transfusion rate of 19 
23.5% was at least four times greater than normal practice in the UK. The methodology 20 
employed in other studies, including a retrospective review,44 case series and isolated case 21 
reports,45-53 precluded definitive conclusions but supported the safety of cell salvage in 22 
obstetrics.  23 
The abovementioned NICE review of cell salvage37 focused on the lack of high quality 24 
research and called for randomised controlled trials. The Royal College of Obstetricians and 25 
Gynaecologists (RCOG) Guidelines (12/2007)39 recognised that "cell salvage in obstetrics 26 
remains controversial". The evidence was graded C as a result of the absence of robust trials 27 
on which to base recommendations.  28 
An economic model, drawn from primary cost studies and randomised trials, concluded that 29 
cell salvage had lower costs and higher quality-adjusted life years compared with all other 30 
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alternative transfusion strategies except acute normovolaemic haemodilution.21 However, this 1 
model did not include caesarean section, limiting generalisability to the obstetric setting.  2 
A pilot randomised controlled trial of cell salvage in elective (planned) caesarean section was 3 
performed at one prospective SALVO participating centre54 to help refine the trial processes 4 
and assess feasibility. At closure, 57 women undergoing elective caesarean section had been 5 
randomised. The consent rate was 71% of women approached. The primary outcome data 6 
were collected for 100% of randomised women. The use of cell salvage was feasible and 7 
acceptable to staff and to women randomised. Blood salvage and return was technically 8 
unproblematic requiring minimal additional resource. Of 30 women randomised to cell 9 
salvage, it was set up and deployed in 28 (93%), with sufficient blood collected to enable 10 
return of an average of 284 ± 113 ml of blood to five women. Adherence to the 11 
randomisation strategy was high with 1 case of use of cell salvage in the control group, 12 
following intraoperative haemorrhage due to undiagnosed placenta accreta. No woman in the 13 
cell salvage group required allogeneic transfusion compared to 1 woman (3.7%) in the 14 
routine treatment group, with an undiagnosed placenta accreta, who received two units of 15 
allogeneic blood. 16 
Objectives 17 
The primary objective of the SALVO trial was to determine if the routine use of cell salvage 18 
during both elective and emergency caesarean section, in women at risk of haemorrhage, 19 
reduced the need for donor blood transfusion in comparison to current practice where salvage 20 
is not routinely used. In addition, we sought to assess the consistency of the effect across 21 
subgroups defined by indication for caesarean, and to determine the effect on secondary 22 
outcomes including the number of units of donor blood transfused, fall in haemoglobin level, 23 
maternal morbidity resulting from postoperative anaemia (time to first mobilisation, duration 24 
of hospital stay, and postnatal fatigue), maternal exposure to fetal blood, and its cost-25 
effectiveness in comparison to current practice. 26 
27 
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Chapter 2  Methods 1 
Trial design 2 
The SALVO trial was a multicentre individually randomised controlled trial with cost-3 
effectiveness analysis.  4 
Setting 5 
The trial was conducted in 26 hospitals with large obstetric units, in 23 NHS Trusts in 6 
England, Wales and Scotland (see Appendix 1 for a list of sites). These units each cared for 7 
between 3800 and 8000 births annually and performed between 900 and 2000 caesarean 8 
sections per year.  9 
Participants 10 
Eligibility criteria 11 
Inclusion criteria: 12 
Women who were admitted to a participating labour ward and who fulfilled all of the 13 
following inclusion criteria were eligible to be randomised: 14 
• 16 years of age or older 15 
• Ability to provide informed consent 16 
• Delivery by caesarean section with an identifiable increased risk of haemorrhage, 17 
defined as all emergency caesarean sections, and elective caesarean section for all 18 
indications other than maternal request or breech presentation.  19 
A number of systems for classifying the urgency of caesarean section have been suggested,55 20 
both to improve communication between healthcare professionals, and to assign maximum 21 
time intervals for audit purposes between decision for performing caesarean section and 22 
actually carrying out the delivery.56, 57 The classification system recommended by the Royal 23 
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College of Obstetricians and Gynaecologists56 was in use in the UK hospitals during SALVO. 1 
For stratification purposes, the important distinction for our purposes was between elective 2 
(Category 4: No maternal or fetal compromise and timing to suit the woman and maternity 3 
services), which has a lower incidence of haemorrhage and transfusion, and emergency 4 
categories. We use the term emergency to mean caesareans distinct from the elective 5 
category, in that early delivery was mandated clinically. In this category, the immediacy of 6 
threat to life of woman or fetus varies and accordingly the urgency to deliver varies too 7 
(Category 1: immediate threat and timing immediate; Categories 2 and 3: No immediate 8 
threat and timing flexible depending of assessment of maternal or fetal compromise). We 9 
have avoided the use of words such as crash, urgent and scheduled, as these have different 10 
meanings in different classification systems.  11 
Abnormality of placentation was based on the degree of abnormal myometrial invasion 12 
(placenta accreta, increta and percreta) and the localisation of its insertion within the lower 13 
uterine segment (placenta praevia major or minor) as assessed by antenatal ultrasound 14 
examination. In these circumstances, current guidelines suggest that cell salvage may be 15 
considered in women at high risk of massive haemorrhage, especially in women who would 16 
refuse donor blood. Routine use in these cases is not recommended. 17 
Exclusion criteria: 18 
• Elective first caesarean section for maternal request or breech presentation, with no 19 
additional prognostic factor for haemorrhage. Maternal request included women with 20 
personal reasons for wishing to avoid vaginal delivery, such as previous traumatic 21 
delivery, or psychiatric or psychological problems. These indications do not put the 22 
mother at increased risk of haemorrhage. All other indications for caesarean sections, 23 
including all emergency cases, were considered an identifiable increased risk of 24 
haemorrhage. 25 
• Sickle cell disease or trait. Use of cell salvage may lead to the presence of abnormal 26 
red blood cells, which can deform and block the microscopic blood vessels in the 27 
body, leading to a sickle cell "crisis". Even if only the trait form, there is an increased 28 
chance that this "sickling" may occur while the blood is in the cell salvage collection 29 
reservoir awaiting processing due to the low oxygen levels, and thus a risk that a 30 
sickle cell crisis could be precipitated if this blood is returned to the woman. 31 
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• Active malignancy contraindicated to caesarean section, especially cancer in the 1 
abdominal region, as there is a theoretical risk of spreading the cancer should cell 2 
salvage be used. 3 
• Cultural or religious beliefs contraindicating blood transfusion (e.g. Jehovah’s 4 
Witnesses), since donor red blood cell transfusion was the primary study outcome. 5 
• Significant antibodies making it difficult to find cross-matched blood for transfusion. 6 
This is because allogeneic blood for this group of patients is likely to be scarce or 7 
unavailable. We considered it appropriate to give these patients cell salvage from the 8 
start of their case. 9 
• Inability to understand written and spoken English. 10 
In some circumstances, some of the participating sites applied clinical judgment not to recruit 11 
patients with a high risk of haemorrhage and instead preferred to use cell salvage a priori, 12 
outside the study. 13 
Screening and consent procedures 14 
Screening and antenatal information 15 
In addition to patient information sheets and informed consent forms, we provided sites with 16 
short patient pamphlets (which were used to provide information about the study during the 17 
antenatal period) as well as posters. All patient recruitment materials were approved by the 18 
REC prior to use. 19 
Information about the study was distributed to as many women as possible, “booked” to 20 
deliver at participating centres during their pregnancy and again on admission to delivery 21 
suite, whether they were intending a normal (vaginal) delivery or an elective caesarean 22 
section. This process was individualised at each participating centre depending on their 23 
routine practice to ensure that the maximum number of women were offered information well 24 
in advance of delivery. In some centres, women were provided with information about the 25 
trial at their routine anomaly scan appointment, at 18-22 weeks’ gestation. The provision of 26 
study information was documented in the woman’s medical record or handheld notes, and a 27 
sticker applied to indicate whether they were or were not interested in taking part in the 28 
study. It was also documented at this point whether in an emergency situation they would still 29 
be interested in taking part in the study. Written informed consent was obtained by a trained 30 
health professional (obstetrician, anaesthetist or midwife) with delegated authority from the 31 
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Principal Investigator. All women were assessed to ensure that they had the capacity to 1 
provide consent. The process and timing for obtaining written consent varied according to 2 
clinical urgency (see below and Figure 1). 3 
Recruiting women undergoing elective caesarean section 4 
Eligible women requiring elective caesarean section were provided with further information 5 
and the opportunity to ask questions at the time the operation was booked, and approached 6 
for written consent at pre-operative assessment clinic or on the day of surgery. 7 
Randomisation took place on the day of surgery. 8 
Recruiting women undergoing emergency caesarean section 9 
Women booked for delivery received information regarding the trial during their pregnancy, 10 
so there was sufficient time to consider participation in the trial should an emergency 11 
caesarean section be required. On admission to delivery suite, women’s notes were checked 12 
to ensure this information had been supplied, and the opportunity for further discussion 13 
provided.  14 
After recruitment of half the required target sample, a substantial protocol amendment was 15 
submitted and approved in order to facilitate recruitment of women undergoing emergency 16 
caesarean section. This allowed women to be approached for the first time on delivery suite if 17 
they were found to be in the latent stage of labour (i.e. not yet in established first stage of 18 
labour according to NICE guidelines24, 25) or were comfortable with epidural analgesia, 19 
provided that all of the following criteria were fulfilled: 20 
• They were willing to receive the trial information and were subsequently willing to 21 
discuss the PIS and have any questions answered if desired. 22 
• They had either 0-3cm cervical dilation, not contracting regularly (i.e. a maximum of 23 
one contraction in ten minutes, with contraction lasting less than 30 seconds), or were 24 
comfortable with effective epidural analgesia in place. 25 
• They were given at least one hour to decide whether they would be interested in 26 
taking part, should they require a caesarean section. If their situation changed (i.e. 27 
labour became established during that hour or they were no longer comfortable under 28 
epidural analgesia, or required a caesarean section before the hour elapsed), they were 29 
not approached for inclusion. After an hour, the women were approached for further 30 
discussion and the opportunity for questions about the study. If the women had a 31 
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contraction during the discussion, the health professional involved would pause and 1 
wait for the contraction to finish. Permission to continue with the discussion was then 2 
sought.  3 
Women in established labour (i.e. 4 cm cervical dilation and regular painful contractions), or 4 
who were not comfortable with epidural analgesia, were not approached for the first time on 5 
delivery suite. Women who were distressed and not in a position to absorb the information on 6 
the patient leaflet were not approached for the first time on delivery suite. 7 
Consent was obtained if a decision for caesarean section was made (see below).  8 
Documenting written informed consent 9 
Consent comprised a dated signature from the woman and the dated signature of the person 10 
who obtained informed consent. It was clearly stated that the participant was free to withdraw 11 
from the trial at any time, for any reason, without prejudice to future care and with no 12 
obligation to give the reason for withdrawal. A copy of the signed informed consent 13 
document was given to the woman. One copy was retained in the woman’s medical notes, 14 
and another by the Principal Investigator in the investigator site file.  15 
Verbal consent and timing of written informed consent  16 
All participants undergoing elective caesarean section gave written informed consent before 17 
the intervention. Likewise, the majority of emergency caesarean sections in the absence of 18 
acute fetal distress were conducted in a controlled manner with ample time for regional 19 
anaesthesia to be established, and written consent was obtained at this stage once the decision 20 
for caesarean section had been made. 21 
In some emergency situations, the urgency meant that there would be insufficient time for 22 
written consent to be obtained prior to the emergency caesarean section. Under these 23 
circumstances, if the woman had the capacity to consent and had previously indicated an 24 
interest in taking part in the trial, verbal consent was obtained by an authorised health 25 
professional as described above, and documented on the randomisation checklist. Written 26 
consent was then sought once the urgency of the situation was over and the caesarean section 27 
complete. 28 
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Figure 1 Consent procedure flowchart 1 
 
Abbreviations: CS = Caesarean Section; IOCS = Intra-Operative Cell Salvage; PIS = Patient Information Sheet.  2 
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Intervention 1 
All staff were sufficiently trained and familiar in the use of the cell salvage machine, in 2 
accordance with local procedures and requirements. The majority of sites used conventional 3 
cell saver machines with separate set-up for collection and processing of shed blood, whereas 4 
some sites used continuous transfusion systems. To confirm eligibility for randomisation, 5 
investigators needed to verify that women met the inclusion/exclusion criteria for the trial as 6 
well as gaining informed consent. An eligibility checklist was completed prior to 7 
randomisation. 8 
Women were randomly allocated to either: 9 
1. Caesarean section with cell salvage (intervention group), set up routinely with collection of 10 
shed blood from the outset of surgery, and return of any processed blood obtained. 11 
2. Caesarean section without cell salvage (control group), with transfusion of donor blood 12 
according to standard local guidelines. 13 
The intervention group was treated as follows: Blood was aspirated from the surgical field; 14 
the red cell component isolated by centrifugation and re-transfused after washing and 15 
filtration. The ability to return salvaged blood is dependent on sufficient volume being 16 
collected and processed. Blood was uniformly returned to women in the cell salvage group if 17 
this volume threshold was reached, and it was a protocol requirement that cell saver machines 18 
were fully set up for both collection and processing upfront at commencement of surgery and 19 
that all available processed blood was re-transfused regardless of volume. The use of a 20 
leukocyte depletion filter for transfusion of salvaged blood was not mandated as part of the 21 
study intervention protocol, but left up to local guidance. We monitored any reports of 22 
severe, unanticipated hypotension and their potential association with the presence of 23 
leukocyte depletion filters. Likewise, the use of one versus two suction devices, the latter 24 
having one dedicated to amniotic fluid only at uterotomy as well as salvage machine “bowl 25 
size” was at the discretion of the participating site. Swab washing was encouraged, as it was 26 
thought to increase the volume of blood available for processing and thus for re-transfusion,58 27 
but was ultimately also left to the local investigator’s discretion.  28 
The control group was treated as follows: participants received standard current practice 29 
(without cell salvage), with allogeneic donor blood transfusion as standard treatment if 30 
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required. In life threatening acute haemorrhage, women were managed at the discretion of 1 
attending clinicians in line with the standard of care for such an emergency,1, 39 potentially 2 
including the use of cell salvage in the control group.  3 
Follow-up 4 
Participants were followed up until discharge or transfer from the participating hospital only. 5 
Postnatal investigations included assessment of postoperative haemoglobin levels, collection 6 
of Multidimensional Fatigue Inventory (MFI)59 questionnaires completed by patients (with 7 
any missed MFI questionnaires followed up for completion up to two weeks after discharge), 8 
documentation of adverse events, mobilisation and discharge times, and for RhD-negative 9 
women with RhD-positive babies, assessment of exposure to fetal blood by Kleihauer tests 10 
and anti-D given.  11 
We took the opportunity to undertake an observational study of practice around anti-D 12 
prophylaxis in RhD-negative women who gave birth to a RhD-positive baby. There are UK 13 
guidelines stating that all RhD-negative women giving birth to a RhD-positive baby should 14 
receive a minimum of 500IU anti-D Ig as a standard dose following delivery to minimise the 15 
risk of RhD allo-immunisation. These guidelines published in 2014 also recommend that 16 
after cell salvage the minimum standard dose should be higher at 1500IU anti-D. The 17 
maternal sample should be tested after delivery to assess the level of fetomaternal 18 
haemorrhage (FMH) to guide if additional anti-D doses are needed following the standard 19 
dose. In the majority of centres the Kleihauer test is undertaken as an initial screening test but 20 
since this is a manual test with a high coefficient of variation the guidelines also make further 21 
recommendations. Given the crudeness of Kleihauer results, these guidelines recommend 22 
flow cytometry tests to be performed for Kleihauer results ≥ 2ml, and repeat administrations 23 
and repeat testing after 72 hours for any Kleihauer results > 4ml.60 All centres participating in 24 
the SALVO trial would have been expected to have local guidelines on anti-D prophylaxis. 25 
We aimed to collect data around anti-D prophylaxis and FMH testing in all D-negative 26 
women recruited to this study to assess current practice. We did not attempt to collect follow-27 
up data on the development of red cell sensitisation either to the RhD or indeed other red cell 28 
antigens in either group since this was outside the scope of this particular study. 29 
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Outcomes 1 
The primary outcome was the use of donor blood transfusion. Reducing the proportion of 2 
women with this outcome should lead to fewer transfusion-related complications.  3 
Primary outcome 4 
The primary outcome was the proportion of women receiving donor blood transfusion to deal 5 
with haemorrhage and its consequences, either during caesarean section, or between surgery 6 
and discharge.  7 
Secondary outcomes  8 
The secondary outcomes analysed included: Severity of events (quantified as units of donor 9 
blood transfused); time to first mobilisation after caesarean section (calculated as the time 10 
from delivery until documented first mobilisation, i.e. ability of the woman to walk 11 
unassisted); length of hospital stay (calculated as time from delivery until discharge of the 12 
mother); pre- and postoperative serum haemoglobin, mean fall in haemoglobin level; 13 
maternal exposure to fetal blood, defined as fetomaternal haemorrhage as quantified by 14 
Kleihauer test and defined as Kleihauer ≥2ml, and administration of anti-D antibody; 15 
maternal fatigue measured with the MFI,59 a 20-item self-report questionnaire, covering five 16 
different dimensions of fatigue (general fatigue, physical fatigue, mental fatigue, reduced 17 
motivation, and reduced activity; each question is scored between 1 and 5, with each of the 18 
five fatigue dimensions yielding a maximum score of 20); resources used intra- and 19 
postoperatively (including cell salvage consumables and donor blood transfusions); adverse 20 
and serious adverse events, including proportion of transfusion reactions associated with 21 
allogeneic blood transfusion; and costs of staff training, service procurement and provision of 22 
care, collected alongside clinical outcomes (for full details on health economics methods, see 23 
Chapter 4). Additionally, we collected process outcomes including the volume of blood 24 
returned in cell salvage, the proportion of transfusion reaction associated with allogeneic 25 
donor blood transfusion and any episodes of technical failure of cell salvage. 26 
Safety considerations 27 
Adverse events (AE) were defined as any untoward medical occurrence in a participant 28 
receiving trial intervention, including occurrences which were not necessarily caused by or 29 
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related to that intervention. An AE was therefore defined as any unfavourable and unintended 1 
sign (including an abnormal laboratory finding), symptom or disease temporarily associated 2 
with study activities. 3 
A Serious Adverse Event (SAE) was defined as an adverse event that fulfilled at least one of 4 
the following criteria: fatal; life-threatening; required prolongation of hospitalisation beyond 5 
7 nights after caesarean section for maternal reasons; resulted in persistent or significant 6 
disability; was a congenital anomaly or birth defect; or was otherwise considered medically 7 
significant by the investigator.  8 
AEs and SAEs were documented if they occurred between randomisation and discharge. 9 
They were only reported if they related to the mother, except for SAEs that fulfilled the 10 
criteria of congenital anomaly above. The local principal investigator responsible for the care 11 
of the participant, or in his or her absence an authorised medic within the research team, was 12 
responsible for assessing the severity, causality and expectedness of an adverse event, and for 13 
assessing whether the event was serious according to the definitions given above. 14 
If an AE was not defined as serious, the AE was documented in the participants’ medical 15 
notes (where appropriate) and on the Case Report Form. All reported adverse events were 16 
subject to a central medical review and coded and grouped by a clinician member of the trial 17 
team.  18 
All SAEs occurring during the trial observed by the investigator or reported by the 19 
participant, whether or not attributed to the trial, were documented in the participants’ 20 
medical notes (where appropriate) and reported to the trials office within 24 hours of the site 21 
becoming aware of the event. All SAEs were followed up until resolution or the event being 22 
considered stable. The chief investigator or a delegated clinical co-applicant reviewed all 23 
SAE reports within 24 hours, and raised any queries to be addressed to the sites.  Locally, all 24 
serious incidents (such as maternal deaths) occurring at a UK NHS site were subject to Root 25 
Cause Analyses.61 26 
Any SAEs considered both related to the intervention and unexpected were reported to the 27 
sponsor and the PCTU QA manager within 24 hours, and to the main REC within 15 days. 28 
Although there were some known or theoretical potential risks associated with the trial 29 
(including maternal exposure to fetal blood, amniotic fluid embolism, severe hypotension and 30 
transfusion reaction), none were considered to fulfil the criteria of being ‘expected’. 31 
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Therefore, any serious adverse events that were at least possibly related to the trial 1 
intervention were reported as unexpected SAEs. 2 
If applicable, it was the chief investigator’s responsibility to take any urgent safety measures 3 
to ensure the safety and protection of the clinical trial participants from any immediate hazard 4 
to their health and safety, in which case the REC was informed immediately by telephone, 5 
and in writing within 3 days.  6 
Annual progress reports to the REC included a listing of all related and unexpected SAEs. All 7 
SAEs were reported to the Data Monitoring Committee (DMC) and Trial Steering Committee 8 
(TSC) on the occasion of their meetings, i.e. every 6-12 months. The DMC viewed data with 9 
knowledge of treatment. In the event of a participant dying as a result of the study protocol or 10 
study interventions, any post-mortem findings were to be provided to the chief investigator, 11 
who would report the findings to the DMC for continuous safety review. 12 
Data collection and quality assurance 13 
The SALVO study met the requirements of the Data Protection Act 199862, NHS Caldicott 14 
principles63, the Research Governance Framework for Health and Social Care64 and Research 15 
Ethics Committee approval. Identifiable information collected from participants, including 16 
name, date of birth, hospital number and contact details, was considered confidential and 17 
collected and stored only at the local NHS site. Study data was collected using paper Case 18 
Report Forms, with all data being pseudonymised using a unique participant number, and 19 
transmitted to the trials office by secure NHS e-mail transmission or post. 20 
The following data were collected through Case Report Forms (CRF): 21 
• Before surgery: eligibility, obstetric history, indication for caesarean section, 22 
prognostic factors for haemorrhage, demographics, due dates and labour data, pre-23 
operative haemoglobin and platelet count.  24 
• During surgery: time of delivery, time into and out of theatre, transfusion of donor 25 
blood products, set-up of cell salvage machine (if applicable), including consumables 26 
used and volume of blood returned, reasons for no return of salvaged blood, 27 
documentation of any technical failure of cell salvage, additional staff required in 28 
theatre due to cell salvage. 29 
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• Between surgery and discharge: transfusion of donor blood products, postoperative 1 
haemoglobin, fetomaternal haemorrhage measured by Kleihauer test, anti-D 2 
administration, flow cytometry for Kleihauer results >2ml, repeat Kleihauer and anti-3 
D administration for initial Kleihauer results >4ml,  time of mobilisation and 4 
discharge, MFI, adverse events including admission to higher level of care. 5 
CRF data were verified by the trials office and queries raised with individual sites for 6 
discrepancies identified. Data were input at the trials office by delegated staff into a bespoke 7 
Oracle database with a Java user interface, set up and managed by the PCTU. Data quality 8 
was monitored through source data verification on samples of patient records during on-site 9 
monitoring and during remote self-monitoring activities, and through central statistical 10 
monitoring with discrepancies raised from database extracts, highlighting outliers and 11 
discrepancies. On-site and self-monitoring activities also included verification of eligibility, 12 
informed consent and completeness of local trial documents according to a predefined trial 13 
monitoring plan. 14 
On 69 occasions, stratification factors were found to be entered incorrectly during the 15 
randomisation procedure, but these were corrected to the true values in the analysis, which 16 
adjusted for stratification factors. 17 
Additional quality control measures undertaken included a cross-check of primary outcome 18 
data against local transfusion laboratory records, upon recommendation of the Trial Steering 19 
Committee. Manual data entry was also subject to quality control procedures according to 20 
predefined procedures, with 100% of primary outcome data being checked, and 10% of all 21 
other data being checked with an allowable error threshold of 2% for non-primary outcome 22 
data. 23 
Sample size 24 
Establishing a baseline rate for the primary outcome was not straightforward, since estimates 25 
in the published literature for blood transfusion in caesarean section varied widely (1.8% to 26 
23.5%).43, 65 Factors influencing this figure include country of origin, indication for caesarean 27 
section (emergency or elective) and local transfusion policy. Our audits in two centres 28 
conducted at the time of study planning put transfusion rates for an unselected caesarean 29 
section population at around 5%: A detailed audit of donor blood use at the Royal 30 
Page 36 of 132 
Hallamshire Hospital Sheffield 2009-10, without cell salvage in routine use, was performed 1 
by cross-reference of perioperative records, blood bank data and electronic records stored in 2 
cell salvage machines. It reported that in a recent series of 1647 caesarean section over 10 3 
months, 89 women were transfused with donor blood, giving a rate of 5.4% (I. Wrench, 4 
personal communication). A similar audit at Birmingham Women’s Hospital of all caesarean 5 
section carried out in 2006, showed that of 1674 women, 83 (5.0%) received a transfusion.42 6 
Both auditing units delivered approximately 7300 women per year with a comparable 7 
caesarean section rate and could thus be considered representative of UK tertiary obstetric 8 
unit practice. Our pilot sample54 was too small to assist in providing reliable information on 9 
sample size calculations. In the light of reported contemporary observations and audited data 10 
on transfusion rates, the assumption of a 5% event rate was used to base the main sample size 11 
calculation on. 12 
The expected effect estimate was informed by the literature. Our systematic review42 and its 13 
most recent update35 showed only one small trial published in 1998,43 which randomised a 14 
total of 68 participants to either cell salvage or standard care. The transfusion rate in the 15 
control group was 23.5% and 2.9% in the cell salvage group. The control event rate was 16 
considerably higher than that observed in current UK practice and inconsistent with literature 17 
from other sources. This was likely due to a sample at exceptionally high risk of 18 
haemorrhage. Weaknesses that raise the risk of bias (e.g. inadequate concealment of 19 
randomisation) precluded reliance on it alone to inform our calculations. Non-obstetric 20 
literature evaluating cell salvage in interventions with a moderate to high risk of transfusion 21 
had two high quality systematic reviews: an HTA report citing a RR of exposure to 22 
allogeneic blood of 0.59 (95% CI 0.48-0.73) with salvage;21 and a Cochrane review reporting 23 
a RR of 0.62 (95% CI 0.50-0.70) for transfusion with salvage compared with normal 24 
practice.20 Detecting a smaller effect size would have been possible but the larger sample size 25 
required had to be balanced against the cost and practicability of undertaking such a trial. 26 
From the current best literature we assumed an intervention effect at or around 0.6 (at a 27 
control event rate of 5%, the intervention group would have a transfusion rate of 3%). 28 
Therefore, the planned sample size was a total of 3,050 women (1,525 per group), to detect 29 
an absolute difference in the transfusion rate of 2% and given a power of 80% for a 2-sided 30 
test, a type I error rate of 5% and event rate of 5% in the control group. Our sample size 31 
allowed for primary outcome data and follow-up loss of 1% of randomised cases. 32 
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The planned trial sample was also to represent an even split between elective and emergency 1 
caesarean sections, the rationale for which was as follows: The primary event rate in the 2 
control group was based on data representing caesarean section across ‘all-comers’ in 3 
obstetric units, including both emergencies and elective cases.  It included all indications at 4 
increased risk of haemorrhage. Ideally, this distribution would be faithfully and 5 
proportionally represented in the trial population, but there was good reason to suspect that 6 
clinicians would find it much more difficult or be more reticent to recruit those patients at 7 
higher risk of haemorrhage, such as emergency indications or in cases of placental 8 
abnormality. Equally, a decision to limit recruitment to these high risk groups alone, whilst 9 
desirable to maximize the primary outcome event rate and reduce sample size, was likely to 10 
result in reticence to take part in the study at all.  Adoption of such narrow eligibility criteria 11 
may have restricted sites from ever gaining a sufficient rate of recruitment to become 12 
confident in the trial processes and rendered the conduct of the trial unviable. Additionally, at 13 
the time the study was designed, there was an increasing trend for obstetric units to have 14 
started utilizing cell salvage in the routine, uncomplicated elective caesarean section 15 
population to facilitate the generation of an effective skill-base among clinical staff to support 16 
the deployment of the technology when deemed necessary, even though the majority of these 17 
would not suffer significant blood loss. A pragmatic compromise to these conflicting 18 
requirements was therefore to exclude those elective cases with the very lowest risk of 19 
haemorrhage (elective first caesarean section for breech or maternal request) while at the 20 
same time pre-specifying a desired equal distribution across elective and emergency cases.  21 
Between June 2013 and March 2014, the majority of the elective patient population was 22 
recruited relatively rapidly, exceeding our projected target accrual. The emergency patient 23 
population was recruited more slowly, along with high risk elective cases (See Appendix 2, 24 
Figure 11). Although sites adapted to the more challenging recruitment of these participants, 25 
particularly once the changes to the consenting procedures, introduced through a substantial 26 
protocol amendment, had started to take effect, an extension of the projected recruitment 27 
duration by 11 months was necessary to allow completion of the target sample size.  28 
Interim analyses 29 
There were no planned interim analyses for this trial. In the lead up to the recruitment 30 
extension request, the funding body recommended an interim futility analysis be presented to 31 
the unblinded DMC to assess the probability of achieving a significant result, should the trial 32 
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be allowed to recruit to completion. This was performed in March 2015, but the DMC did not 1 
feel as though it was within their remit to make a decision on the future of the trial based on 2 
said analysis. The DMC made their recommendation without the use of the futility analysis 3 
results. 4 
Randomisation 5 
Randomisation to the allocated intervention (allocation ratio 1:1) was done using a bespoke 6 
web-based randomisation system hosted by the University of Bristol. Randomisation of 7 
participants was done on the delivery ward by local study staff. The randomisation used 8 
random permuted blocks of variable sizes to ensure that trial staff conducting randomisation 9 
could not reliably predict the next allocation. Randomisation was stratified by four criteria: 10 
Centre; type of caesarean section (emergency versus elective); presence of abnormal 11 
placentation versus normal placentation; and multiple pregnancy (twins or more) versus 12 
singleton pregnancy. 13 
Blinding 14 
Allocation concealment with third party randomisation helped minimise selection bias. 15 
However, given the nature of the intervention, it was not possible to blind local treatment 16 
staff and data entry staff to the allocation. Performance bias may lead transfusion rates to 17 
vary. This risk was minimised by ensuring that each centre had an intraoperative transfusion 18 
protocol for use in theatre and recovery to standardise operative transfusion triggers across 19 
both study groups in each centre. Some centres adopted an agreed haemoglobin threshold for 20 
transfusion, which was to be applied equally to both groups.  21 
Sites were encouraged to blind postnatal carers to group allocation after caesarean section. 22 
The allocation was not recorded in routine case notes, but this did not represent formal 23 
blinding as theatre notes were available. The carers on postnatal wards were a different group 24 
of staff to the carers on labour wards and operating theatres, and it was on the postnatal wards 25 
where the decisions for postoperative donor blood transfusions were made, based on the 26 
postoperative haemoglobin level and maternal symptoms. In the event of the need for a donor 27 
blood transfusion, serum haemoglobin was measured by blood sample, and pre and post-28 
transfusion and results recorded. This allowed monitoring of numeric transfusion thresholds 29 
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between units and groups. In the event that between group variations in haemoglobin 1 
transfusion triggers were indeed evident, consideration was given for adjusting for such 2 
differences in the final analysis.  3 
The study statistician remained blinded until completion of data collection and sign-off of the 4 
statistical analysis plan so as not to bias the analysis, and the chief investigator remained 5 
blinded until completion of the analysis. For interim reporting purposes to the Data 6 
Monitoring Committee (DMC) during the running of the trial, an independent statistician 7 
employed by the PCTU produced summaries of unblinded data for a closed report to the 8 
DMC. 9 
Statistical methods 10 
General considerations 11 
A detailed analysis plan was developed and agreed by the Trial Steering Committee and the 12 
Data Monitoring Committee, prior to unblinding and data analysis. All coding and analyses 13 
were performed using Stata version 12. 66 All analyses were intention-to-treat. Where 14 
baseline covariates were missing, we used  mean imputation of the covariate  in adjusted 15 
analyses (note that epidemiological arguments against the use of a missing indicator do not 16 
apply in randomised trials).67 An intention-to-treat approach does not dictate that all outcome 17 
data must have been collected,68 though pilot work for this trial suggested that all or close to 18 
all of the primary outcome data would be obtained. Where outcome data were missing we 19 
analysed those who did have outcome data, adjusting for baseline covariates. This approach 20 
is unbiased if missingness for the outcome is related to observed covariates ("missing at 21 
random"). If missingness in the primary outcome had been >5% then a sensitivity analysis 22 
was to be conducted to explore the missing at random assumption. In this case, a 23 
pattern/mixture model estimated by a mean score approach would have been adopted.68 24 
Post-randomisation exclusions 25 
Although analysis was by intention to treat, certain exclusions were made post-26 
randomisation. These included all women who were enrolled in error (e.g. who did not meet 27 
all eligibility criteria) or did not provide valid written informed consent.  28 
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Women who withdrew their consent were still analysed unless they specified that their data 1 
were not to be used, in which case the data were safely destroyed and excluded from the trial 2 
analysis. We also excluded women who experienced a vaginal delivery, as this was not 3 
applicable to the outcomes analyses in the sense of the trial, although their baseline 4 
characteristics remained available.  5 
Post-randomisation exclusions were not replaced during the recruitment phase, as they were 6 
considered part of the 1% anticipated loss to follow-up (see section “Sample size” above). 7 
Evaluation of Demographics, Baseline Covariates and Implementation of 8 
Intervention 9 
Demographic factors and clinical characteristics were summarised with counts (percentages) 10 
for categorical variables, mean with standard deviation (SD) for normally distributed 11 
continuous variables or median with interquartile (IQR) for other continuous variables. The 12 
number of participants who were eligible, recruited and followed up were recorded in a 13 
CONSORT flowchart. We also included summaries detailing implementation of the 14 
intervention, for example whether swabs were washed.  15 
Primary Analysis 16 
For the primary outcome measure of patient requirement of peripartum transfusion, 17 
differences in treatment effect between treatment groups were assessed using logistic 18 
regression. Univariate and multivariable logistic regression models were used to estimate 19 
crude and adjusted odds ratios with 95% confidence intervals. A two-sided p-value was 20 
reported in each case. The primary analysis was adjusted.  21 
Adjusted analysis adjusts for a random effect of treatment centre and fixed effects of 22 
stratification variables and other baseline characteristics believed to be associated with the 23 
outcome measure of haemorrhage. The latter are factors deemed to be associated antenatally 24 
with a substantial increase in the incidence of postpartum haemorrhage, according to Royal 25 
College of Obstetricians and Gynaecologists (RCOG) guidelines:69 Known placenta praevia 26 
and pre-eclampsia/gestational hypertension. 27 
Another factor believed to substantially increase risk of postpartum haemorrhage is placental 28 
abruption.31 As the number of individuals observed with this event was likely to be low, it 29 
was decided a priori that this covariate would not be adjusted for in the primary analysis. 30 
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Instead, the analysis was redone excluding those who experienced placental abruption, as a 1 
sensitivity analysis. 2 
Analysis of Primary Outcome – Subgroup Analysis 3 
The following subgroup analyses were pre-specified for the primary outcome:  4 
• Analysis of treatment effect by indication for caesarean section.  5 
• Analysis of treatment effect by recruitment centre. 6 
The first of these was analysed by statistically testing for an interaction term between 7 
treatment and indication for caesarean section; the second was analysed by testing for a 8 
random slope for the effect of treatment at different treatment centres in addition to a random 9 
intercept. 10 
Analysis of Primary Outcome – Sensitivity Analysis  11 
The trial groups were compared according to this outcome on an intention-to-treat basis. 12 
However, because clinicians managing women in the control group had access to a cell 13 
salvage machine, it was anticipated that some women in the control group might receive cell 14 
salvage in place of a donor blood transfusion. As a sensitivity analysis, we therefore analysed 15 
the primary outcome assuming that all instances of the return of cell salvaged blood in the 16 
control group would have been instances of donor blood transfusion had the cell salvage 17 
machine not been present.  18 
As mentioned above, the primary analysis was redone excluding those participants who 19 
experienced placental abruption as an additional sensitivity analysis. 20 
Analysis of other outcomes 21 
Secondary outcome measures were compared between groups using appropriate methods. 22 
Linear regression was used to analyse quantitative outcomes where a symmetric unimodal 23 
distribution is expected (number of units transfused, postoperative serum haemoglobin, mean 24 
fall in serum haemoglobin level, and multidimensional fatigue inventory scales). We 25 
analysed 5 scales of fatigue (each the total score of 4 items from the 20 statements pertaining 26 
to a specific type of fatigue). The analysis of serum haemoglobin allowed for change from 27 
baseline by including the pre-operative level as an additional covariate.  28 
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Time to event variables (time to first mobilisation, length of hospital stay) were analysed with 1 
Cox proportional hazard regression.  2 
Fetomaternal haemorrhage was dichotomised into a Kleihauer test measurement of <2ml 3 
versus ≥2ml and analysed using logistic regression. Other measures detailing fetomaternal 4 
haemorrhage, such as dose of anti-D prophylaxis were summarised accordingly. In the 5 
analysis of fetomaternal haemorrhage, we used a cut-off of a Kleihauer result of ≥2ml to 6 
dichotomise the measurement into a binary variable60. However, due to the phrasing of our 7 
CRFs, certain measures, such as flow cytometry or repeat Kleihauer tests, were only taken in 8 
the event that the initial Kleihauer test results were >2ml or >4ml, in accordance with 9 
guidelines.33 In addition, any results reported as e.g. <4ml could not be dichotomised as 10 
described above and was therefore classified as missing data.  11 
Adverse events were analysed using logistic regression. Transfusion reaction associated with 12 
donor blood transfusion was not analysed as we only saw one event. 13 
Crude and adjusted estimates of treatment effect were obtained for each outcome, using 14 
univariate and multivariable analyses with the same covariates as in the primary analysis. 15 
Further exploratory analyses 16 
Further to the pre-specified subgroup analyses, an analysis of treatment effect on donor blood 17 
transfusion by abnormal placentation was undertaken for exploratory purposes. We also 18 
conducted further analysis to test for consistency of treatment effect in secondary outcomes 19 
across subgroups of elective and emergency caesarean section. 20 
We conducted a further sensitivity analysis assuming that a donor blood transfusion would 21 
have been required, had salvaged blood not been returned in the control when the cell salvage 22 
machine was set up in an emergency situation only (as opposed to all cases of salvaged blood 23 
return in the control group). We included this further analysis as an amendment to our 24 
original pre-specified sensitivity analysis as we recognised with hindsight that our 25 
assumptions about the erroneous return of salvaged blood in the control group were broad. 26 
We therefore only reclassified cases where blood was returned in an emergency as an attempt 27 
to more accurately reflect the truth. 28 
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There was also interest surrounding the effect of swab washing on the effectiveness of the 1 
intervention. We compared transfusion rates between participants who did and did not have 2 
swabs washed, within participants who had the cell salvage machine set up. 3 
Governance and oversight 4 
The SALVO trial was undertaken following clinical trials database registration (ISRCTN 5 
registry number 66118656) and the required regulatory approvals and local NHS permissions 6 
(UK research ethics committee North West – Haydock, reference number 12/NW/0513). The 7 
study was funded by the National Institute for Health Research as part of the Health 8 
Technology Assessment programme (HTA reference number: 10/57/32). 9 
A trial management group (TMG) was responsible for the day-to-day running of the trial, 10 
with support from the Pragmatic Clinical Trials Unit (PCTU) at Queen Mary University of 11 
London. The TMG reported to the Trial Steering Committee (TSC), which was composed of 12 
an obstetrician, an independent statistician and a consumer representative, and which 13 
convened every 6 to 12 months and provided overall supervision of the trial. This included 14 
giving advice on trial protocol and changes thereof, resolving problems brought to it by the 15 
TMG, monitoring the progress of the trial, protocol adherence and patient safety, considering 16 
new information and recommendations of the Data Monitoring Committee (DMC) and other 17 
authorities, and approving reports and papers for publication. 18 
The DMC consisted of an independent statistician, obstetrician and anaesthetist. The DMC 19 
met approximately every 12 months during the running of the trial and reviewed accruing 20 
trial data, in order to assess whether there were any ethical or safety issues why the trial 21 
should not continue. Interim reports were supplied to the DMC in strict confidence and 22 
included unblinded data provided by a PCTU statistician independent of the trial. The DMC 23 
formulated recommendations for the attention of the TSC. Both committees also monitored 24 
the pooled primary outcome event rate (i.e. across both arms) and formulated 25 
recommendations to encourage recruitment of the full spectrum of patients likely to benefit 26 
from the intervention. 27 
Patient and public involvement 28 
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Working with organised consumer groups capable of identifying research priorities and 1 
introducing their ideas into research programmes was a crucial part of our activities leading 2 
to the trial.  The National Childbirth Trust (NCT) significantly strengthened the project, being 3 
well placed to reflect on their experience in relation to avoiding the need for donor blood 4 
transfusion and to encourage participation. A volunteer for the NCT collaborated with the 5 
project from its inception, advised on the pilot protocol and agreed to provide representation 6 
on the TSC. An additional patient and public representative was identified through “Katie’s 7 
Team”, the QMUL women’s health research advisory group, and included in the project at a 8 
later stage, who participated in TSC and clinical investigator group meetings, reviewed the 9 
plain English summary for this report, and advised on dissemination strategies. 10 
In preparation for the trial, a survey was conducted among women who received cell salvage, 11 
showing that they perceived the intervention as reassuring, safe, and preferable to donor 12 
blood transfusion (our primary outcome). 13 
Summary of changes to the project protocol 14 
No changes were made to the objectives, outcomes, eligibility criteria, sample size or 15 
statistical parameters during the course of the trial. Three substantial and four minor 16 
amendments to the protocol were implemented during the trial; they concerned changes to 17 
recruitment materials and strategies, clarifications and administrative changes to the protocol, 18 
and an extension of the overall recruitment period.   19 
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Chapter 3 Results 1 
Participants 2 
Between June 2013 and April 2016, 3054 participants requiring caesarean section from 26 3 
participating hospitals were recruited (Figure 2). Of these, 26 participants had to be excluded 4 
due to issues surrounding consent or eligibility as follows:   5 
• 9 participants gave verbal consent as per protocol, but written consent could not be 6 
obtained postoperatively 7 
• 4 participants gave written informed consent, but the consent form was destroyed or 8 
missing and consent could not be re-obtained 9 
• 4 participants had not given consent and were randomised in error, but were not 10 
exposed to any trial intervention 11 
• 1 participant was found to have given invalid consent, due to language issues 12 
• 1 participant gave verbal consent but withdrew consent after surgery 13 
• 7 participants were found not to have met the eligibility criteria 14 
Therefore 1517 participants were assigned to cell salvage (intervention) and 1511 to usual 15 
care (control). Pregnancies resulting in vaginal delivery after assignment (n=17 in the cell 16 
salvage group and n=18 in the control group) were excluded from the analysis, as were 17 
patients who were transferred to a different hospital prior to delivery (n=2 in the cell salvage 18 
group and n=1 in the control group) and who were therefore lost to follow-up; the baseline 19 
characteristics for these 38 patients are however included in the tables of baseline 20 
characteristics. For the analysis, this left 2990 participants (n=1498 in the cell salvage and 21 
n=1492 in the control group, respectively). 22 
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Figure 2 Participant enrolment and follow-up 1 
 
 
  
Initially randomised (n=3054) 
Exclusions: 
- Eligibility criteria not met (n=7) 
- No written consent available (n=18) 
- Withdrawn and specified that data should 
not be used (n=1) 
Control group: Analysed (n=1492) Intervention group: Analysed (n=1498) 
Excluded from analysis: vaginal delivery (n=18) 
Lost to follow-up: moved centre prior to delivery 
(n=1) 
  
Received allocated intervention (n=1434) 
Did not receive allocated intervention (n=58) 
Excluded from analysis: vaginal delivery (n=17) 
Lost to follow-up: moved centre prior to delivery 
(n=2) 
  
Received allocated intervention (n=1432) 
Did not receive allocated intervention (n=66) 
Allocated to Control (n=1511) Allocation Allocated to Cell Salvage (n=1517) 
Follow-up 
Analysis 
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Baseline data 1 
The main characteristics of participants were similar at baseline (Table 1). The distribution of 2 
participants across the different sites is summarised in Table 2.  3 
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Table 1 Characteristics of participants at baseline 
  Control (n=1511)(a) Cell Salvage (n=1517)(a) 
Age at Randomisation 31.8 (5.8) 31.6 (5.7) 
Pre-operative Haemoglobin (g/l)(b) 118.1 (11.5) [19] 118.4 (11.3) [11] 
   
Type of Caesarean     
Elective 687 (45.5%) 669 (44.1%) 
Emergency 824 (54.5%) 848 (55.9%) 
   
Multiple Births     
Singleton 1428 (94.5%) 1428 (94.1%) 
Twins or multiple 83 (5.5%) 89 (5.9%) 
   
Placentation     
Abnormal(c) 135 (8.9%) 136 (9.0%) 
Normal 1376 (91.1%) 1381 (91.0%) 
   
Placenta Praevia 130 (8.6%) 133 (8.8%) 
Placenta Accreta 8 (0.5%) 4 (0.3%) 
Pre-Eclampsia 74 (4.9%) 69 (4.5%) 
Previous Emergency Caesarean 602 (39.8%) 633 (41.7%) 
Previous Elective Caesarean 241 (15.9%) 231 (15.2%) 
Placental Abruption 3 (0.2%) 2 (0.1%) 
   
Ethnicity     
White 1213 (80.3%) 1219 (80.4%) 
Mixed 23 (1.5%) 14 (0.9%) 
Asian or Asian British 158 (10.5%) 173 (11.4%) 
Black or Black British 67 (4.4%) 71 (4.7%) 
Other 50 (3.3%) 40 (2.6%) 
      
Parity   
0 571 (37.8%) 583 (38.4%) 
1 556 (36.8%) 562 (37.0%) 
2 240 (15.9%) 238 (15.7%) 
3+ 144 (9.5%) 134 (8.8%) 
   
Gravidity     
1 420 (27.8%) 441 (29.1%) 
2 467 (30.9%) 465 (30.6%) 
3+ 624 (41.3%) 611 (40.3%) 
Data presented are n (%) or mean (sd) [n missing] 
(a) Denominator includes 38 patients lost to follow-up due to vaginal delivery or transfer. 
(b) Haemoglobin <105 (g/l): Control group: n=159 (10.7%), Cell Salvage group: n=150 (10.0%) 
(c) Placenta Praevia and / or Placenta Accreta  
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Table 2 Participants recruited per site 
  
Control (n=1511)(a) Cell Salvage (n=1517)(a) 
Centre     
Birmingham Heartlands Hospital 41 (2.7%) 44 (2.9%) 
Birmingham Women's Hospital 7 (0.5%) 6 (0.4%) 
Croydon University Hospital 48 (3.2%) 48 (3.2%) 
Derriford Hospital Plymouth 57 (3.8%) 59 (3.9%) 
Hinchingbrooke Hospital 83 (5.5%) 84 (5.5%) 
James Cook University Hospital 109 (7.2%) 108 (7.1%) 
Leicester General Hospital 5 (0.3%) 4 (0.3%) 
Leicester Royal Infirmary 78 (5.2%) 75 (4.9%) 
Norfolk and Norwich University Hospital 5 (0.3%) 5 (0.3%) 
Northwick Park Hospital 13 (0.9%) 15 (1.0%) 
Nottingham City Hospital 15 (1.0%) 16 (1.0%) 
Queens Hospital Romford 60 (4.0%) 58 (3.8%) 
Queens Medical Centre Nottingham 15 (1.0%) 13 (0.9%) 
Royal Hallamshire Hospital Sheffield 138 (9.1%) 139 (9.2%) 
Royal London Hospital 84 (5.6%) 87 (5.7%) 
Royal Stoke University Hospital, Stoke-on-Trent 72 (4.8%) 73 (4.8%) 
Royal United Hospital Bath 88 (5.8%) 87 (5.7%) 
Royal Victoria Infirmary Newcastle 119 (7.9%) 116 (7.7%) 
Simpson Centre Edinburgh 47 (3.1%) 51 (3.4%) 
Singleton Hospital Swansea 84 (5.6%) 88 (5.8%) 
St. Michaels Hospital Bristol 26 (1.7%) 21 (1.4%) 
Sunderland Royal Hospital 192 (12.7%) 190 (12.5%) 
Torbay Hospital 28 (1.9%) 30 (2.0%) 
West Middlesex University Hospital 49 (3.2%) 52 (3.4%) 
Whipps Cross University Hospital 29 (1.9%) 27 (1.8%) 
Whiston Hospital 19 (1.3%) 21 (1.4%) 
   
Data presented are n (%) 
(a) Denominator includes 38 patients lost to follow-up due to vaginal delivery or transfer. 
 
Implementation of cell salvage 1 
In the intervention group, 1432 (95.6%) participants received their allocated treatment with 2 
the cell salvage machine set up. There were 24 cases (1.6%) where the cell salvage machine 3 
was unavailable or out of order and 42 cases (2.8%) where the machine was simply not set up 4 
in deviation of the protocol. In the group receiving salvage, 50.8% had salvaged blood 5 
returned averaging 259.9 ml (Table 3).  In the control group, 1434 (96.1%) participants 6 
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received their assigned intervention without the cell salvage machine set up. In 15 cases 1 
(1.0%) the cell salvage machine was used in an emergency and in 43 cases (2.9%) it was set 2 
up from the start of the operation, in deviation of the protocol.  3 
Table 3 Detail regarding cell salvage use 
  
Control (n=1492) Cell Salvage (n=1498) 
Cell Salvage Machine Set Up     
Set up 43 (2.9%) 1432 (95.6%) 
Emergency use 15 (1.0%) 0 (0.0%) 
Not set up 1434 (96.1%) 42 (2.8%) 
Unavailable/out of order 0 (0.0%) 24 (1.6%) 
   
Received Allocated Treatment 1434 (96.1%) 1432 (95.6%) 
   
If Cell Salvage Set Up (Including Emergency Use) (n=1490) 
Suckers Used     
1 27 (48.2%) 829 (58.1%) 
2 29 (51.8%) 598 (41.9%) 
Missing(a) 2 5 
      
Swabs Washed 21 (36.8%) [1] 781 (54.8%) [6] 
      
Size of Centrifuge Bowl Used (ml)(b) 183.2 (59.2) [2] 177.1 (59.8) [37] 
      
Leukocyte Depletion Filter Used 25 (43.9%) [1] 782 (54.9%) [7] 
      
Salvaged Blood Returned 35 (60.3%) [0] 726 (50.8%) [3] 
      
If Blood Returned During Cell Salvage (n=761) 
Volume of Blood Returned to Mother (ml) 288.4 (198.3) 259.9 (149.7) 
   
If No Blood Returned During Cell Salvage (n=726) 
Reason For No Return   
No blood produced 14 (63.6%) 575 (88.9%) 
Technical error 0 (0.0%) 25 (3.9%) 
Other(c) 8 (36.4%) 47 (7.3%) 
Missing 1 56 
   
Data presented are n (%) or mean (sd) [n missing] 
(a) Missing observations are not included in percentage calculations. Where variables are categorical, missing values are listed in a 
separate row, but are similarly not included in percentage calculations. 
(b) Measure not applicable for sites with a continuous transfusion machine only (Control group: n=22, Cell Salvage group: n=180) 
(c) Other reasons include 'Clinical decision' (n=7), 'Human error' (n=5), 'Meconium, infection risk or contamination' (n=12), 'Minimal 
processed blood' (n=25), 'Patient declined' (n=2), 'Tubing trapped next to centrifuge bowl' (n=1), 'Unclear' (n=3) 
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Primary outcome  1 
Overall, the donor blood transfusion rate was 2.5% in the group assigned to cell salvage 2 
versus 3.5% in control, though this result did not reach statistical significance (adjusted OR 3 
0.65, 95% CI 0.42 to 1.01, p=0.056, Table 4). In a subgroup analysis exploring the 4 
consistency of treatment effects in procedures undertaken at different levels of urgency, the 5 
transfusion rate was 3.0% in women assigned to salvage versus 4.6% in control among 6 
emergency caesareans (adjusted OR 0.58, 95% CI 0.34 to 0.99), whereas it was 1.8% versus 7 
2.2% among elective caesareans (adjusted OR 0.83, 95% CI 0.38 to 1.83), though the 8 
interaction was not statistically significant (p=0.46, Table 4). 9 
There was no significant difference in the effectiveness of the intervention between centres 10 
(p-value for random slope=0.091). In a pre-specified sensitivity analysis assuming that a 11 
donor blood transfusion would have been required, had salvaged blood not been returned in 12 
the control group (n=31), the effect of cell salvage was significant (5.6% vs. 2.5%, adjusted 13 
OR 0.39, 95% CI 0.26 to 0.59, p<0.001, Table 4). When excluding cases of placental 14 
abruption from the primary analysis, little difference in the results was seen, with 1 15 
transfusion excluded in the control group as a result (3.4% vs. 2.5%, adjusted OR 0.67, 95% 16 
CI 0.43 to 1.03, p=0.071, Table 4).  17 
We also reviewed primary outcome events against available transfusion guidelines, in order 18 
to determine whether the lack of blinding introduced bias. Where specific haemoglobin 19 
thresholds were defined in local guidelines, we compared these to participants’ reported 20 
postoperative haemoglobin values. We found 25 instances (14 cell salvage group, 11 control 21 
group) where donor blood was administered post-operatively without locally defined 22 
haemoglobin thresholds having been reached. The trial management group did not deem the 23 
difference between intervention groups a cause for concern, also accounting for the fact that 24 
other less quantifiable factors may also be taken into account when deciding on donor blood 25 
transfusion. We therefore did not adjust our analysis accordingly.26 
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Table 4 Effect of intervention on donor blood transfusion 
  Control 
(n=1492) 
Cell Salvage 
(n=1498) 
Crude Risk Difference % 
(95% CI) 
Crude Intervention 
Odds Ratio (95% CI) 
P Value - 
Crude 
Analysis 
Adjusted(a) Intervention 
Odds Ratio (95% CI) 
P Value - 
Adjusted 
Analysis 
                
Primary analysis         
Overall  52 (3.5%) 37 (2.5%) -1.0 (-2.2, 0.2)  0.70 (0.46, 1.08) 0.10 0.65 (0.42, 1.01) 0.056 
        
Sub-group analysis                
Emergency caesarean (n=1641) 37 (4.6%) 25 (3.0%)    0.58 (0.34, 0.99)  
Elective caesarean (n=1349) 15 (2.2%) 12 (1.8%)       0.83 (0.38, 1.83)   
P value for interaction       0.46 
                
Sensitivity analysis        
Assumption: return of cell salvaged 
blood in the control group avoided 
transfusions  
83 (5.6%) 37 (2.5%) -3.1 (-4.5, -1.7) 0.43 (0.29, 0.64) <0.001 0.39 (0.26, 0.59) <0.001 
Excluding participants with placental 
abruption (Cell Salvage group: n=2, 
Control group: n=3) 
51 (3.4%) 37 (2.5%)  -1.0 (-2.2, 0.3)  0.72 (0.47, 1.10) 0.13 0.67 (0.43, 1.03) 0.071 
        
CI: Confidence Interval 
(a) Adjusted for stratification factors (elective vs. emergency caesarean section, presence of abnormal placentation, singleton vs. twins or multiple births, recruitment centre (as a random effect)) 
and other factors believed to be prognostic a-priori (known placenta praevia, pre-eclampsia) 
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Secondary outcomes 1 
Allocation to cell salvage did not have an effect on the units of donor blood transfused 2 
(adjusted MD -0.12, 95% CI -0.8 to 0.57, p=0.74, Error! Reference source not found.).  3 
A small difference was detected between cell salvage and control groups for time to 4 
mobilisation (median 0.74 vs. 0.72 days, adjusted HR 1.11, 95% CI 1.03 to 1.19, p=0.006, 5 
Error! Reference source not found.); this represented a shorter absolute median time to 6 
mobilisation of 0.02 days, i.e. around half an hour. A small difference was also observed in 7 
length of hospital stay (median 2.131 vs. 2.126 days adjusted HR 1.08, 95% CI 1.00 to 1.16, 8 
p=0.050, Error! Reference source not found.); this represented a shorter absolute median 9 
hospital stay by 0.005 days or around 10 minutes.  10 
Analysis of postoperative haemoglobin levels showed no difference between cell salvage and 11 
control groups (adjusted MD 0.63, 95% CI -0.09 to 1.35, p=0.085, Error! Reference source 12 
not found.) and this was also the case for fall in haemoglobin level from baseline (adjusted 13 
MD -0.68, 95% CI -1.40 to 0.04, p=0.066, Error! Reference source not found.).  14 
Among RhD-negative women giving birth to RhD-positive babies, allocation to cell salvage 15 
was associated with greater fetomaternal haemorrhage, defined as Kleihauer testing ≥2ml 16 
(10.5% vs. 25.6%, adjusted OR 5.63, 95% CI 1.43 to 22.14, p=0.013, Table 5). It should be 17 
noted that for 67 patients, Kleihauer testing was done but results could not be classified as 18 
they were reported as “<4ml” or similar estimations, according to local guidelines; these 19 
results are therefore not available for analysis. Anti-D was routinely administered in the vast 20 
majority of RhD-negative mothers with RhD-positive babies (99.2% cases in control group, 21 
98.6% cases in cell salvage group, Error! Reference source not found.), although a total of 22 
3 women across both groups did not seem to have received a minimum standard dose of anti-23 
D following delivery, with a risk of RhD allo-immunisation. The dose of anti-D that was 24 
administered is summarised in Error! Reference source not found., with further detail on 25 
management of large FMH detailed in Table 7. Of the 140 RhD-negative mothers in the cell 26 
salvage group, only 40.6% received a dose of 1500 IU, with 56.5% receiving 500 IU. It is 27 
worth nothing that the updated guidance33 recommending a higher standard anti-D dose of 28 
1500 IU after cell salvage was published in 2014, so practice in some centres with doses of 29 
500 IU may predate publication of these guidelines. 30 
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Table 5 Analysis of secondary outcomes 
    Control (n=1492) Cell Salvage (n=1498) 
 Crude Intervention 
Odds Ratio / Mean 
Difference / Hazard 
Ratio (95% CI) 
P Value - 
Crude 
Analysis 
 Adjusted(a) 
Intervention Odds 
Ratio / Mean 
Difference / Hazard 
Ratio (95% CI) 
P Value - 
Adjusted 
Analysis 
Secondary Outcomes               
Units of Blood Transfused(b) mean (sd) 2.65 (1.66) 2.70 (1.70) 0.05 (-0.67, 0.76) 0.89 -0.12 (-0.80, 0.57) 0.74 
Time to Mobilisation (days)(c)(g) median (IQR) [n missing] 0.74 (0.45) [49] 0.72 (0.45) [61] 1.07 (0.99, 1.15) 0.079 1.11 (1.03, 1.19) 0.006 
Length of Hospital Stay (days)(c)(h) median (IQR) [n missing] 2.13 (1.41) [24] 2.13 (1.37) [12] 1.04 (0.97, 1.12) 0.26 1.08 (1.00, 1.16) 0.050 
Safety Outcomes               
Postoperative Haemoglobin Level 
(g/l)(d) mean (sd) [n missing] 103.1 (12.1) [47] 103.8 (12.2) [61] 0.74 (-0.15, 1.63) 0.10 0.63 (-0.09, 1.35) 0.085 
Fall in Haemoglobin Level (g/l)(d) mean (sd) [n missing] 15.0 (11.2) [65] 14.5 (11.1) [72] -0.49 (-1.31, 0.33) 0.24 -0.68 (-1.40, 0.04) 0.066 
Any Adverse Event Experienced n (%) [n missing(e)] 191 (12.8%) [0] 199 (13.3%) [1] 1.04 (0.84, 1.29) 0.69 1.02 (0.81, 1.29) 0.84 
Fetomaternal haemorrhage(f) n (%) [n missing] 9 (10.5%) [33] 21 (25.6%) [51] 2.95 (1.26, 6.89) 0.013 5.63 (1.43, 22.14) 0.013 
        
Note: Analysis of transfusion reaction associated with allogeneic donor blood omitted due to observing only one event (Control group) 
CI: Confidence Interval; sd: Standard Deviation; IQR: Inter-quartile Range 
(a) Adjusted for stratification factors (elective vs. emergency caesarean section, presence of abnormal placentation, singleton vs. twins or multiple births, recruitment centre (as a random effect)) and other 
factors believed to be prognostic a-priori (known placenta praevia, pre-eclampsia) 
(b) Analysis within the subgroup of participants who received donor blood 
(c) Taken from time of delivery 
(d) Adjusted analysis also adjusts for pre-operative measurement, as well as time postoperative measurement was taken after delivery (log transformed), with mean imputation of missing values for both 
covariates. Please note that the decision to adjust for the latter was made by blinded members of the trial team after the signing off of the Statistical Analysis Plan. Haemoglobin post-operatively <105 (g/l): 
Control group: n=787 (54.5%), Cell Salvage group: n=750 (52.2%) 
(e) Missing observations are not included in percentage calculations 
(f)  Measured by Kleihauer test and dichotomised into a result of <2ml vs. ≥2ml. Analysis within the subgroup of participants who had a Kleihauer test. Measure set to missing where results are not 
categorisable, e.g. Kleihauer result reported as <4ml (Control group: n=25; Cell Salvage group: n=42) 
(g) Test of proportional hazards assumption crude analysis P=0.67, adjusted analysis P=0.18 
(h) Test of proportional hazards assumption crude analysis P=0.57, adjusted analysis P=0.39 
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Table 6 Results concerning maternal RhD status 
    Control (n=1492) Cell Salvage (n=1498) 
RhD-Negative Mother With RhD-Positive Baby n (%) 130 (8.7%) 140 (9.3%) 
    
If Mother Negative and Baby Positive (n=270)   
Anti-D Prophylaxis Administered? n (%) 129 (99.2%) 138 (98.6%) 
        
Anti-D Prophylaxis Dose (IU)    
500 n (%) 59 (46.1%) 78 (56.5%) 
1500 n (%) 67 (52.3%) 56 (40.6%) 
Other(a) n (%) 2 (1.6%) 4 (2.9%) 
Missing(b) n 1 0 
        
Kleihauer Test Performed? n (%) [n missing] 119 (92.2%) [1] 133 (95.0%) [0]  
        
Fetomaternal haemorrhage  
(Kleihauer test ≥2ml) n (%) [n missing
(c)] 9 (10.5%) [33] 21 (25.6%) [51] 
        
Sample Sent For Flow Cytometry(d) n (%) 1 (33.3%) 9 (75.0%) 
        
Repeat Kleihauer Test Performed?(e) n (%) 1 (50.0%) 6 (100.0%) 
        
Further Anti-D Prophylaxis Administered?(e) n (%) [n missing] 1 (100.0%) [1] 1 (16.7%) [0]  
        
Further Anti-D Prophylaxis Dose (IU)    
250 n (%) 0 (0.0%) 1 (100.0%) 
1500 n (%) 1 (100.0%) 0 (0.0%) 
    
(a) Other doses include Control group: 1250, 4000; Cell Salvage group: 1000, 1000, 4500, 5000. See Table 7 for details. 
(b) Missing observations are not included in percentage calculations. Where variables are categorical, missing values are listed in a 
separate row, but are similarly not included in percentage calculations 
(c)  Measure set to missing where results are not categorisable, e.g. Kleihauer result reported as <4ml (Control group: n=25; Cell Salvage 
group: n=42) 
(d) Measure only collected for participants with Kleihauer >2ml (Control group: n = 3, Cell Salvage group n = 12) 
(e) Measure only collected for participants with Kleihauer >4ml (Control group: n=2, Cell Salvage group: n=6). Kleihauer results >4ml are 
Control group: >4ml, =37ml; Cell Salvage group: =5ml, =6ml, =6ml, =10ml, =11ml, =26ml. See Table 7 for details. 
 
  
Page 56 of 132 
Table 7 Management of RhD-negative women with fetomaternal haemorrhage ≥ 2mls by Kleihauer 
FMH by 
Kleihauer (ml)  
Anti-D dose 
(IU) 
Flow 
cytometry 
undertaken(a) 
Flow 
cytometry 
result (ml) 
Repeat 
Kleihauer 
undertaken(b) 
Blood returned 
during cell 
salvage? 
Cell salvage group (n=21)     
26 4500 Yes 26 Yes Yes 
11 1500 Yes 9 Yes Yes 
10 1500 Yes 10 Yes Yes 
6 1000 Yes 5 Yes No 
6 1000 Yes 6 Yes Yes 
5 1500 Yes 12 Yes(c) Yes 
4 5000 No -   No 
4 500 Yes 2  No 
3 500 No -   Yes 
3 None No -  No 
>2 500 Yes 2   Yes 
>2 1500 Yes 7  Yes 
2 1500       Yes 
2 1500    No 
2 1500       Yes 
2 500    Yes 
2 500       Yes 
2 500    Yes 
2 500       Yes 
2 500    Yes 
2 500       No 
Control group (n=9)     
37 4000 Yes 37 Yes(c) Not set up 
>4 1500 No - No Not set up 
3 500 No -  Not set up 
2 500       Not set up 
5pts with 2 1500       Not set up 
        
FMH: Fetomaternal haemorrhage. 
(a) Flow cytometry data was only collected for Kleihauer > 2ml.  
(b) Repeat Kleihauer data was only collected for Kleihauer > 4ml. 
(c) Repeat anti-D also administered. 
 
Kleihauer tests were undertaken on the majority of RhD-negative participants in both groups 
(92.2% cases in control group, 95.0% cases in cell salvage group, Error! Reference source 
not found.). Five per cent of women in cell salvage group and 7.8% women in the control 
group did not have Kleihauer tests undertaken following delivery. It should be noted that a 
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dose of 500IU of anti-D covers an FMH of 4mls, and while a 1500 IU anti-D dose covers an 
FMH of ~12mls, a small proportion of women may have had an even higher fetomaternal 
bleed. A Kleihauer test is therefore recommended to determine if additional doses of anti-D 
are needed in addition to the standard dose. 
Repeat Kleihauer tests were undertaken 72 hours post anti-D administration for the majority 
of applicable participants and further anti-D was administered for 2 participants (Table 
6Error! Reference source not found.). Overall 8 women (n=2 in the control group and n=6 
in the intervention group) had larger instances of fetomaternal haemorrhage with >4ml 
Kleihauer results. Of the two in the control group, one woman had the largest observed FMH 
on the study, with 37ml. She was managed as per guidelines with flow cytometry for 
confirmation of the FMH volume, additional anti-D dose administered and repeat Kleihauer 
test undertaken. The other had an initial Kleihauer result of >4ml, was administered 1500IU 
of anti-D but had no flow cytometry undertaken. Neither of these two women in the control 
group received cell salvage. Of the 6 women in the intervention group, five had received cell 
salvaged blood back. All 6 women had confirmatory flow cytometry done and repeat 
Kleihauer tests undertaken. 
Breakdowns of fetomaternal haemorrhage by sucker use and return of salvaged blood were 
also summarised (see Table 8). On a descriptive level, sucker use appeared to have little 
effect on the proportion of participants experiencing fetomaternal haemorrhage (28.3% when 
one sucker was used versus 25.0% when two suckers were used). Return of salvaged blood 
appeared to increase fetomaternal haemorrhage (13.0% in cases of no salvaged blood 
returned versus 48.4% in cases where salvaged blood was returned).  
Table 8 Fetomaternal haemorrhage by sucker use and by return of salvaged blood 
  
One Sucker Used (n=53) Two Suckers Used (n=24) 
Fetomaternal Haemorrhage (a) 15 (28.3%)  6 (25.0%) 
  No Blood Returned (n=46) Blood Returned (n=31) 
Fetomaternal Haemorrhage (b) 6 (13.0%)  15 (48.4%) 
   
Data presented are n (%) 
(a)  Measured by Kleihauer test and dichotomised into a result of <2ml vs. ≥2ml. Summaries within participants who had the cell 
salvage machine set up (including Emergency use), for those with complete data on fetomaternal haemorrhage and sucker use  
(b)  Summaries within participants who had the cell salvage machine set up (including emergency use), for those with complete 
data on fetomaternal haemorrhage and return of blood during cell salvage  
 
Page 58 of 132 
Administration of other donor products (namely Fresh Frozen Plasma, Platelets and 
Cryoprecipitate) is summarised in Table 9 below. 
Table 9 Detail of Administration of Donor Products 
    Control (n=1492) Cell Salvage (n=1498) 
Intraoperative       
Donor Blood Given n (%) 20 (1.3%) 12 (0.8%) 
Units(a) of Blood mean (sd) 2.60 (1.27) 2.08 (0.51) 
FFP Given n (%) 9 (0.6%) 3 (0.2%) 
Units of FFP mean (sd) 2.11 (0.33) 3.00 (1.00) 
Platelets Given n (%) 2 (0.1%) 0 (0.0%) 
Units of Platelets mean (sd) 1.50 (0.71) - 
Cryoprecipitate Given n (%) 2 (0.1%) 0 (0.0%) 
Units of Cryoprecipitate mean (sd) 2.00 (0.00) - 
    
Postnatal       
Donor Blood Given n (%) 36 (2.4%) 30 (2.0%) 
Units of Blood mean (sd) 2.39 (1.57) 2.50 (1.68) 
FFP Given n (%) 8 (0.5%) 7 (0.5%) 
Units of FFP mean (sd) 3.25 (2.19) 3.29 (0.95) 
Platelets Given n (%) 2 (0.1%) 1 (0.1%) 
Units of Platelets mean (sd) 1.00 (0.00) 1.00 (-) 
Cryoprecipitate Given n (%) 3 (0.2%) 0 (0.0%) 
Units of Cryoprecipitate mean (sd) 2.00 (0.00) - 
    
sd: Standard Deviation; FFP: Fresh Frozen Plasma 
(a) Unit summaries considered within participants who received the specified blood product 
 
 
 
The multidimensional fatigue inventory questionnaire was completed for 2408 (80.5%) of 
participants. Analysis of multidimensional fatigue inventory statement scores showed no 
significant differences between allocation groups for the fatigue categories of ‘General 
Fatigue’, ‘Physical Fatigue’, ‘Reduced Motivation’ or ‘Reduced Activity’. There was a 
modest difference between cell salvage and control group for ‘Mental Fatigue’ (adjusted MD 
-0.30, 95% CI -0.59 to -0.01, p=0.043, Table 10Error! Reference source not found.). 
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Table 10 Analysis of Multidimensional Fatigue Inventory 
  Control (n=1187) Cell Salvage (n=1221) Crude Mean Difference (95% CI) 
P Value - 
Crude 
Analysis 
Adjusted(a) Mean 
Difference (95% CI) 
P Value - 
Adjusted 
Analysis 
MFI Groups(b)             
General Fatigue 12.7 (3.6) [52] 12.5 (3.6) [39] -0.18 (-0.47, 0.12) 0.24 -0.18 (-0.47, 0.11) 0.22 
Physical Fatigue 12.3 (3.9) [22] 12.3 (3.9) [31] -0.05 (-0.36, 0.26) 0.75 -0.06 (-0.37, 0.25) 0.69 
Reduced Motivation 9.6 (3.3) [36] 9.8 (3.4) [46] 0.12 (-0.15, 0.40) 0.37 0.13 (-0.14, 0.40) 0.36 
Reduced Activity 11.3 (3.8) [42] 11.4 (3.6) [47] 0.12 (-0.18, 0.43) 0.44 0.12 (-0.18, 0.41) 0.45 
Mental Fatigue 8.7 (3.6) [19] 8.4 (3.6) [41] -0.28 (-0.57, 0.01) 0.061 -0.30 (-0.59, -0.01) 0.043 
       
Data presented are mean (sd) [n missing] 
sd: Standard Deviation; CI: Confidence Interval; MFI: Multidimensional Fatigue Inventory 
(a) Adjusted for stratification factors (elective vs. emergency caesarean section, presence of abnormal placentation, singleton vs. twins or multiple births, recruitment centre (as a random effect)) and 
other factors believed to be prognostic a-priori (known placenta praevia, pre-eclampsia) 
(b) Sum of MFI statement scores (where participants indicate agreement within a statement between 1 and 5) within fatigue categories. Higher scores indicate increased fatigue. 
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As for process outcomes, the cell salvage machine was set up for 1490 participants across 1 
both groups and salvaged blood was processed and returned for a total of 761 participants (35 2 
[60.3%] in the control group and 726 [50.8%] in the cell salvage group). Volume of salvaged 3 
blood was recorded and summarised and reasoning behind no return of salvaged blood was 4 
also denoted, with the most common reason being that no blood was produced by the cell 5 
salvage machine. Further measures detailing implementation of the intervention, such as 6 
machine settings and equipment use, are summarised in Table 11.  7 
 
Table 11 Other Details Regarding Cell Salvage Use 8 
  
Control (n=1492) Cell Salvage (n=1498) 
If Cell Salvage Set Up (Including Emergency Use) (n=1490)   
Collection Sets Used(a)   
0 0 (0.0%) 1 (0.1%) 
1 36 (100.0%) 1240 (99.3%) 
2 0 (0.0%) 7 (0.6%) 
3 0 (0.0%) 1 (0.1%) 
Missing(b) 0 3 
   
Processing Packs Used(a)     
0 2 (5.7%) 50 (4.0%) 
1 32 (91.4%) 1179 (94.5%) 
2 1 (2.9%) 13 (1.0%) 
3 0 (0.0%) 4 (0.3%) 
4 0 (0.0%) 2 (0.2%) 
Missing 1 4 
   
Default Settings Used 54 (94.7%) [1] 1287 (90.3%) [6] 
   
Data presented are n (%) [n missing]   
sd: Standard Deviation 
(a) Measure not applicable for sites with a continuous transfusion machine only (Cell Salvage group: n=180, Control 
group: n=22) 
(b) Missing observations are not included in percentage calculations. Where variables are categorical, missing values are 
listed in a separate row, but are similarly not included in percentage calculations 
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Adverse events 1 
There were 453 adverse events reported in total across both groups, with 191 participants 2 
experiencing 220 adverse events in total in the control group and 199 participants 3 
experiencing a total of 233 adverse events in the cell salvage group. There was no significant 4 
difference between allocation groups for experiencing an adverse event (adjusted OR 1.02, 5 
95% CI 0.81 to 1.29, p=0.84, see Table 5). See Table 12 for details and descriptions of 6 
adverse events. One case of transfusion reaction associated with allogeneic donor blood was 7 
observed in the control group. There was no case of amniotic fluid embolism observed, with 8 
or without use of leukocyte depletion filter. 9 
Table 12 Detail of Adverse Event 
  Control (n=1492) Cell Salvage (n=1498) 
Any Adverse Event Experienced 191 (12.8%) [0] 199 (13.3%) [1] 
   
Total Adverse Events 220 233 
   
Breakdowns Per Adverse Event (n=453)     
Adverse Event Severity   
Mild 89 (40.5%) 101 (43.3%) 
Moderate 88 (40.0%) 92 (39.5%) 
Severe 34 (15.4%) 35 (15.0%) 
Life threatening 9 (4.1%) 4 (1.7%) 
Fatal 0 (0.0%) 1 (0.4%) 
   
Adverse Event Relatedness To Intervention (If Cell 
Salvage Set Up (Including Emergency Use) (n=238))     
Unrelated 8 (57.1%) 160 (71.4%) 
Unlikely 5 (35.7%) 47 (21.0%) 
Possible(a) 1 (7.1%) 14 (6.3%) 
Probable(a) 0 (0.0%) 2 (0.9%) 
Definite(a) 0 (0.0%) 1 (0.4%) 
      
Is the Adverse Event Serious(b) 20 (9.1%) 15 (6.4%) 
      
Adverse Event Descriptions(c) by System Organ Class   
      
Blood and lymphatic system disorders     
Thrombocytopaenia 0 (0.0%) 3 (1.3%) 
Anaemia 2 (0.9%) 6 (2.6%) 
Cardiac disorders     
Sinus tachycardia 0 (0.0%) 5 (2.2%) 
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  Control (n=1492) Cell Salvage (n=1498) 
Hypotension 2 (0.9%) 2 (0.9%) 
Supraventricular tachycardia 1 (0.5%) 1 (0.4%) 
Gastrointestinal disorders     
Diarrhoea 0 (0.0%) 1 (0.4%) 
Ileus 4 (1.8%) 3 (1.3%) 
Incontinence 0 (0.0%) 1 (0.4%) 
General disorders and administration site 
conditions     
Pain 4 (1.8%) 3 (1.3%) 
Non-cardiac chest pain 1 (0.5%) 0 (0.0%) 
Immune system disorders     
Reaction to cell salvaged blood 0 (0.0%) 5 (2.2%) 
Reaction to donor blood 1 (0.5%) 0 (0.0%) 
Allergic reaction 1 (0.5%) 0 (0.0%) 
Infections and infestations     
Lung infection 2 (0.9%) 0 (0.0%) 
Wound infection 5 (2.3%) 6 (2.6%) 
Uterine infection 1 (0.5%) 2 (0.9%) 
Sepsis 11 (5.0%) 11 (4.7%) 
Unknown source 12 (5.5%) 21 (9.0%) 
Injury, poisoning and procedural complications     
Wound dehiscence 1 (0.5%) 2 (0.9%) 
Metabolism and nutrition disorders     
Hyperglycaemia 0 (0.0%) 1 (0.4%) 
Musculoskeletal and connective tissue disorders     
Pain in extremity 0 (0.0%) 2 (0.9%) 
Back pain 1 (0.5%) 0 (0.0%) 
Nervous system disorders     
Presyncope 2 (0.9%) 3 (1.3%) 
Seizure 2 (0.9%) 1 (0.4%) 
Limb weakness 0 (0.0%) 1 (0.4%) 
Pregnancy, puerperium and perinatal conditions - 
Other     
Hypertensive disease of pregnancy 32 (14.6%) 34 (14.6%) 
Uterine atony 1 (0.5%) 0 (0.0%) 
Placental abnormality 2 (0.9%) 1 (0.4%) 
Maternal exposure to fetal blood 1 (0.5%) 0 (0.0%) 
Renal and urinary disorders     
Urinary retention 3 (1.4%) 2 (0.9%) 
Oliguria 3 (1.4%) 0 (0.0%) 
Chronic kidney disease 0 (0.0%) 1 (0.4%) 
Prolonged catheterisation 1 (0.5%) 3 (1.3%) 
Proteinuria 1 (0.5%) 1 (0.4%) 
Hematuria 1 (0.5%) 1 (0.4%) 
Reproductive system and breast disorders     
Fibroids 1 (0.5%) 0 (0.0%) 
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  Control (n=1492) Cell Salvage (n=1498) 
Uterine haemorrhage 106 (48.4%) 93 (39.9%) 
Respiratory, thoracic and mediastinal disorders     
Cough 0 (0.0%) 1 (0.4%) 
Dyspnea 1 (0.5%) 0 (0.0%) 
Hypoxia 1 (0.5%) 1 (0.4%) 
Pulmonary edema 0 (0.0%) 1 (0.4%) 
Sleep apnea 1 (0.5%) 0 (0.0%) 
Skin and subcutaneous tissue disorders     
Pruritus 0 (0.0%) 1 (0.4%) 
Surgical and medical procedures - Other     
Anaesthetic complication 3 (1.4%) 1 (0.4%) 
Surgical complication 5 (2.3%) 2 (0.9%) 
Wound haematoma 1 (0.5%) 5 (2.2%) 
Vascular disorders     
Venous eczema 0 (0.0%) 1 (0.4%) 
Hypertension 1 (0.5%) 3 (1.3%) 
Thromboembolic event 1 (0.5%) 1 (0.4%) 
Missing(d) 1 0 
   
Data presented are n (%) [n missing]   
(a) For further detail see Table 13 
(b) For further detail see Table 14 
(c) Descriptions are coded by the trial team 
(d) Missing observations are not included in percentage calculations. Where variables are categorical, missing values are listed in a 
separate row, but are similarly not included in percentage calculations 
 
In 18 cases adverse events were considered to be related to cell salvage, with 15 events 1 
possibly related, 2 events probably related and 1 event definitely related to the intervention. 2 
See Table 13 for details of related adverse events. Of the 18 adverse events classed as related 3 
to cell salvage, the majority (n=16) were also in the context of the use of a leukocyte 4 
depletion filter. These included transient episodes of hypotension which might have been 5 
related to the return of cell salvaged blood, as well as haemorrhagic and infective 6 
complications; as cell salvage removes clotting factors and platelets, it can theoretically lead 7 
to coagulopathy unless coagulation products are simultaneously given, and there is also a 8 
potential risk of returning infective agents such as bacteria in the salvaged blood. The 9 
ultimate judgement on whether these complications might have been caused by cell salvage 10 
lay with the local principal investigator.11 
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Table 13 Further Detail for Events Potentially Related to Cell Salvage 
Adverse Event Relatedness to 
Intervention  Allocation   System Organ Class of Adverse Event Adverse Event Description 
Possible   Control Reproductive system and breast disorders   Uterine haemorrhage   
Possible   Cell Salvage   Cardiac disorders   Hypotension   
Possible   Cell Salvage   Immune system disorders   Reaction to cell salvaged blood   
Possible   Cell Salvage   Immune system disorders   Reaction to cell salvaged blood   
Possible   Cell Salvage   Infections and infestations   Sepsis   
Possible   Cell Salvage   Infections and infestations   Unknown source   
Possible   Cell Salvage   Infections and infestations   Unknown source   
Possible   Cell Salvage   Infections and infestations   Unknown source   
Possible   Cell Salvage   Infections and infestations   Unknown source   
Possible   Cell Salvage   Infections and infestations   Unknown source   
Possible   Cell Salvage   Infections and infestations   Unknown source   
Possible   Cell Salvage   Reproductive system and breast disorders   Uterine haemorrhage   
Possible   Cell Salvage   Reproductive system and breast disorders   Uterine haemorrhage   
Possible   Cell Salvage   Surgical and medical procedures - Other   Wound haematoma   
Possible   Cell Salvage   Infections and infestations   Wound infection   
Probable   Cell Salvage   Immune system disorders   Reaction to cell salvaged blood   
Probable   Cell Salvage   Immune system disorders   Reaction to cell salvaged blood   
Definite   Cell Salvage   Immune system disorders   Reaction to cell salvaged blood   
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There were 36 Serious Adverse Events (SAEs) reported during the SALVO trial. Of these, 32 1 
are included in the adverse event table (Table 14), with one SAE having 3 adverse events 2 
pertaining to it. There were 4 additional serious adverse events concerning the offspring (such 3 
as congenital anomalies), which did not require reporting for the main adverse event analysis. 4 
One fatal event was observed among trial participants. It was considered unrelated to the 5 
intervention. This maternal death occurred in a patient who died on the sixth day following 6 
her delivery. 7 
Two serious adverse reactions were reported in this trial, i.e. SAEs which were considered 8 
related to the intervention. The first was reported as a reaction to salvaged blood. The patient 9 
became tachycardic, flushed and had difficulty breathing, starting shortly after the start of the 10 
re-transfusion and resolving completely once the transfusion was stopped. The event was 11 
classed by the local investigator as life-threatening, and as most likely due to the use of a 12 
leukocyte depletion filter. The second event was a sudden onset of hypotension, after re-13 
transfusion of 600ml of cell salvaged blood; the patient recovered fully. The event was also 14 
reported as life-threatening, and as most likely secondary to the use of a leukocyte depletion 15 
filter.16 
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Table 14 Further Detail for Serious Adverse Events 
Description(a) of Serious Adverse Event Allocation Reason for Seriousness Serious Adverse Event Relatedness to Intervention 
Bladder damage during surgery(b) Control Hospitalisation > 7 days Unrelated 
Concealed obstetric haemorrhage Control Life-threatening Unrelated 
HELLP Syndrome Control Other Unrelated 
Infection of unknown origin Control Hospitalisation > 7 days Unrelated 
Massive obstetric haemorrhage Control Life-threatening Unrelated 
Massive obstetric haemorrhage Control Life-threatening Unlikely 
Massive obstetric haemorrhage Control Life-threatening Unrelated 
Massive obstetric haemorrhage Control Life-threatening Unrelated 
Massive obstetric haemorrhage Control Life-threatening Unrelated 
Massive obstetric haemorrhage Control Life-threatening Unrelated 
Massive obstetric haemorrhage Control Life-threatening Unrelated 
Pneumonia Control Hospitalisation > 7 days Unrelated 
Pre-eclampsia Control Hospitalisation > 7 days Unrelated 
Pre-eclampsia Control Hospitalisation > 7 days Unrelated 
Pulmonary embolism and obstetric haemorrhage Control Life-threatening Unrelated 
Sepsis Control Hospitalisation > 7 days Unrelated 
Vertebral disc prolapse Control Disability/incapacity Unlikely 
Wound complication Control Hospitalisation > 7 days Unrelated 
Bowel obstruction, caecal gangrene Cell Salvage Hospitalisation > 7 days Unrelated 
Bowel perforation, sepsis, multi-organ failure Cell Salvage Fatal Unrelated 
Fetal congenital abnormality(c) Cell Salvage Congenital abnormality / birth defect Unrelated 
Fetal congenital abnormality(c) Cell Salvage Congenital abnormality / birth defect Unrelated 
Fetal epidermolysis bullosa(c) Cell Salvage Congenital abnormality / birth defect Unrelated 
Hypertension Cell Salvage Hospitalisation > 7 days Unrelated 
Massive obstetric haemorrhage Cell Salvage Life-threatening Unlikely 
Massive obstetric haemorrhage Cell Salvage Life-threatening Unrelated 
Palpitations and shortness of breath. Post-partum 
echocardiogram suggested mild left ventricular systolic 
dysfunction 
Cell Salvage Hospitalisation > 7 days Unlikely 
Pre-eclampsia Cell Salvage Hospitalisation > 7 days Unrelated 
Pre-eclampsia Cell Salvage Hospitalisation > 7 days Unrelated 
Pre-existing atrial fibrillation and wound complication Cell Salvage Hospitalisation > 7 days Unrelated 
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Description(a) of Serious Adverse Event Allocation Reason for Seriousness Serious Adverse Event Relatedness to Intervention 
Reaction to salvaged blood or leukocyte depletion filter 
(hypotension) Cell Salvage Life-threatening Probably 
Reaction to salvaged blood or leukocyte depletion filter 
(tachycardia, dyspnoea) Cell Salvage Life-threatening Definitely 
Sepsis Cell Salvage Hospitalisation > 7 days Unlikely 
Sepsis Cell Salvage Hospitalisation > 7 days Unlikely 
Stillbirth(c) Cell Salvage Congenital abnormality / birth defect Unrelated 
Wound complication Cell Salvage Hospitalisation > 7 days Unrelated 
Wound complication Cell Salvage Hospitalisation > 7 days Unrelated 
    
(a) Descriptions are coded by the trial team 
(b) Participant had 3 adverse events which were ticked as serious, all falling under the serious adverse event described 
(c) Serious adverse events not included in Error! Reference source not found. as they concern the baby, not the mother 
Page 68 of 132 
Further exploratory analyses 1 
There was no significant difference in the effectiveness of cell salvage on secondary 2 
outcomes between elective and emergency caesarean section (Table 15), or in the effect of 3 
cell salvage on reducing donor blood transfusion between participants with normal and 4 
abnormal placentation (p-value for interaction term=0.28, Table 16).  5 
In a sensitivity analysis assuming that a donor blood transfusion would have been required, 6 
had salvaged blood not been returned in the control when the cell salvage machine was set up 7 
in an emergency (n=8), the effect of cell salvage on donor blood transfusion was significant 8 
(4.0% vs. 2.5%, adjusted OR 0.56, 95% CI 0.36 to 0.86, p=0.008, Table 17). 9 
We observed that swab washing greatly increased the proportion of participants who received 10 
salvaged blood (16.0% when swabs were not washed vs. 81.3% when swabs were washed) 11 
and that the volume of blood returned was higher when swabs were washed (mean (sd) = 12 
32.8 (100.5) when swabs were not washed vs. 219.3 (169.8) when swabs were washed) 13 
(Table 18). In a comparison between participants who did and did not have swabs washed 14 
within those who had the cell salvage machine set up, no significant difference in the 15 
transfusion rates was observed  (adjusted OR 0.79, 95% CI 0.39 to 1.57, p=0.50, Table 19). 16 
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Table 15  Analysis of Secondary Outcomes: Further Exploratory Subgroup Analysis 
   Elective caesarean section (n=1349) Emergency caesarean section (n=1641)   
    Control  (n=684) 
Cell Salvage 
(n=665) 
Adjusted(a) 
Intervention Odds 
Ratio / Mean 
Difference / Hazard 
Ratio (95% CI) 
Control 
 (n=808) 
Cell Salvage 
(n=833) 
Adjusted 
Intervention 
Odds Ratio / 
Mean Difference 
/ Hazard Ratio 
(95% CI) 
P Value For 
Interaction 
Term 
Units of Blood 
Transfused(b) mean (sd) 3.33 (2.53) 2.92 (2.35) -0.20 (-1.42, 1.02) 2.38 (1.06) 2.60 (1.32) -0.08 (-0.92, 0.77) 0.87 
Time to 
Mobilisation 
(days)(c) 
median (IQR) [n 
missing] 0.79 (0.43) [30] 0.79 (0.46) [29] 1.03 (0.92, 1.15) 0.69 (0.45) [19] 0.66 (0.43) [32] 1.18 (1.07, 1.30) 0.083 
Length of 
Hospital Stay 
(days)(c) 
median (IQR) [n 
missing] 2.10 (1.21) [19] 2.08 (1.00) [10] 1.06 (0.95, 1.18) 2.20 (1.81) [5] 2.18 (1.49) [2] 1.09 (0.99, 1.20) 0.70 
Postoperative 
Haemoglobin 
Level (g/l)(d) 
mean (sd) [n 
missing] 104.28 (11.19) [17] 106.18 (12.05) [25] 1.19 (0.12, 2.25) 102.03 (12.78) [30] 101.91 (12.03) [36] 0.17 (-0.80, 1.14) 0.17 
Fall in 
Haemoglobin 
Level (g/l)(e) 
mean (sd) [n 
missing] 12.37 (9.41) [21] 11.66 (9.92) [27] -1.18 (-2.24, -0.11) 17.32 (12.17) [44] 16.86 (11.53) [45] -0.26 (-1.23, 0.72) 0.21 
Any Adverse 
Event 
Experienced 
n (%) [n 
missing(5)] 48 (7.0) [0] 48 (7.2) [0] 1.08 (0.70, 1.66) 143 (17.7) [0] 151 (18.1) [1] 1.00 (0.77, 1.31) 0.78 
Fetomaternal 
haemorrhage(f) 
n (%) [n 
missing] 4 (10.3) [13] 9 (26.5) [17] 9.71 (1.11, 85.11) 5 (10.6) [20] 12 (25.0) [34] 4.08 (0.81, 20.51) 0.51 
*Analysis of Transfusion Reaction Associated with Allogeneic Donor Blood omitted due to observing only one event (Control group) 
CI: Confidence Interval; sd: Standard Deviation; IQR: Inter-quartile Range 
(a) Adjusted for stratification factors (elective vs. emergency caesarean section, presence of abnormal placentation, singleton vs. twins or multiple births, recruitment centre (as a random effect)) and other factors 
believed to be prognostic a-priori (known placenta praevia, pre-eclampsia) 
(b) Analysis within the subgroup of participants who received donor blood 
(c) Taken from time of delivery 
(d) Adjusted analysis also adjusts for pre-operative measurement, as well as time postoperative measurement was taken after delivery (log transformed), with mean imputation of missing values for both covariates. 
Please note that the decision to adjust for the latter was made by blinded members of the trial team after the signing off of the Statistical Analysis Plan 
(e) Missing observations are not included in percentage calculations 
(f) Measured by Kleihauer test and dichotomised into a result of <2 vs. ≥2ml. Analysis within the subgroup of participants who had a Kleihauer test 
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Table 16 Analysis of Primary Outcome: Further Exploratory Subgroup Analysis; placentation 
    Normal Placentation (n=2720) Abnormal Placentation (n=270)   
    Control (n=1357) 
Cell Salvage 
(n=1363) 
Adjusted(a) 
Intervention Odds 
Ratio (95% CI) 
Control 
(n=135) 
Cell Salvage 
(n=135) 
Adjusted 
Intervention Odds 
Ratio (95% CI) 
P Value For 
Interaction 
Term 
Donor Blood 
Transfusion  40 (2.9%) 24 (1.8%) 0.56 (0.34, 0.94) 12 (8.9%) 13 (9.6%) 0.98 (0.42, 2.32) 0.28 
         
CI: Confidence Interval 
(a) Adjusted for stratification factors (elective vs. emergency caesarean section, presence of abnormal placentation, singleton vs. twins or multiple births, recruitment centre 
(as a random effect)) and other factors believed to be prognostic a-priori (known placenta praevia, pre-eclampsia) 
 
Table 17  Analysis of Primary Outcome: Further Exploratory Sensitivity Analysis 
    Control (n=1492) 
Cell Salvage 
(n=1498) 
Crude Risk 
Difference % 
(95% CI) 
Crude 
Intervention 
Odds Ratio 
(95% CI) 
P Value - 
Crude 
Analysis 
Adjusted(a) 
Intervention 
Odds Ratio 
(95% CI) 
P Value - 
Adjusted 
Analysis 
Donor Blood Transfusion: 
Sensitivity Analysis 3(b) n (%)  60 (4.0%) 37 (2.5%) -1.6 (-2.8, -0.3) 0.60 (0.40, 0.92) 0.018 0.56 (0.36, 0.86) 0.008 
         
CI: Confidence Interval 
(a) Adjusted for stratification factors (elective vs. emergency caesarean section, presence of abnormal placentation, singleton vs. twins or multiple births, recruitment centre (as a random 
effect)) and other factors believed to be prognostic a-priori (known placenta praevia, pre-eclampsia) 
(b) Assuming all instances of blood returned using cell salvage set up in an emergency in the control group would have been transfusions had the cell salvage machine not been present 
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Table 18 Summaries Specific to Swab Washing 
    Swabs Not Washed (n=681) Swabs Washed (n=802) 
Salvaged Blood Returned n (%) [n missing(a)] 109 (16.0%) [1] 651 (81.3%) [1] 
    
Volume of Blood Returned to 
Mother (ml) mean (sd) 32.8 (100.5) 219.3 (169.8) 
    
sd: Standard Deviation 
(a) Missing observations are not included in percentage calculations 
 
Table 19  Analysis of Primary Outcome: Further Exploratory Analysis by Swab Washing 
    
Swabs Not 
Washed 
(n=681) 
Swabs Washed 
(n=802) 
Crude Odds Ratio 
(95% CI) 
P Value - 
Crude 
Analysis 
Adjusted(a) Odds 
Ratio (95% CI) 
P Value - 
Adjusted 
Analysis 
Donor Blood Transfusion(b) n (%) 18 (2.6%) 18 (2.2%) 0.85 (0.44, 1.64) 0.62 0.79 (0.39, 1.57) 0.50 
        
CI: Confidence Interval 
(a) Adjusted for stratification factors (elective vs. emergency caesarean section, presence of abnormal placentation, singleton vs. twins or multiple births, recruitment centre (as a 
random effect)) and other factors believed to be prognostic a-priori (known placenta praevia, pre-eclampsia) 
(b) Analysis within participants who had the cell salvage machine set up (including Emergency use), for those with complete swab washing data 
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Chapter 4 Health Economic Evaluation 1 
Introduction 2 
This chapter reports the economic evaluation carried out alongside the SALVO trial. The 3 
primary objective of the study was to determine whether the routine use of cell salvage 4 
during caesarean section, in women at risk of haemorrhage, reduced the need for donor blood 5 
transfusion compared to standard care.  6 
Methods 7 
To compare the costs and outcomes of cell salvage and standard care in the SALVO trial, a 8 
decision analytic model was deemed the most suitable method of presenting the alternative 9 
pathways and collating the data for analysis and sensitivity analysis. In a decision analytic 10 
model, consequences are expressed as probabilities, weighted against costs and outcomes to 11 
derive an expected value for each alternative option.70 The economic evaluation took the 12 
form of a cost-effectiveness analysis (CEA) from the perspective of the healthcare provider 13 
based on the principal clinical outcome of the trial. The main comparison is the use of cell 14 
salvage versus standard care. The results are reported in terms of the additional cost per donor 15 
blood transfusion avoided by using cell salvage compared to standard care. Standard care is 16 
defined for the purposes of the trial as “transfusion of donor blood according to standard local 17 
guidelines”. Costs were calculated in 2014-2015 UK pounds (£). Given the objectives of the 18 
trial and the duration of follow-up, only a within trial economic analysis was carried out and 19 
outcomes beyond this point were not considered relevant. 20 
Model Structure 21 
A decision tree model was developed in TreeAge Pro 2016 (TreeAge Software, Inc., 22 
Williamstown, MA, USA). The structure was informed by the objectives of the study and the 23 
pathways indicated by the clinical data. The model pathways (Figure 3) represent that of the 24 
trial in which patients undergoing a caesarean section were randomised to receive either cell 25 
salvage or standard care. Square boxes represent decision nodes, where there is a choice to be 26 
made between strategies. Circles represent chance nodes, where there are a number of 27 
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subsequent events that could happen and each event is assigned a probability that it will 1 
occur. Triangles represent terminal nodes, signifying the last stage in the model.  2 
Figure 3 Decision tree structure 3 
 
Figure 3 shows the model starts with the choice of transfusion strategies considered in the 4 
SALVO trial:  5 
• Cell salvage 6 
• Standard care 7 
 8 
Women allocated to either transfusion strategy have a possibility of receiving the treatment to 9 
which they were allocated or not.  In both pathways, if the cell salvage machine was switched 10 
on, women have a possibility of receiving cell salvage, either on its own or in combination 11 
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with donor blood transfusion. There is also a possibility that the woman may not require a 1 
transfusion.  2 
The pathways of the model represent, as far as possible, the clinical procedures carried out in 3 
the study. The model combines the probability of a woman following a particular path and 4 
the associated costs. Probabilities, detailed in Table 20, were obtained from the trial and 5 
attached to each pathway. The cost and outcome measures that were incorporated into the 6 
model were collected prospectively during the SALVO trial using forms filled out at the pre-, 7 
intra-, and postoperative phase and at the time of discharge from hospital. Intraoperative 8 
resource use and costs were estimated as the mean cost per caesarean section procedure 9 
conducted for each treatment pathway in the model and postoperative resource use and costs 10 
were estimated as the mean cost per patient in both treatment strategies represented in the 11 
model. 12 
Table 20  Probabilities used in the model 13 
 Trial data Probability Distribution 
Cell salvage intended    
Cell salvage intended → allocated treatment received (machine was on) 1432 / 1498 0.96 Beta 
Allocated treatment received → salvaged blood returned 726/1432 0.51 Beta 
Allocated treatment received → salvaged blood not returned 703/1432 0.49 Beta 
Salvaged blood returned → donor blood transfusion given 22/726 0.03 Beta 
Salvaged blood returned → donor blood transfusion not given 704 /726 0.97 Beta 
Salvaged blood not returned → donor blood transfusion given 9/703 0.01 Beta 
Salvaged blood not returned → donor blood transfusion not given 697 / 703 0.99 Beta 
Cell salvage intended → allocated treatment not received (machine was off) 66/1498 0.04 Beta 
Allocated treatment not received → donor blood transfusion given 6/66 0.09 Beta 
Allocated treatment not received → donor blood transfusion not given 60/66 0.91 Beta 
 
Standard care intended 
   
Standard care intended → allocated treatment received (machine was off) 1434/1492 0.96 Beta 
Allocated treatment received → donor blood transfusion given 47/1434 0.03 Beta 
Allocated treatment received → donor blood transfusion not given 1387 / 1434 0.97 Beta 
Standard care intended → allocated treatment not received (machine was 
on) 
58/1492 0.04 Beta 
Allocated treatment not received → salvaged blood returned 35/58 0.60 Beta 
Allocated treatment not received → salvaged blood not returned 23/58 0.40 Beta 
Salvaged blood returned → donor blood transfusion given 4/35 0.11 Beta 
Salvaged blood returned → donor blood transfusion not given 31/35 0.89 Beta 
Salvaged blood not returned → donor blood transfusion given 1/23 0.04 Beta 
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Salvaged blood not returned → donor blood transfusion not given 22/23 0.96 Beta 
 
Data 1 
Resource use and costs 2 
The resource use for both groups of the trial was estimated by evaluating the individual 3 
components of these procedures (bottom-up costing). Unit cost data was then attached to the 4 
resource use.  Data were collected on all major NHS resource use for each patient using the 5 
trial case report forms. The main resource use monitored included: 6 
Intraoperative: 7 
• Equipment and disposables required for the cell salvage procedure 8 
• Additional staff called into theatre solely for the purposes of cell salvage 9 
• Drugs used in the caesarean section procedure 10 
• The use of donor blood transfusion to deal with haemorrhage and its consequences 11 
• The use of salvaged blood transfusion to deal with haemorrhage and its consequences 12 
Postoperative: 13 
• Length and type of hospital inpatient stay including additional treatment required 14 
attributed to the caesarean section procedure. 15 
• The use of donor blood transfusion to deal with haemorrhage and its consequences 16 
Intraoperative resource use and costs 17 
For the analysis intraoperative resource use data were obtained from the SALVO trial. Costs 18 
were estimated for each item to arrive at a mean cost per caesarean section procedure 19 
conducted for each treatment pathway in the model. To estimate the cost of a caesarean 20 
section procedure some costs were calculated at the patient level (e.g. swab washing) and 21 
some at the procedural level (e.g. drugs used in the caesarean section procedure). This is 22 
outlined in Table 21Error! Reference source not found. and further detail is provided 23 
below.24 
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Table 21 Intraoperative resource use and costs per procedure 1 
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1 
Item Resource Use Unit Cost Mean cost per procedure Assumption / Working Source 
 Cell salvage 
(n=1498) 
Control 
(n=1492) 
 Cell salvage  
(n-=1498) 
Control 
(n=1492) 
  
Running 
costs 
1432 58 £6.14 £6.14 £6.14 Based on annual maintenance costs for Haemonetics 
Cell Saver 5 machine and estimated annual usage 
UHB, personal communication (Aug 2016) 
NICE costing statement blood transfusion 
(Nov2015)11  
Collection 
Set 
1 1 £41.71 £41.71 £41.71 Based on the assumption that one collection set is used 
per procedure 
NHS Supply Chain Catalogue (accessed Aug 2016): 
Autotransfusion reservoir 3 litre71 
Processing 
Pack 
1 1 £77 £77 £77 Based on the assumption that one processing pack is 
used per procedure 
NHS Supply Chain Catalogue (accessed August 2016): 
Intraoperative autologous blood system cell saver 5+ 
bowl set 125ml71 
Leukocyte 
depletion 
filter 
782 25 n/a n/a n/a Cost not included in the analysis as leukocyte depletion 
filter included in the collection set for Haemonetics Cell 
Saver 5 machine 
NHS Supply Chain Catalogue (accessed August 2016): 
Autotransfusion reservoir 3 litre71 
Additional 
sucker 
598 29 £15.41 £6.43 £7.70 Mean cost based on the number of additional suckers 
used in each treatment group / total number of patients 
who received cell salvage 
NHS Supply Chain Catalogue (accessed August 2016): 
Aspiration & anticoagulation line Cell Saver. 
£308.02 for 2071 
Swab 
washing 
781 21 £0.80 £0.44 £0.29 Mean cost based on the number of times swabs were 
washed in each treatment group / total number of 
patients who received cell salvage 
ICS Factsheet 1 Swab Washing March 2015,72 based 
on the cost of 1L of sodium chloride 0.9%, BNF73 
Staff   £0.72 
(min) 
£11.57 £12.03 Based on the staff type most frequently called into 
theatre.  
Unit cost for hospital based nurse, band 5, PSSRU 
unit costs 2015 (costs include qualifications)74  
Saline 
(litres) 
2 2 £0.80 £1.60 £1.60 Based on the assumption that 2 litres of saline would be 
administered to all patients undergoing cell salvage prior 
to collection11 
Based on the cost of 1L of sodium chloride 0.9%, 
BNF73 
Heparin 
sodium 
(30,000 IU) 
2 2 £10.60 £21.20 £21.20 Based on the assumption that 60,000 iu heparin would 
be administered to all patients undergoing cell salvage 
prior to collection11 
Based on the cost of 1ml amp of heparin sodium 
25,000 iu/ml and 1ml amp of heparin sodium 5,000 
iu/ml, BNF73 
Anti-D  
(500 IU) 
1 1 £33.75 £3.04 £3.04 Based on the assumption that all D negative women 
delivering a D positive baby receive at least 500 IU of 
anti-D.33 Mean cost per procedure based on the 
probability of a woman requiring anti-D in each 
treatment group (0.09) 
Based on the cost of 500-unit vial of anti-D 
immunoglobulin, BNF73 
Anti-D 
(1500 IU) 
1 1 £58 £5.22 £5.22 Based on the assumption that women who receive cell 
salvage are offered 1500 IU of anti-D.33 Mean cost per 
procedure based on the probability of a woman 
requiring anti-D in each treatment group (0.09) 
Based on the cost of 1,500-unit vial of anti-D 
immunoglobulin, BNF73 
 
RBC 
transfusion  
(units) 
3 3 First unit: 
£194 
Subsequent 
units: 
£166 
£520 £520 Based on the assumption that all units transfused in 
each treatment group were RBC11 
NICE costing statement for blood transfusion 
(November 2015).11 Unit cost for RBC obtained from 
NHSBT 2016/1775 
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Equipment and disposables required for the cell salvage procedure 1 
Many centres reported that their cell salvage machines were obtained on lease and as such 2 
only the running costs and cost of consumables would be incurred. Therefore the acquisition 3 
costs for a cell salvage machine were not included in the analysis but the addition of this cost 4 
was explored in a sensitivity analysis. The costs of materials used by participating centres 5 
varied. The acquisition cost and annual maintenance cost for a Haemonetics® Cell Saver® 5 6 
machine was obtained from one centre. Costs for consumables were sourced from the NHS 7 
Supply Chain Catalogue (August 2016)71 and correspond to the consumables used with this 8 
machine. The annual number of procedures that would use the cell salvage machine was 9 
based on the NICE costing statement for blood transfusion published in November 2015.11  10 
The Haemonetics Cell Saver 5 machine uses two separate kits of consumables for collection 11 
and re-infusion. In the SALVO trial, some centres (n=202 participants treated; see Table 11) 12 
used a continuous-transfusion cell saver machine that required the use of different 13 
consumables. However, for this analysis it was assumed that each centre used one set of 14 
consumables for collection and reinfusion. This was tested in a sensitivity analysis. The cost 15 
of a collection set and processing pack (used for reinfusion) with a 125ml bowl for a 16 
Haemonetics Cell Saver 5 machine was obtained from the NHS Supply Chain Catalogue 17 
(August 2016).71  For some cell salvage procedures in the study (n=807), a leukocyte 18 
depletion filter was used, while this was not used for the remaining procedures. As this item 19 
is included in the collection set, no additional cost was incurred. Contained in the processing 20 
pack is one aspiration and anticoagulation line (sucker). For some caesarean section 21 
procedures in the study (n=627), an additional sucker was used and this additional cost was 22 
apportioned across all caesarean section procedures where cell salvage was conducted. The 23 
cost of an additional sucker was obtained from the NHS Supply Chain Catalogue (August 24 
2016)71   and the total cost based on usage was divided by the number of patients in each 25 
group of the trial that set up the cell saver machine to arrive at a mean cost of the procedure 26 
per patient in each group.  27 
Blood loss can also be removed from the operative site by swabs. By washing swabs, the 28 
blood that is normally discarded can be collected and the overall efficiency of red cell 29 
recovery improved.58 Swab washing occurred in 802 procedures in the SALVO trial, 781 30 
procedures in the cell salvage group and 21 procedures in the control group. The UK Cell 31 
Salvage Action Group recommends that swabs are washed in one litre of saline.72 The cost of 32 
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saline (0.9% Sodium Chloride) was obtained from the British National Formulary.73 The total 1 
cost of swab washing in each group of the trial was apportioned by the number of patients 2 
who received cell salvage in that group of the trial.  3 
Additional staff called into theatre solely for the purposes of cell salvage 4 
The amount of time additional staff, called into theatre solely for the purposes of cell salvage, 5 
spent in the operating theatre was recorded in the SALVO trial. Staff grade was identified at a 6 
broad level (Nurse, ODP, and Doctor) and job band distinction was not recorded, though it 7 
was frequently included in the notes if a midwife was called into theatre. The analysis is 8 
based on the staff type most frequently called into theatre (ODP in both groups) and assumed 9 
the lowest possible cost within this job grade (Hospital based nurse, band 5). Staff unit costs 10 
were obtained from the PSSRU unit costs (2015).74 The total cost of additional staff required 11 
for cell salvage was distributed by the number of times the cell salvage machine was set up in 12 
both groups of the trial. 13 
Drugs used in the caesarean section procedure 14 
Typically saline and an anticoagulant (for example heparin) would be used for people 15 
undergoing cell salvage. The saline is required for collection of the blood (separate to saline 16 
used for swab washing) and the heparin to stop the collected blood clotting.11 It was assumed, 17 
as per the NICE costing statement, that 2 litres of saline and 60,000 IU heparin (30,000 IU 18 
per litre of saline) would be used for collection in any caesarean section procedure where the 19 
cell salvage machine was turned on. The cost of saline (0.9% Sodium Chloride) and heparin 20 
were obtained from the British National Formulary.73 These costs were added to the average 21 
cost of the cell salvage procedure. 22 
Guidelines suggest that all D-negative unsensitised women delivering a RhD-positive baby 23 
should be routinely offered a standard dose of anti-D immunoglobulin (at least 500 IU) as 24 
prophylaxis, to minimise this risk of sensitisation, and all women who receive cell salvage 25 
should be offered a higher dose (1,500 IU).33 The probability of a woman requiring 26 
administration of anti-D i.e. a rhesus D-negative mother with rhesus D-positive baby was 27 
0.09 in both groups of the SALVO trial. The cost of anti-D (RH0) immunoglobulin was 28 
obtained from the British National Formulary73 and the total cost based on usage was divided 29 
by the number of women in each arm of the model to arrive at a mean cost per patient in each 30 
treatment pathway.  31 
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 Donor blood transfusion 1 
The cost of donor blood transfusion used in the model was based on the costing methodology 2 
employed by NICE in which the resource use and costs for both blood bank and ward 3 
procedures were split to reflect the cost of transfusing the first unit and the cost of transfusing 4 
subsequent units.11 For simplicity, the cost of transfusion of red blood cells (RBC) is used in 5 
the model. RBC made up the largest proportion of the blood products transfused in the 6 
SALVO trial. Adjusting the cost of transfusion to reflect the different proportions of different 7 
blood products transfused is complex and unlikely to result in a significant cost difference. 8 
This approach is supported by NICE.11  The unit cost of RBC was taken from NHS Blood 9 
and Transfusion list price for 2016/2017.75 The mean number of units transfused per patient 10 
in each group of the trial was obtained and rounded up to represent the fact that any 11 
remaining blood in a unit would be disposed. The following approach was taken to calculate 12 
the mean cost: CostTransfusion = CostFirstUnit + CostSubsequentUnits. 13 
All patients in the model required blood grouping and antibody screening, even if they did 14 
not end up requiring a donor blood transfusion. The cost of these procedures was obtained 15 
from the NICE costing statement11 and applied once to people in the model that did not 16 
receive a donor blood transfusion. Note that for those that did receive a donor blood 17 
transfusion this cost is incorporated into the cost of the first unit of blood. 18 
Postoperative resource use and costs 19 
For the analysis, postoperative resource use data were obtained from the SALVO trial. Costs 20 
were estimated for each item based on their occurrence in each branch of the model to arrive 21 
at a mean cost per patient for each branch. This is outlined in Table 22Error! Reference 22 
source not found. and further detail is provided below. 23 
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Table 22  Postoperative resource use and costs 
  
Item Resource Use Unit Cost Mean cost per patient Assumption / Working Source 
 Cell salvage 
(n=1498) 
Control 
(n=1492) 
 Cell salvage  
(n-=1498) 
Control 
(n=1492) 
  
Inpatient stay (normal days) 3,734.5 3,852 £431.45 £1,074 £1,113 
 
See Table 23 and Table 25 NHS reference costs 2014/1576 
Inpatient stay (HLC) 189.5 136 See Table 24 £78 £56 
 
See Table 24 and Table 25 NHS reference costs 2015/1576 
National tariff payment system 
2016/1777 
Adverse events 3 0 n/a n/a n/a 
 
Based on the assumption that 
transfusion would be discontinued in 
the event of an adverse reaction 
BCSH guidelines78 
Hospital transfer 2 2 £99 £0.13 £0.13 
 
n/a PSSRU 201574 
Investigations 6 10 See Table 27 £0.42 £0.70 
 
n/a NHS reference costs 2014/1576 
Additional surgery 11 8 See Table 
28Error! 
Reference 
source not 
found. 
£13 £9 
 
See Table 34 NHS reference costs 2014/1576 
RBC transfusion (units) 3 3 First unit: £190 
Subsequent units: 
£165 
£13 £17 Based on the assumption that all units 
transfused in each treatment group 
were RBC 
NICE costing statement for blood 
transfusion (November 2015).11 Unit 
cost for RBC obtained from NHSBT 
2016/1775 
Total cost of postnatal care per patient £1,178.55 £1,195.83   
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Length and type of hospital inpatient stay 1 
Total time in hospital was recorded for each participant in the SALVO trial (cell salvage 2 
group mean = 2.64 days, standard care group mean = 2.72 days). Within the trial a higher 3 
level of care (HLC) form was completed for 212 patients. This form indicated the number of 4 
days or partial days the patient received level 0, 1, 2 and 3 care. For this study a partial day 5 
was costed as half a full day. Level 0 care is defined in the trial literature as “patients whose 6 
needs can be met through general ward care”. Admission to HLC where level 0 care was 7 
administered was therefore costed as normal care. The total number of days spent receiving 8 
HLC (level 1-3) was deducted from the total time spent in hospital to arrive at the total 9 
number of days in normal care for each group. The weighted average cost per inpatient day 10 
was obtained from NHS reference costs 2014/201576 (Table 23) and was applied to arrive at a 11 
mean cost per patient of normal care.  12 
Table 23  Cost per inpatient day of normal care 
Currency code Currency description Activity National average unit cost 
Elective inpatient excess bed days 
NZ50A Planned Caesarean Section with CC Score 4+ 11 £99.22 
NZ50B Planned Caesarean Section with CC Score 2-3 46 £415.20 
NZ50C Planned Caesarean Section with CC Score 0-1 116 £740.07 
NZ51A Emergency Caesarean Section with CC Score 4+ 12 £358.93 
NZ51B Emergency Caesarean Section with CC Score 2-3 83 £231.87 
NZ51C Emergency Caesarean Section with CC Score 0-1 93 £311.29 
 
Non-elective inpatient excess bed days 
NZ50A Planned Caesarean Section with CC Score 4+ 2,316 £412.57 
NZ50B Planned Caesarean Section with CC Score 2-3 7,670 £438.31 
NZ50C Planned Caesarean Section with CC Score 0-1 6,022 £437.22 
NZ51A Emergency Caesarean Section with CC Score 4+ 2,840 £408.49 
NZ51B Emergency Caesarean Section with CC Score 2-3 5,388 £417.82 
NZ51C Emergency Caesarean Section with CC Score 0-1 9,806 £440.84 
  
Weighted average cost per inpatient day 
  
£431 
 
The cost for a day receiving level 3 care was obtained from the National tariff payment 13 
system 2016/17 – maternity pathway77 which gives costs for a day of intensive care. 14 
Information on the cost per day at level 1 and 2 was not available. For the purposes of this 15 
study it was assumed that level 1 care was 25% more expensive per day than level 0 care and 16 
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level 2 care was 25% more expensive than  level 1 care (Table 24). The following approach 1 
was taken to calculate the mean cost per patient in each arm of the model (Table 25): 2 
CostHLC = (TotalCostLevel1Care + TotalCostLevel2Care + TotalCostLevel3Care)  / 3 
npatients. 4 
Table 24  Level of care 
Level of care Cost per day Assumption/working Source 
0 £431 See Table 23 NHS reference costs 2014/1576 
1 £539 Based on the assumption that level 1 care is 25% 
more expensive than level 0 care 
n/a 
2 £674 Based on the assumption that level 2 care is 25% 
more expensive than level 1 care 
n/a 
3 £848 n/a National tariff payment system 
2016/1777 
Table 25  Inpatient stay resource use and costs 
Item Source / working Cell salvage (n=1498) Control (n=1492) 
Normal days in hospital 
Total days in hospital Trial data 3,924 3,988 
Total days in HLC Trial data (level 1-3) 189.5 136 
Total normal days Total days in hospital less total days 
in HLC 
3,734.5 3,852 
Cost per normal day  See  Table 23 £431 £431 
Total cost for normal days in 
hospital 
Total normal days x cost per day £1,609,354 £1,660,212 
Cost per patient Total cost / n in trial group £1,074 £1,113 
 
HLC days in hospital 
Total days spent at level 1 care Trial data 96.5 67.5 
Cost per day at level 1 care See Table 24 £539 £539 
Total cost per treatment arm Total days x cost per day £52,014 £36,383 
Total days spent at level 2 care Trial data 84.5 67 
Cost per day at level 2 care National tariff payment system 
2016/1777 
£674 £674 
Total cost per treatment arm Total days x cost per day £56,953 £45,158 
Total days spent at level 3 care Trial data 8.5 1.5 
Cost per day at level 3 care National tariff payment system 
2016/1777 
£848 £848 
Total cost per treatment arm Total days x cost per day £7,208 £1,272 
Total cost of HLC per treatment 
arm 
Total cost level 1 + 2 + 3 £116,175 £82,813 
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Cost per patient Total cost / n in trial group £78 £56 
 
Adverse events 1 
Although the occurrence of all adverse events deemed relevant to the procedure were 2 
recorded as a categorical outcome (yes/no), only clinically defined serious adverse events that 3 
occurred within the trial and were deemed relevant to the procedure were considered 4 
potentially relevant to this analysis (n=2). This is based on the assumption that non serious 5 
adverse events deemed relevant to the procedure would have limited or zero resource impact. 6 
The two adverse events considered potentially relevant to this analysis were recorded in the 7 
trial as life-threatening acute transfusion reactions. Guidelines recommend that for life-8 
threatening acute transfusion reactions the correct procedure is to discontinue transfusion.78 9 
Therefore, no additional costs were incurred and the occurrence of adverse events is not 10 
included in this analysis. 11 
Hospital transfer 12 
Costs for hospital transfer were obtained from PSSRU (2015).74 The following approach was 13 
taken to calculate the mean cost per patient in each arm of the model (Table 26): 14 
CostHospitalTransfer = TotalCostHospitalTransfer * ProbabilityHospitalTransfer. 15 
Table 26  Hospital transfer resource use and costs 
Item Source / working Cell salvage 
(n=1498) 
Control 
(n=1492) 
Resource use Trial data 2 2 
Unit cost Based on cost per ambulance service. PSSRU 
201574 
£99 £99 
Total cost Resource use x unit cost £198 £198 
n patients requiring hospital 
transfer 
Trial data 2 2 
Probability of hospital transfer n patients requiring hospital transfer / n in 
trial group 
0.0013 0.0013 
Cost per patient Total cost per patient * probability £0.13 £0.13 
 
Investigations 16 
Data on the number of x-rays, CT scans and MRI scans were recorded in the SALVO trial. 17 
As stated in NHS reference costs 2014/2015, plain film x-rays that are part of an admission or 18 
outpatient attendance are not reported separately due to their high volume and low cost.76 The 19 
occurrence of x-rays is therefore not included in this analysis. Costs for CT scans and MRI 20 
scans were obtained from NHS reference costs 2014/2015.76 The following approach was 21 
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taken to calculate the mean cost per patient in each arm of the model (Table 27): 1 
CostInvestigations = TotalCostInvestigations * ProbabilityInvestigations. 2 
Table 27  Investigations resource use and costs 
 
Additional surgery 3 
24 additional surgeries were recorded in the SALVO trial (Cell salvage group n=15, control 4 
group n=9). The cost for each additional surgery was obtained from NHS reference costs 5 
(2015).76 The cost for time spent in hospital as a result of the additional surgery was 6 
subtracted from the NHS reference cost on the assumption that these costs would have been 7 
incorporated in the cost of hospital inpatient stay. The following approach was taken to 8 
calculate the mean cost per patient in each arm of the model (Table 28Error! Reference 9 
source not found.): CostAdditionalSurgery = TotalCostAdditionalSurgery * 10 
ProbabilityAdditionalSurgery.11 
Item Source / working Cell salvage 
(n=1498) 
Control 
(n=1492) 
CT Scan 
Resource use Trial data 6 9 
Unit cost NHS reference costs 2014/201576 £94 £94 
Total cost Resource use x unit cost £564 £846 
MRI Scan 
Resource use Trial data 0 1 
Unit cost NHS reference costs 2014/201576 n/a £138 
Total cost Resource use x unit cost n/a £138 
    
Total cost investigations Total cost CT + Total cost MRI £564 £984 
n patients requiring investigations Trial data 4 7 
Probability of requiring 
investigations 
n patients requiring investigations / n in trial 
group 
0.003 0.005 
Cost per patient Total cost per patient * probability £0.42 £0.70 
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Table 28 Additional surgeries resource use and costs 
 
 
Item Resource Use Unit Cost Total Cost Source 
 Cell salvage 
(n=1498) 
Control 
(n=1492) 
 Cell salvage  
(n=1498) 
Control 
(n=1492) 
 
Sutures 2 2 £2,991 £5,982 £5,982 NHS reference costs 2014/1576 
Hysterectomy 3 2 £1,621 £4,863 £3,242 NHS reference costs 2014/15. See Table 29Error! 
Reference source not found. 
Laparotomy 3 2 £690 £2,070 £1,380 NHS reference costs 2014/15. See Table 30 
Evacuation 2 2 £1,042 £2,084 £2,084 NHS reference costs 2014/15. See Table 31 
Colon procedure 2 0 £1,088 £2,176 n/a NHS reference costs 2014/15. See Table 32 
Bowel procedure 0 1 £399 n/a £399 NHS reference costs 2014/15. See Table 33 
Drainage 3 0 £690 £2,070 n/a NHS reference costs 2014/15 
Total cost additional surgery    £19,245 £13,087  
n patients requiring additional surgery 11 8     
Probability of requiring additional 
surgery 
0.0073 0.0054     
Cost per patient    £13 £9  
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Table 29 Hysterectomy procedure cost 
 
Table 30  Laparotomy procedure cost 
 
Table 31  Evacuation procedure cost 
 
 
Currency code Currency description Activity National average Average length of stay  
   unit cost elective non-elective 
MAO7E Major open upper genital tract procedures 
with CC score 5+ 
578 £5,909.25 5.37 11 
MAO7F Major open upper genital tract procedures 
with CC score 3-4 
1,780 £4,387.14 3.49 6 
MAO7G Major open upper genital tract procedures 
with CC score 0-2 
24,190 £3,511.27 2.49 3 
MAO8A Major, laparoscopic or endoscopic, upper 
genital tract procedures with CC score 2+ 
3,076 £3,445.44 1.86 3 
MAO8B Major, laparoscopic or endoscopic, upper 
genital tract procedures with CC score 0-1 
16,845 £2,889.92 1.47 2 
Weighted average cost per procedure £3,345    
Average length of stay 4    
Cost per day of care (level 0) £431    
Total cost of hospital stay £1,724    
Average cost per procedure excluding cost of hospital stay £1,621    
Currency code Currency description Activity National average  Average length of stay  
   unit cost elective non-elective 
(ii) Laparotomy procedure cost     
MA10Z Minor, laparoscopic or endoscopic, upper 
genital tract procedures 
17,787 £1,341.48 1.02 2 
Average cost per procedure £1.341    
Average length of stay 1.51   
Cost per day of care (level 0) £431    
Total cost of hospital stay £651    
Average cost per procedure excluding cost of hospital stay £690    
Currency code Currency description Activity National average  Average length of stay  
   unit cost elective non-elective 
MA17D Dilation and evacuation, 14 to 20 weeks 
gestation 
763 £2,011.19 1.60 3 
Average cost per procedure £2,011    
Average length of stay 2.25   
Cost per day of care (level 0) £431    
Total cost of hospital stay £969    
Average cost per procedure excluding cost of hospital stay £1,042    
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Table 32 Colon procedure cost 
 
Table 33  Small bowel procedure cost 
 
Donor blood transfusion 1 
The cost of donor blood transfusion received postnatally is based on the same costs as those 2 
used for transfusion received intraoperatively in this model. For simplicity, the cost of 3 
transfusion of RBC is used. The mean number of units transfused to each patient in each 4 
group of the trial was obtained and rounded up to represent the fact that any remaining blood 5 
in a unit would be disposed of. The following approach was taken to calculate the mean cost 6 
per patient in each arm of the model (Table 34): CostTransfusion = (CostFirstUnit + 7 
CostSubsequentUnits) * ProbabilityTransfusion_PostOp. 8 
Currency code Currency description Activity National average  Average length of stay  
   unit cost elective non-elective 
FZ75C Proximal colon procedures, 19 years and over, 
with CC score 6+ 
809 £8,952.50 11.26 16 
FZ75D Proximal colon procedures, 19 years and over, 
with CC score 3-5 
2,139 £6,751.80 7.18 11 
FZ75E Proximal colon procedures, 19 years and over, 
with CC score 0-2 
6,430 £5,795.71 5.28 8 
Weighted average cost per procedure £6,286    
Average length of stay 10   
Cost per day of care (level 0) £431    
Total cost of hospital stay £5198    
Average cost per procedure excluding cost of hospital stay £1,088    
Currency code Currency description Activity National average  Average length of stay  
   unit cost elective non-elective 
FZ67C Major small intestine procedures, 19 years and 
over, with CC score 7+ 
860 £9,719.99 15.84 21 
FZ67D Major small intestine procedures, 19 years and 
over, with CC score 4-6 
1,476 £7,127.58 8.86 14 
FZ67E Major small intestine procedures, 19 years and 
over, with CC score 2-3 
2,751 £5,164.47 5.83 10 
FZ67F Major small intestine procedures, 19 years and 
over, with CC score 0-1 
4,662 £3,561.35 4.66 7 
Weighted average cost per procedure £5,097    
Average length of stay 11   
Cost per day of care (level 0) £431    
Total cost of hospital stay £4,703    
Average cost per procedure excluding cost of hospital stay £399    
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Table 34  Blood transfusion resource use and costs 
  
Outcomes 1 
The outcome of interest in the trial was the use of donor blood transfusion in response to 2 
haemorrhage and its consequences. 3 
Assumptions 4 
It was necessary to make the following pragmatic assumptions before the analysis could be 5 
carried out: 6 
(i) Trial Centres 7 
All of the centres involved in the trial were assumed to have the same expertise and to have 8 
followed similar protocols in the management of patients. 9 
(ii) Equipment and disposables required for the cell salvage procedure 10 
It was assumed that all centres performing cell salvage used consumables and that one 11 
collection set and one processing pack were used per cell salvage procedure. Costs for 12 
equipment and disposables were obtained for a Haemonetics Cell Saver 5 machine. Variance 13 
in costs was explored in sensitivity analysis. Where swab washing occurred, it was assumed 14 
that the swabs were washed in one litre of saline.72  15 
(iii) Use of cell salvage machine 16 
Item Source / working Cell salvage 
(n=1498) 
Control 
(n=1492) 
Resource use (mean units 
transfused) 
Trial data 3 3 
Unit cost 1st unit NHSBT 201675,  NICE costing statement for 
blood transfusion11 
£190 £190 
Unit cost subsequent units NHSBT 201675,  NICE costing statement for 
blood transfusion11 
£165 £165 
    
Total cost Resource use x unit cost £520 £520 
n patients requiring transfusion Trial data 38 49 
Probability of transfusion n patients requiring transfusion / n in trial 
group 
0.025 0.033 
Cost per patient Total cost per patient * probability £13 £17 
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Where the cell salvage machine was switched on it was assumed that running costs would be 1 
incurred and a collection set would be used even if no salvaged blood was returned to the 2 
patient. It was also assumed that heparin and saline would be used prior to collection.11  3 
(iv) Additional staff called into theatre solely for the purposes of cell salvage 4 
We based our analysis on the staff type most frequently called into theatre in the trial and 5 
assumed the lowest possible cost within this job band distinction. Staff cost variance was 6 
explored through sensitivity analysis. 7 
(v) Salvaged Blood 8 
The threshold setting on a cell salvage machine to process can be set to engage for salvaged 9 
blood above a certain volume and in this study trial centres displayed variance in the 10 
minimum volume threshold they selected. Trial guidance given to participating centres stated 11 
that all processed blood produced by the machines should be returned to the patient. This 12 
analysis assumed that all minimum threshold settings were disengaged. The cost of collection 13 
of all shed blood was considered, regardless of whether that blood was subsequently returned 14 
to the patient. 15 
(vi) Donor Blood 16 
All units transfused were assumed to be RBC.11 The mean number of units transfused per 17 
patient was rounded up to account for the fact that any remaining blood in a bag would be 18 
disposed of. 19 
(vii) Length and type of inpatient stay 20 
Where patients received level 0 care when admitted to HLC it was assumed that their needs 21 
could be met through general ward care. It was assumed that level 1 care was 25% more 22 
expensive per day than level 0 care and level 2 care was 25% more expensive than  level 1 23 
care. 24 
(viii) Additional surgeries 25 
Additional surgeries were included in this analysis with the cost of inpatient bed days 26 
excluded to avoid double counting. Inpatient bed days were assumed to be the equivalent of 27 
level 0 care. 28 
(ix) Adverse events 29 
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It was assumed that non serious adverse events deemed relevant to the procedure would have 1 
limited or zero resource impact. It was assumed that in the case of an acute transfusion 2 
reaction, the transfusion would be discontinued.10  3 
(x) Infant health 4 
In this study the health of the infant was not considered relevant to the intervention. 5 
Information relating to the clinical status and care of the infant was therefore not included in 6 
the analysis.  7 
Analysis 8 
Given the objectives of the trial and the duration of follow-up, a within trial economic 9 
analysis was carried out. The analysis took the perspective of the NHS following current 10 
recommendations from NICE.79 The main economic analysis was a cost-effectiveness 11 
analysis with results expressed as cost per donor transfusion avoided. 12 
We carried out three main analyses on the trial data. In Analysis 1 the base-case was based on 13 
the intention-to-treat (ITT) principle. In this method, patients are compared within the 14 
treatment groups to which they were originally randomised irrespective of the treatment 15 
received.80 This method of analysis allows the estimates to follow real-life scenarios in which 16 
patients may not always receive the planned treatment. Not using ITT analysis can often 17 
exaggerate the benefits of a given intervention.80  18 
Analysis 2 was based on the treatment received by patients irrespective of randomisation (the 19 
‘per protocol’ (PP) analysis). Within the SALVO trial, equal numbers of patients were 20 
randomised to either cell salvage or control. However, because some clinicians managing 21 
women in the control group had access to a cell salvage machine, it was possible that women 22 
in the control group could receive cell salvage in place of a donor blood transfusion. A PP 23 
analysis was carried out to look at the effect of treatment received on the outcome estimates. 24 
Therefore, in analysis 2 all patients who received cell salvage were compared with those who 25 
received standard care, irrespective of the treatment to which they were randomised.  26 
Analysis 3 considered only patients who underwent an emergency caesarean section.  This 27 
analysis was considered necessary as the SALVO trial found that numerically, there was a 28 
greater reduction in rate of transfusion within the emergency patient group compared to the 29 
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elective patient group. This analysis followed the same methodology as analyses 1 and 2. 1 
Probabilities were obtained from the trial and attached to each pathway in the existing model. 2 
For the analysis, intra- and post-operative resource use data were obtained from the SALVO 3 
trial. Intraoperative costs were estimated for each item to arrive at a mean cost per caesarean 4 
section procedure for each treatment pathway in the model. Postoperative costs were 5 
estimated for each item based on their occurrence in each branch of the model to arrive at a 6 
mean cost per patient for each branch (See Tables 35 to 37 below). 7 
Table 35 Probabilities used in the emergency caesarean section model 
 Trial data Probability Distribution 
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Cell salvage intended    
Cell salvage intended → allocated treatment received (machine was on) 794 / 833 0.953 Beta 
Allocated treatment received → salvaged blood returned 390/794 0.491 Beta 
Allocated treatment received → salvaged blood not returned 401/794 0.509 Beta 
    
Salvaged blood returned → donor blood transfusion given 5/390 0.013 Beta 
Salvaged blood returned → donor blood transfusion not given 385/390 0.987 Beta 
    
Salvaged blood not returned → donor blood transfusion given 2/401 0.005 Beta 
Salvaged blood not returned → donor blood transfusion not given 399/401 0.995 Beta 
    
Cell salvage intended → allocated treatment not received (machine was off) 39/833 0.047 Beta 
Allocated treatment not received → donor blood transfusion given 1/39 0.026 Beta 
Allocated treatment not received → donor blood transfusion not given 38/39 0.974 Beta 
 
Standard care intended 
   
Standard care intended → allocated treatment received (machine was off) 780/808 0.965 Beta 
Allocated treatment received → donor blood transfusion given 9/780 0.012 Beta 
Allocated treatment received → donor blood transfusion not given 771/780 0.988 Beta 
    
Standard care intended → allocated treatment not received (machine was on) 28/808 0.035 Beta 
Allocated treatment not received → salvaged blood returned 14/28 0.5 Beta 
Allocated treatment not received → salvaged blood not returned 14/28 0.5 Beta 
    
Salvaged blood returned → donor blood transfusion given 1/14 0.071 Beta 
Salvaged blood returned → donor blood transfusion not given 13/14 0.929 Beta 
    
Salvaged blood not returned → donor blood transfusion given 0/14 0 Beta 
Salvaged blood not returned → donor blood transfusion not given 14/14 1 Beta 
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Table 36 Emergency caesarean section intraoperative resource use and costs per procedure 
Item Resource Use Unit Cost Mean cost per procedure Assumption / Working Source 
 Cell salvage 
(n=833) 
Control 
(n=808) 
 Cell salvage 
(n-=833) 
Control 
(n=808) 
  
Running 
costs 
  £6.14 £6.14 £6.14 Based on annual maintenance costs for Haemonetics Cell 
Saver 5 machine and estimated annual usage 
UHB, personal communication (Aug 2016) 
NICE costing statement blood transfusion (Nov2015) 
Collection 
Set 
1 1 £41.71 £41.71 £41.71 Based on the assumption that one collection set is used 
per procedure 
NHS Supply Chain Catalogue (accessed Aug 2016): 
Autotransfusion reservoir 3 litre 
Processing 
Pack 
1 1 £77.00 £77.00 £77.00 Based on the assumption that one processing pack is 
used per procedure 
NHS Supply Chain Catalogue (accessed August 2016): 
Intraoperative autologous blood system cell saver 5+ 
bowl set 125ml 
Filter n/a n/a n/a n/a n/a No usage of leukocyte depletion filter recorded in the 
trial 
n/a 
Additional 
sucker 
321 14 £15.41 £6.23 £7.70 Mean cost based on the number of additional suckers 
used in each treatment arm / total number of patients 
who received cell salvage 
NHS Supply Chain Catalogue (accessed August 2016): 
Aspiration & anticoagulation line Cell Saver. 
£308.02 for 20 
Swab 
washing 
444 11 £0.80 £0.45 £0.31 Mean cost based on the number of times swabs were 
washed in each treatment arm / total number of patients 
who received cell salvage 
ICS Factsheet 1 Swab Washing March 2015,based on 
the cost of 1L of sodium chloride 0.9%, BNF 
Staff 82.21 (min) 30 (min) £0.72 
(min) 
£11.70 £1.54 Based on the staff type most frequently called into 
theatre.  
Unit cost for hospital based nurse, band 5, PSSRU 
unit costs 2015 (costs include qualifications) 
Saline 
(litres) 
2 2 £0.80 £1.60 £1.60 Based on the assumption that 2 litres of saline would be 
administered to all patients undergoing cell salvage prior 
to collection 
Based on the cost of 1L of sodium chloride 0.9%, BNF 
Heparin 
sodium 
(30,000 IU) 
2 2 £10.60 £21.20 £21.20 Based on the assumption that 60,000 iu heparin would 
be administered to all patients undergoing cell salvage 
prior to collection 
Based on the cost of 1ml amp of heparin sodium 
25,000 iu/ml and 1ml amp of heparin sodium 5,000 
iu/ml, BNF 
Anti-D  
(500 IU) 
1 1 £33.75 £3.04 £3.04 Based on the assumption that all D negative women 
delivering a D positive baby receive at least 500 IU of 
anti-D. Mean cost per procedure based on the 
probability of a woman requiring anti-D in each 
treatment arm (0.09) 
Based on the cost of 500-unit vial of anti-D 
immunoglobulin, BNF 
Anti-D 
(1500 IU) 
1 1 £58.00 £5.22 £5.22 Based on the assumption that women who receive cell 
salvage are offered 1500 IU of anti-D. Mean cost per 
procedure based on the probability of a woman requiring 
anti-D in each treatment arm (0.09) 
Based on the cost of 1,500-unit vial of anti-D 
immunoglobulin, BNF 
 
RBC 
transfusion  
(units) 
2 3 First unit: 
£190 
Subsequent 
£355 £520 Based on the assumption that all units transfused in each 
treatment arm were RBC 
NICE costing statement for blood transfusion 
(November 2015). Unit cost for RBC obtained from 
NHSBT 2016/17 
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units: £165 
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Table 37 Emergency caesarean postoperative resource use and costs per patient 
1 
Item Resource Use Unit Cost Mean cost per patient Assumption / Working Source 
 Cell salvage 
(n=833) 
Control 
(n=808) 
 Cell salvage 
(n-=833) 
Control 
(n=808) 
  
Inpatient stay (normal days) 2,212 2,246 £431 £1,147 £1,205 
 
See Table 23 & 25 NHS reference costs 2014/15 
Inpatient stay (HLC) 135 99.5 See Table 24 £100 £78 
 
See Table 24 & 25 NHS reference costs 2015/15 
National tariff payment system 
2016/17 
Adverse events n/a n/a n/a n/a n/a 
 
No adverse events recorded in the trial  
Hospital transfer 1 2 £99 £0.12 £0.25 
 
n/a PSSRU 2015 
Investigations 2 6 See Table 27 £0.23 £0.75 
 
n/a NHS reference costs 2014/15 
Additional surgery 8 3 See Error! 
Reference 
source not 
found. 
£11 £3 
 
See Table 34 NHS reference costs 2014/15 
RBC transfusion (units) 3 3 First unit: £190 
Subsequent units: 
£165 
£13 £19 Based on the assumption that all units 
transfused in each treatment arm were 
RBC 
NICE costing statement for blood 
transfusion (November 2015). Unit cost 
for RBC obtained from NHSBT 2016/17 
Total cost of postnatal care per patient £1,271 £1,306   
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Sensitivity analysis 1 
Deterministic and probabilistic sensitivity analyses (PSAs) were carried out for each analysis 2 
to explore the effects of the inherent uncertainty in parameter estimates on model results. 3 
Deterministic sensitivity analysis involves varying one or more parameters while keeping the 4 
others at their baseline value. Although deterministic sensitivity analyses can be helpful to 5 
identify which model inputs are important in driving a decision or to identify threshold 6 
values, comprehensive representation can be obtained by undertaking a PSA, in which the 7 
uncertainty around a parameter is represented with a probability distribution. Monte Carlo 8 
simulation was used to sample from these distributions to allow the effect of parameter 9 
uncertainty to be evaluated. This involved 1000 repeated random draws from the distributions 10 
to indicate how variation in the model parameters would affect the results and hence illustrate 11 
the decision uncertainty. Beta distributions were used for probability data and Gamma 12 
distributions for costs.81, 82  13 
The results of the analyses are presented in terms of incremental cost-effectiveness ratios 14 
(ICERs), which reflect the additional cost per donor blood transfusion avoided of cell salvage 15 
compared with standard care. The results of the cost-effectiveness analysis are presented 16 
using scatterplots and cost-effectiveness acceptability curves (CEACs) to reflect sampling 17 
variation and uncertainties in the appropriate threshold cost-effectiveness value. 18 
Deterministic sensitivity analyses 19 
A number of deterministic sensitivity analyses were conducted in each analysis: 20 
(i) Equipment and disposables required for the cell salvage procedure  21 
The main analyses used costs for consumables based on a particular model of cell saver 22 
machine. To assess the difference that variation in these estimates would make, the unit costs 23 
were replaced with unit costs obtained from the NICE costing statement for blood 24 
transfusion.11 We then explored the impact of the inclusion of acquisition costs for a cell 25 
salvage machine and the impact of using a continuous-transfusion cell salvage machine that 26 
requires a suction set and reservoir (prices sourced from participating unit) where the 27 
machine is only set up for processing in patients having blood returned and where swab 28 
washing was not conducted.. 29 
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(ii) Staff 1 
The main analyses used the mean length of time additional staff were present in theatre in 2 
each group solely for the purposes of cell salvage. We explored the impact of not calling an 3 
additional member of staff into theatre. 4 
(iii) Donor blood 5 
To facilitate robust evaluation in cost-effectiveness analyses relating to donor blood, a 6 
comprehensive estimate for the cost of a unit of donor blood is required. The NHS Blood and 7 
Transplant Authority have valued the cost of RBC to be £120 per unit based on direct costs to 8 
the healthcare services.75 However, there is significant uncertainty surrounding this figure. 9 
We conducted a study (submitted for publication) parallel to the SALVO trial that aimed to 10 
dissect the current price of blood. We explored what elements are contributing to the current 11 
cost of blood and what elements are missing. Our study concluded that the current costing 12 
approach of assuming there will always be an adequate supply of donor blood must be 13 
replaced with including provisions for the continued shrinking of the donor pool and the 14 
impact that future shocks to the blood supply system could have. The sensitivity analysis 15 
assessed the difference that variation in the estimated cost of blood made to the overall cost-16 
effectiveness of cell salvage.  17 
Results 18 
Analysis 1:  Intention-to-treat 19 
The results of the analysis are shown in Table 38. The strategy in which standard care was 20 
intended was the least costly, with the average cost per patient estimated at £1,244. However 21 
the cell salvage intended group was only slightly more expensive with the average cost per 22 
patient estimated at £1,327. The cell salvage intended strategy was the most effective at 23 
avoiding a transfusion. The estimated ICER for the cell salvage intended strategy compared 24 
with standard care was £8,110 per donor blood transfusion avoided. This means that it would 25 
cost an additional £8,110 to avoid a donor blood transfusion through cell salvage compared to 26 
standard care.  27 
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The scatterplot (Figure 4) shows the modelled uncertainty in the cost and effectiveness of the 1 
cell salvage intended strategy compared with the standard care intended strategy from 1,000 2 
Monte Carlo simulations. In this, the ICER of each simulation is plotted on the cost-3 
effectiveness plane providing information about the joint density of the differences in cost 4 
and effectiveness between the two strategies. From Figure 4, it is evident that although cell 5 
salvage is a more effective transfusion strategy, it is uncertain whether it is less or more 6 
costly than standard care. The CEAC (Figure 5) shows that the probability that cell salvage is 7 
cost-effective increases as the willingness to pay for a donor blood transfusion avoided 8 
increases. Given that there is not a pre-specified threshold of willingness to pay for a blood 9 
transfusion avoided, as in the case of quality adjusted life years where £20,000 to £30,000 are 10 
the recommended cut-off points by NICE, the identification of the probability of cell salvage 11 
being cost-effective is less straightforward. However, the CEAC shows that if the maximum 12 
willingness to pay for a donor blood transfusion avoided was, for example, £50,000, the 13 
probability of cell salvage being cost-effective would be 62%. 14 
Table 38  Results for the base-case analysis 
Transfusion Strategy Average cost per patient  
(£) 
Effectiveness 
Donor Blood Transfusion Avoided 
ICER  
(£) 
Standard care intended 1,244 0.965  
Cell salvage intended 1,327 0.975 8,110 
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Figure 4 Incremental cost-effectiveness scatterplot for donor blood transfusion avoided (ITT)       
 
 
Figure 5 Cost-effectiveness acceptability curve for donor blood transfusion avoided (ITT) 
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Analysis 2:  Per-protocol 1 
The results of the analysis are shown in Table 39.  In terms of cost, standard care is again the 2 
least costly strategy with mean cost per patient estimated at £1,238. The cell salvage strategy 3 
was the most effective at avoiding a transfusion. The estimated ICER for the cell salvage 4 
strategy compared with standard care was £8,252 per donor blood transfusion avoided.  5 
The scatterplot (Figure 6) shows that although cell salvage is a more effective transfusion 6 
strategy, it is again uncertain whether it is less or more costly than standard care. This 7 
uncertainty has been graphed in the CEAC (Figure 7). The graph shows that if the maximum 8 
willingness to pay for a donor blood transfusion avoided was £50,000, the probability that 9 
cell salvage was cost-effective would be 63%. 10 
 
Table 39  Results for the per-protocol analysis 
Transfusion strategy Average cost per patient (£) Effectiveness 
Donor Blood Transfusion Avoided 
ICER  
(£) 
Standard care 1,238 0.967  
Cell salvage 1,330 0.978 8,252 
 
Figure 6 Incremental cost-effectiveness scatterplot for donor blood transfusion avoided (per protocol) 
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Figure 7 Cost-effectiveness acceptability curve for donor blood transfusion avoided (per protocol) 
 
Analysis 3:  Emergency caesarean 1 
The results of the analysis are shown in Table 40. The strategy in which standard care was 2 
followed remains the least costly, though higher in comparison to the previous two analyses, 3 
with the average cost per patient estimated at £1,352. The cell salvage group had an average 4 
cost per patient estimated at £1,407, also slightly higher than the previous analyses. The cell 5 
salvage strategy continues to be the most effective at avoiding a transfusion. The estimated 6 
ICER for the cell salvage strategy compared with standard care was £13,713 per donor blood 7 
transfusion avoided.  8 
The scatterplot (Figure 8) shows again that although cell salvage is a more effective 9 
transfusion strategy, it remains uncertain whether it is less or more costly than standard care. 10 
The CEAC (Figure 9) shows that the probability that cell salvage is cost-effective remains 11 
between 47% and 55% as the willingness to pay for a donor blood transfusion avoided 12 
increases. 13 
Table 40  Results for the emergency caesarean analysis 
Transfusion strategy Average cost per patient (£) Effectiveness 
Donor Blood Transfusion Avoided 
ICER 
(£) 
Standard care 1,352 0.986  
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Cell salvage 1,407 0.990 13,713 
 
 
Figure 8 Incremental cost-effectiveness scatterplot for donor blood transfusion avoided (emergency only) 
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Figure 9 Cost-effectiveness acceptability curve for donor blood transfusion avoided (emergency only) 
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Table 41, the results of the deterministic sensitivity analysis were as follows:  1 
(i) Varying the cost of consumables to those used by NICE had a marginal impact on 2 
the ICER in each analysis. Similarly, including acquisition costs in the analysis 3 
had only a minimal impact on the ICER. In the trial 202 centres used a 4 
continuous-transfusion cell saver machine which required different consumables 5 
to the ones included in the main analyses. The impact of including costs for the 6 
consumables used by this machine, where the machine is only set up for 7 
processing in patients having blood returned and where swab washing is not 8 
conducted resulted in an ICER of £1,022 in analysis 1, £1,184 in analysis 2 and a 9 
dominant ICER in analysis 3 i.e. cell salvage was considered less costly and more 10 
effective compared to standard care. 11 
(ii) In this sensitivity analysis the cost of additional staff called into theatre solely for 12 
the purposes of cell salvage was removed. This reduced the ICER to £7,065 in the 13 
ITT analysis, £7,210 in the PP analysis, and £10,932 in the emergency caesareans 14 
analysis. 15 
(iii) Raising the cost of a three unit transfusion of RBC to £1,500 reduced the ICER by 16 
£974 in both analysis 1 and 2 and it reduced the ICER by over £1,000 in analysis 17 
3. Threshold analysis showed that for cell salvage to be considered cost-effective, 18 
the cost of a transfusion would have to be £8,637 in analysis 1, £8,778 in analysis 19 
2, and £13,186 in analysis 3.  20 
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Table 41  Deterministic sensitivity analysis 
Discussion 1 
Principal findings 2 
The results of this economic evaluation suggest that routine cell salvage is more costly than 3 
standard care with the average cost per patient estimated at £1,327 compared to £1,244. The 4 
ICER of this strategy compared with standard care is approximately £8,110 to avoid a donor 5 
blood transfusion. The PSA suggests that at a willingness to pay threshold of £50,000, the 6 
probability of routine cell salvage being cost-effective is 62%. The results of this analysis 7 
were shown to be robust for the majority of deterministic sensitivity analyses with one 8 
 Original value Revised value Original result 
 Cost per donor blood transfusion avoided 
 Analysis 1 Analysis 2 Analysis 3 
 £8,110 £8,252 £13,713 
 Revised result 
(i) Equipment and disposables required for the cell salvage procedure 
Applying the cost of 
consumables (collection set 
+ processing pack) used by 
NICE 
£118.71 £119.75 £8,205 £8,346 £13,952 
 
Including acquisition costs 
based on Haemonetics Cell 
Saver machine 
 
- 
 
£22.13 
 
£10,114 
 
£10,246 
 
 
£18,805 
 
Using a continuous-
transfusion cell saver where 
the machine is only set up 
for processing in patients 
having blood returned and 
swab washing is not 
conducted 
 
Cell 
salvage 
Control  
£34.73 
 
£1,022 
 
£1,184 
 
Dominates 
£125.14 £126.40 
(ii) Staff  
No additional member of 
staff being called into 
theatre solely for the 
purposes of cell salvage 
 
Cell 
salvage 
Control £0 £7,065 £7,210 £10,932 
£11.57 £12.03 
(iii) Donor blood 
Variation in the estimate of 
the cost of a 3 unit RBC 
transfusion 
£520 £750 £7,886 £8,028 £13,330 
 £1,000 £7,636 £7,778 £13,080 
 £1,250 £7,386 £7,528 £12,830 
 £1,500 £7,136 £7,278 £12,580 
 
For cell salvage to be considered cost-effective in this model the price of 
a 3 unit RBC transfusion would have to be: 
 
 
£8,637 
 
£8,778 
 
£13,186 
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exception; using a cell salvage machine that required different consumables to those included 1 
in the main analyses where the machine is only set up for processing in patients having blood 2 
returned and where swab washing is not conducted resulted in a significant effect on the 3 
ICER, reducing it to £1,022 per donor blood transfusion avoided.  4 
A per protocol analysis produced an ICER of £8,252 per transfusion avoided, but this result 5 
should be considered with caution as the population in this analysis is a subset of the ITT 6 
population who completed the study without any major protocol violations.80 In clinical 7 
practice uptake of cell salvage is unlikely to be “per-protocol”. In a third analysis, looking at 8 
emergency caesareans only, cell salvage appears to be more effective than standard care for 9 
avoiding a donor blood transfusion but the resulting ICER of £13,713 is driven by the 10 
increased probability that these patients will require a higher level of postoperative care. 11 
Strengths and limitations of the economic evaluation 12 
The strength of this model based economic evaluation is that it was based on a rigorously 13 
conducted RCT. The cost and outcome data measures that were incorporated into the model 14 
were collected prospectively during the RCT using forms filled out at the pre-, intra-, and 15 
postoperative phase and at the time of discharge from hospital. In addition the economic 16 
evaluation benefitted from significant clinical and statistical input throughout its design and 17 
development. All assumptions used in the model were agreed with the trial team before the 18 
analysis was carried out and without knowledge of how these assumptions would affect the 19 
results. 20 
In terms of limitations, not all potential outcomes have been included, because of the limited 21 
time scale in our model and the lack of long-term data, for example we could not account for 22 
long-term implications relating to fetomaternal haemorrhage as data relating to this was not 23 
available from the trial. In addition, information relating to the clinical status and care of the 24 
infant was not included in the analysis.  A further limitation of the evaluation is that 25 
outcomes were expressed in terms of clinical effectiveness rather than in terms of a standard 26 
unit of benefit, the quality-adjusted life-year (QALY). Finally, the use of platelets and other 27 
blood products has not been included in the evaluation. However, the results of the sensitivity 28 
and threshold analyses demonstrated that including these costs would not have impacted on 29 
the cost-effectiveness results. 30 
Strengths and weaknesses in relation to other studies 31 
Page 108 of 132 
To date, there has only been one, small, RCT looking at the elective use of cell salvage at 1 
caesarean section43 and this study did not include an economic element. A Cochrane review 2 
of cell salvage in adult elective surgery assessed the clinical and cost-effectiveness of cell 3 
salvage and other autologous transfusion strategies in elective surgery.21 It suggested that cell 4 
salvage may be an ‘effective and cost-effective alternative to the allogeneic blood transfusion 5 
strategy’. However, no obstetric papers were identified for this review.  6 
Meaning of the economic evaluation 7 
The results of the economic evaluation suggest that while cell salvage is a marginally more 8 
effective strategy than standard care in avoiding a donor blood transfusion, it is unlikely that 9 
cell salvage would be considered cost-effective. However, the results in natural units of cost 10 
per transfusion avoided are difficult to interpret and are very subjective. They will vary 11 
depending on the context. The lack of long term data on the health and quality of life of 12 
patients in both groups of the trial means that further research is needed to fully understand 13 
the cost implications of both strategies. For patients undergoing an emergency caesarean 14 
section, where cell salvage is performed using a continuous-transfusion cell saver machine, 15 
the machine is only set up for processing in patients having blood returned and where swab 16 
washing is not conducted, cell salvage would be considered less costly and more effective 17 
compared to standard care. However, this scenario is not necessarily generalisable; therefore 18 
this result should be interpreted with caution. 19 
Unanswered questions and future research 20 
The current evaluation has used data from a large, multicentre randomised trial which 21 
demonstrated modest evidence that routine use of cell salvage during caesarean section 22 
reduced the need for donor blood transfusion. The main cause of uncertainty regards the cost 23 
implications of adopting cell salvage in routine practice. Future studies should explore the 24 
long-term health and economic impacts associated with both transfusion strategies. Also, 25 
evidence on the preferences of women needs to be considered. For example hospitals may 26 
wish to have the option of cell salvage available for Jehovah’s Witness patients where there is 27 
no option to use donor blood.  28 
Finally, and related, the issue of donor blood as a limited resource needs to be considered. It 29 
is important to remember that transfusion with cell salvage can always exist. We have not 30 
considered this in our evaluation. While there is an expectation that donor blood will always 31 
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be there when needed, transfusion using donor blood cannot be guaranteed. In such a 1 
scenario, where the option of donor blood is limited or not available, the routine use of cell 2 
salvage would dominate (less costly and more effective) compared to standard care. 3 
The routine use of cell salvage during caesarean section reduces, to some extent, the need for 4 
donor blood. Whether this treatment strategy is also cost-effective will on one hand depend 5 
on the cost of a donor blood transfusion and on the other hand the operating cost of the cell 6 
salvage procedure. Implementation and more efficient operation of cell salvage machines in 7 
routine care could reduce the associated costs; at the current price level of donor blood and 8 
operating costs of cell salvage, cell salvage appears to be a more costly strategy to reduce the 9 
use of donor blood; and only when the price of a blood transfusion increases to levels beyond 10 
£8,637, cell salvage might become a cost-effective strategy.  11 
Page 110 of 132 
Chapter 5 Discussion 1 
Aim and overview 2 
The provision of a reliable donor blood transfusion service has critical implications for 3 
maternal health; in healthcare systems where this is available, maternal mortality due to 4 
haemorrhage is almost a thousand fold less than in those where it is not.83, 84 Donor blood 5 
transfusion is a safe intervention with remarkably few associated adverse effects, although 6 
these may be serious and even rarely fatal. In the face of such a proven clinical intervention, 7 
any new technique seeking to further reduce mortality would have to be extremely effective, 8 
and require an unfeasibly large trial in order to demonstrate it. Despite these limitations to 9 
evaluation of a new technology, for many clinicians, this would be intuitively considered the 10 
aim of introducing cell salvage into obstetric clinical practice. More realistically, cell salvage 11 
might reduce reliance on donor blood, the production and delivery of which remains 12 
relatively expensive (£120 per unit75) and while representing a “pooled” national resource, 13 
may suffer from local hospital shortages when consumption is increased by a case of 14 
unexpected severe haemorrhage. However, cell salvage is a technology with its own costs 15 
and therefore, it was clear from the outset of the SALVO trial that the health economic 16 
evaluation would be a crucial aspect of the SALVO trial, in order to show a worthwhile 17 
reduction in spend on donor blood units which was greater than the cost of the intervention. 18 
With an increasing reluctance to transfuse donor blood to even quite substantially anaemic 19 
women, due to the possible adverse effects, cell salvage offered the possibility of safely 20 
increasing postoperative haemoglobin levels, leading to additional savings in patient care and 21 
hospital stay. These again, required rigorous health economic evaluation to provide 22 
meaningful conclusions, particularly as other clinical interventions85 for optimising pre-23 
operative haemoglobin levels (e.g. iron therapy) or reducing intraoperative blood loss (e.g. 24 
tranexamic acid or interventional radiology) may be cheaper and more efficacious. 25 
A number of endpoints were considered as candidates for a primary outcome. The selection 26 
of transfusion rate was ultimately a pragmatic one, based on objectiveness, ease of collection 27 
and the existence of pre-existing data. Additionally, a patient questionnaire given to women 28 
who had undergone the procedure highlighted the reassuring nature of receiving one’s own 29 
blood instead of donor blood (see original SALVO protocol). 30 
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Main findings 1 
This large, multicentre randomised trial demonstrated modest evidence that routine, 2 
prophylactic use of cell salvage during caesarean section reduced the need for donor blood 3 
transfusion. It was associated with increased maternal exposure to fetal blood among Rh-4 
negative mothers. Small differences were observed between groups for time to mobilisation 5 
and length of hospital stay but not in other secondary outcomes. Although numerically there 6 
appeared to be a greater effect in the emergency group, compared with the elective group, the 7 
difference in effect between subgroups was not statistically significant. Exploratory analysis 8 
did not suggest a subgroup benefit in women with abnormal placentation. Although it 9 
appeared to increase the volume of salvaged blood returned, the use of “swab washing” when 10 
conducting cell salvage did not appear to effect the need for donor blood transfusion. 11 
Health economic analysis demonstrated that it would cost £8,110 to avoid a blood transfusion 12 
with the use of cell salvage as used in the study. This cost could potentially be reduced by 13 
varying both the indication for cell salvage in caesarean section, and by changing the 14 
technique used. Set-up for a continuous cell saver machine, with “collection” only, until 15 
sufficient volume was obtained for processing could save the cost of the processing 16 
consumables. Swab washing could be relinquished as a technique, since it did not appear to 17 
have any effect on donor blood transfusion rate.   18 
Strengths and limitations of the trial 19 
To our knowledge, SALVO is the largest multicentre evaluation of cell salvage in caesarean 20 
section to date.  The randomised trial was prospectively registered, robustly conducted, 21 
independently monitored, rigorously analysed, and transparently reported (see Figure 2). This 22 
should provide for confidence in validity and reliability of the findings. The study sample 23 
was diverse, spread across more than 20 UK centres. Only two indications for caesarean 24 
section were considered exclusions; first elective caesarean section for either breech or 25 
maternal request. The very low probability that these cases might require donor blood meant 26 
that excluding them left only women with a recognisable increased risk of haemorrhage and 27 
thus potential need for transfusion, increasing the power of the study to detect a difference. 28 
This broad base for inclusion adds to the generalisability of the findings. 29 
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The trial recruited to target, had comparability at baseline and compliance with assignment, 1 
minimal loss on follow-up and primary outcome. A substantial challenge to the conduct of an 2 
individually randomised trial is obtaining consent from women in labour who require 3 
emergency caesarean.86, 87 Therefore, meeting the target for recruitment in a challenging 4 
clinical context was a major achievement. We considered this group to be the one most likely 5 
to derive specific benefit from this health technology. Another challenge was the promotion 6 
of equipoise among participating clinicians, who were keen to adopt the technology, without 7 
robust evidence in cases where anxiety for life threatening haemorrhage was high, 8 
particularly for cases of abnormal placentation.  9 
Due to the nature of the intervention and the fact that mothers are usually awake for 10 
caesarean section, it was considered impractical to formally blind either clinicians or patients 11 
to the group allocation. In view of this and the local variation in transfusion practices, the trial 12 
collected transfusion policies from each unit, and then reviewed transfusion decisions in light 13 
of these. Although clinicians were found to commonly give donor blood in deviation to local 14 
policy, no difference was found in the rate with which this non-adherence to local policy 15 
occurred between intervention and control groups. 16 
A criticism of sample size and power with presumption of likelihood of type II error could 17 
risk erroneous conclusions. We highlight that a p-value that is in the region of a 0.05, 18 
regardless of the side of the threshold in which it lies, deserves careful consideration with 19 
respect to use of the evidence for guiding practice. The failure to achieve statistical 20 
significance cannot be attributed to insufficient data when the study is completed to the 21 
planned size with independent monitoring. We would like to propose the following 22 
considerations in interpretation of our main finding: (a) addition of new data does not 23 
guarantee that the p-value threshold for significance will be reached;88 and (b) the point 24 
estimate is the most plausible estimate of the true effect. This being the case we believe that 25 
our main finding meets the criteria for accurate decision making.   26 
From the outset we were aware that we were investigating the effect of an intervention in a 27 
heterogeneous population in terms of baseline risk.  This heterogeneity is principally derived 28 
from the indication for caesarean section. This situation guided the use of covariate-adjusted 29 
and subgroup analyses as an integral part of trial planning, analysis and inference. The 30 
credibility of findings in subgroup analysis depends on a number of factors. We planned 31 
these a priori and limited the number of subgroup analyses to the bare minimum in order to 32 
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limit the risk of spurious significance associated with multiple hypothesis testing. Caution 1 
must be exercised in the conduct and interpretation of evidence derived from subgroup 2 
analysis, however not investigating or ignoring results of subgroup analyses could also lead 3 
to incorrect inferences. Although interaction proved statistically insignificant, suggesting no 4 
evidence for an inconsistent effect of cell salvage between elective and emergency cases, 5 
taking into account the observed point estimates and confidence intervals from subgroup 6 
analyses for the primary outcome measure, we believe that our findings concerning the effect 7 
in emergency caesareans merits consideration. 8 
The role of our sensitivity analysis was to evaluate the integrity of the primary analysis 9 
conducted based on the intention-to-treat principle. The design and analysis was predicated 10 
on adherence to assignment, whether control or cell salvage. We sought for consistency 11 
between the results of primary analysis and the results of sensitivity analysis to examine the 12 
credibility of the main finding. We planned a priori to assess if the erroneous return of cell 13 
salvaged blood in the control group could potentially avert the use of donor transfusion. In 14 
the throes of a developing surgical emergency, it may be thought a useful intervention to deal 15 
with ongoing haemorrhage by clinicians handling cases in the control group. We could not 16 
prevent such a clinical intervention in an ethically consistent trial policy. We therefore 17 
proposed to reclassify such cases as having experienced the primary outcome. Study 18 
structures and team members strove to promote adherence to assignment but protocol 19 
deviations are common in pragmatic trials and several cases assigned to the control group did 20 
indeed received salvage, even in the absence of such an acute emergency situation. One 21 
proposal to handle this problem could include alternative trial designs, such as cluster 22 
randomisation, but this approach does not necessarily guarantee avoidance of performance 23 
bias and generally reduces statistical power. Our approach to sensitivity analysis maintained 24 
the intention-to-treat principle, avoiding per protocol and as treated analyses that have a 25 
tendency to produce spurious significance. Our sensitivity analyses confirmed the main 26 
finding for the primary outcome. 27 
SALVO studied both emergency and elective (planned) caesarean sections, despite the fact 28 
that due to a higher incidence of haemorrhage in the former, a significant result might be 29 
more likely to be detected if the trial had excluded electives. There were two reasons for this. 30 
First, some centres were known to have already commenced using cell salvage routinely for 31 
elective cases in the absence of any evidence, so the question of evaluating effectiveness in 32 
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this group remained pertinent. Second, emergencies represented a population much more 1 
challenging to recruit. The elective sample gave centres the opportunity to deploy and prove 2 
the trial processes in a much more straightforward population. Despite this, two groups of 3 
electives were known to have extremely low rates of haemorrhage and were therefore 4 
excluded (first caesareans for either breech or maternal request). The effect of cell salvage in 5 
the emergency group, whilst non-significant with regards to interaction with the elective 6 
group, will be interesting to clinicians. On the other hand, the finding of no effect in the 7 
placental abnormalities subgroup is less relevant for policy as guidance already exists for use 8 
of salvage in these high risk cases.39   9 
At the time SALVO was conceived and designed, cell salvage techniques used in obstetrics 10 
was markedly heterogeneous and dependent on local attitudes and expertise. It was clear from 11 
the outset that a robust trial would require close to optimal use of the intervention in order for 12 
the results to be accepted by the clinical community. Optimal use in this context, maximises 13 
the volume of salvaged blood returned to the mother. Therefore a number of technical aspects 14 
of the machine use were made mandatory for trial patients to achieve this aim. Some other 15 
aspects which might increase blood return, were left to local preference, as it was felt that it 16 
would be difficult to commission enough recruiting centres to complete the study if these 17 
technical elements of cell salvage management were made mandatory. Subgroup analysis of 18 
swab washing failed to show any effect on the primary outcome. We conclude that there are 19 
no other identifiable mechanisms, utilising current cell salvage technology, which might 20 
significantly increase the return of salvaged blood to the patient compared to trial practices 21 
capable of casting any doubt on the validity of our results.  22 
External validity and generalisability 23 
We consider the external validity of the SALVO trial to be very robust; it was conducted in a 24 
broad group of obstetric units, including large, tertiary teaching hospitals to small district 25 
general hospitals. It recruited form a diverse range of indications for caesarean section, with 26 
few exclusion criteria. The nature of the intervention was maintained as pragmatic as 27 
possible, consistent with efficacy and adequate recruitment, yet delivered in a predictable 28 
manner which is easy to emulate outside the context of a trial. The adherence to protocol was 29 
higher than expected for an intervention which had already begun to enter routine practice 30 
with a consequent potential loss of equipoise when the trial commenced. 31 
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Red cell immunisation 1 
The UK Serious Hazards of Transfusion (SHOT) haemovigilance scheme has repeatedly 2 
highlighted suboptimal practice in relation to the management of anti-D prophylaxis in cases 3 
of caesarean section with Rhesus incompatibility. They have stressed the need for improved 4 
awareness of national guidelines, supported by education and training amongst all healthcare 5 
professional involved (www.shotuk.org). We had the novel opportunity to observe practice 6 
around anti-D prophylaxis in particular in relation to cell salvage.  7 
Whilst total omissions of anti-D prophylaxis after delivery occurred only a small number of 8 
cases in either group (total n=3), there are many other opportunities for improved adherence 9 
to national guidelines, in particular regarding the recommended minimum anti-D dose of 10 
1500IU following cell salvage33 and the need for fetomaternal haemorrhage (FMH) testing to 11 
assess if further anti-D is needed beyond the standard dose. This highlights a need for close 12 
communication between clinicians and laboratory teams, to ensure relevant testing 13 
undertaken followed by subsequent appropriate management to minimise the risk of RhD 14 
sensitisation. 15 
Whilst secondary analysis indicated a significantly higher risk of FMH ≥2mls based on 16 
Kleihauer testing in the cell salvage group, the clinical implications of this result are unclear. 17 
We have incomplete data on flow cytometry results to confirm FMH volumes.  Further 18 
analysis where results were available indicate that the majority of women with bleeds >4mls 19 
did receive appropriate doses of anti-D with further follow-up testing to check for fetal red 20 
cell clearance as per guidelines, though there were some omissions. We are unable to 21 
comment on the overall efficacy of anti-D prophylaxis and the subsequent risk of RhD 22 
sensitisation. The SHOT scheme is currently collecting data on all pregnant women who have 23 
produced immune anti-D detected for the first time, to better understand the reasons 24 
underlying RhD sensitisation.  25 
Although we are unable to comment on the risk of alloimmunisation to other red cell 26 
antibodies following cell salvage as opposed to standard care, our data support the assertion 27 
that the use of cell salvage significantly increases the risk of fetomaternal haemorrhage. 28 
When just the women receiving cell salvaged blood are considered, the rate of FMH based on 29 
the definition used in the study, is more than 4 times that of the control group. The 30 
implications of this may go beyond the increased cost of a larger anti-D dose required in 31 
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women receiving cell salvaged blood. Although we did not specifically study other red cell 1 
antigens, it is plausible and likely that this increased fetomaternal haemorrhage would cause 2 
increased rates of introduction into the maternal circulation as well. As no anti-D equivalent 3 
is available for these antigens, maternal antibody formation will not be avoided, and these 4 
antibodies (e.g. anti-Kell) may make cross matching blood for these women significantly 5 
more difficult in the future, incurring additional healthcare costs. As the rate and severity of 6 
these potential complications is completely unknown, we were unable incorporate it into our 7 
health economic analysis. 8 
Adverse and Serious Adverse Events 9 
Adverse and serious adverse events were spread evenly across the two groups. An increase in 10 
the rate of amniotic fluid embolism (AFE) has long been considered a potential adverse effect 11 
of returning cell salvaged blood at caesarean section, even though research indicates it is 12 
removed by the cell saver. It is reassuring that we did not observe any cases of AFE in either 13 
group, but particularly not in the sub-group who actually received salvaged blood back, 14 
whether or not a leukocyte depletion filter was used. It is notable that all the adverse events 15 
definitely or probably related to cell salvage occurred when a leukocyte depletion filter was 16 
in use, consisting of acute haemodynamic and respiratory reactions to the return of salvaged 17 
blood. These reactions have been well reported in the literature, and are thought to be due to 18 
an effect the filter induces on the salvaged blood, rather than due to the blood per se. We did 19 
not observe any definitely or probably cell salvage related adverse events when a filter was 20 
not used. Of 15 possibly related adverse events, a filter had been used in 13. These included a 21 
range of adverse events, including infective and haemorrhagic complications which could 22 
easily have been unrelated to the use of cell salvage; ultimately, it was for the local principal 23 
investigator to make this judgement on relatedness. There was one case of reaction to donor 24 
blood in the control group, from which the mother made a full recovery. This is in keeping 25 
with the known rates of reaction.17 One maternal death occurred in a trial participant, who 26 
had been allocated to the cell salvage intervention group. A local case review was carried out 27 
by the Trust involved, and did not find any link to the use of cell salvage. 28 
Adverse events from donor blood transfusion are potentially serious, but are also very rare, 29 
with an incidence of 1 in 16,000.17 Mortality associated with donor blood transfusion is even 30 
more uncommon, with an incidence of 1 in 100,000.17 We have demonstrated that the cost to 31 
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avoid a transfusion event when routinely using cell salvage in caesarean section is £8,110. 1 
When considered with the observed increase in fetomaternal haemorrhage (see below) and 2 
potential long term effects of this, which currently remain uncharacterised, it remains unclear 3 
whether cell salvage is beneficial in this patient group. The exception to this is in cases such 4 
as for Jehovah’s Witnesses, where donor blood cannot be used, and cell salvage represents 5 
the only therapeutic option. We are also unable to comment on the specific benefit in the 6 
group at high risk of torrential haemorrhage such as placenta accreta, since we had 7 
insufficient recruits in this group to come to any meaningful conclusions. 8 
Conclusions 9 
Implications for healthcare service  10 
• Cell salvage may reduce the need for donor blood transfusion. It is unlikely to be 11 
considered cost-effective when routinely set up for use in caesarean section. The cost-12 
effectiveness varies by indication for caesarean section and cost of cell saver 13 
technique used. 14 
• In RhD-negative mothers having RhD-positive babies, there appears to be an 15 
increased chance of fetomaternal haemorrhage when cell salvaged blood is returned to 16 
the mother, which needs to be taken into consideration with regards to applying and 17 
updating guidance on the use of anti-D prophylaxis. Our findings highlight the need 18 
for increased vigilance and appropriate prevention of the risk of RhD-19 
isoimmunisation among RhD-negative mothers. 20 
• If cell salvage continues to be used in groups such as Jehovah’s Witnesses and 21 
placenta accreta, women should be counselled about the balance of risks in using cell 22 
salvage. 23 
Recommendations for further research 24 
• The effect of increased fetomaternal haemorrhage associated with cell salvage on the 25 
incidence of rarer, non-RhD red cell antigens needs to be characterised and quantified 26 
in the long term. 27 
• Investigation is needed to determine if greater amounts of routine anti-D 28 
administration are required where cell salvage has been used on RhD-negative 29 
mothers.  30 
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• Additional factors, e.g. swab washing or number of suckers used, which may increase 1 
the likelihood of blood return during use of cell salvage, should be investigated. 2 
• The effectiveness of cell salvage in specific sub-groups, such as placenta accreta, 3 
remains to be investigated.  4 
• The role of cell salvage in low-middle income countries where caesarean rates are 5 
rising and blood transfusion services are not well developed should be investigated. 6 
• If new, cheaper or more efficient cell salvage technology becomes available, the 7 
conclusions of SALVO may need to be revisited. The same is true if donor blood 8 
shortages should become extreme and acute. 9 
• Recent and ongoing research into the use of tranexamic acid and other strategies to 10 
prevent or manage maternal anaemia to make caesarean safer will merit consideration 11 
in practice and future research alongside our findings.85  12 
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Appendices 1 
Appendix 1 List of participating sites and SALVO research staff 2 
• Barts Health Trust, London: 3 
o Royal London Hospital 4 
o Whipps Cross University Hospital 5 
Matthew Hogg (principal investigator), Sajith Philip, Sarah Weist, Felipe 6 
Castro Cardona, Heike Bojahr, Lilith Loncke, Prudence Jones. 7 
• Royal United Hospitals Bath NHS Foundation Trust: 8 
o Royal United Hospital, Bath 9 
Chris Marsh (principal investigator), Sara Burnard, Wendy Duberry, Elly 10 
Doyle, Karen Patrick, Catherine Bressington, Jenny Pullen, Mel Rich, Jess 11 
Withers, Amy Lloyd. 12 
• Heart of England NHS Foundation Trust: 13 
o Birmingham Heartlands Hospital 14 
Nicky Osborn (principal investigator), Ahmed Mesbah, Katie Trowman, Linda 15 
Bradley, Katie Atterbury, Teresa Melody. 16 
• Birmingham Women's NHS Foundation Trust: 17 
o Birmingham Women's Hospital 18 
James Geoghegan (principal investigator), Philip Moore, Chloe O’Hara, 19 
Elizabeth Ewer. 20 
• University Hospitals Bristol NHS Foundation Trust 21 
o St Michael's Hospital, Bristol  22 
Isobel Gardner (principal investigator), Carole Shahin, Alison Kirby, 23 
Mariethel Gudaca, Eirini Troupkou,  Colleen Hunt, Claire Dowse, Nicola 24 
Harvey, Nicolas Wharton, Mark Scrutton 25 
• Chelsea and Westminster Hospital NHS Foundation Trust: 26 
o West Middlesex University Hospital, Isleworth 27 
Dominika Dabrowska (principal investigator), Marie O’Connell, Bernadette 28 
Tilley, Catherine Sheehan, Philip Barclay, Christine Adamson, Mehari Teklay, 29 
Sherif Omran, Sujatha Vishvanath, Amanpreet Sarna, Sheldon Zhang, Rafiu 30 
Ojo, Lisa Takab, Tina Brough, Emma Fox, Sarah Barker, Ano Rathambegoda, 31 
Edward Twumasi, Jacob Sheen, Belinda White, Wilky Ian Nunal, Emmanuel 32 
Espiritu.  33 
• Croydon Health Services NHS Trust: 34 
o Croydon University Hospital 35 
Bini Ajay (principal investigator), Dhileepan Srinivasan, Temilola Doherty, 36 
Valerie Fuller, Tony Hewitt, Ramandeep Sharma, Ajeet Kumar, Rebecca 37 
Byrne, Vana Wardley. 38 
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• NHS Lothian: 1 
o Simpson Centre for Reproductive Health, Edinburgh 2 
Vicki Clark, Arlene Wise (principal investigators), Ida Hassing, Karen Edgar. 3 
• Hinchingbrooke Health Care NHS Trust: 4 
o Hinchingbrooke Hospital 5 
Sangeeta Pathak (principal investigator), Tara Pauley, Charlotte Clayton, Aarti 6 
Bahirat. 7 
• Leicester University Hospitals NHS Trust 8 
o Leicester Royal Infirmary 9 
o Leicester General Hospital 10 
Tommy Mousa (principal investigator), Molly Patterson, Sharon Bates, Jo 11 
Dickens, Katie Peck, Anna Muggleton, Claire Dodd, Asma Rabab, Tina 12 
Evans, Tracey Bryan, Magda Kierzenkowska, Margaret Weston, Sarah Clarke, 13 
Katie Warwick, C Elton, P Sharpe, A Morris, P Ramasamy, E Hart, R 14 
Leighton, O Navti, O Joseph. 15 
• South Tees Hospitals NHS Foundation Trust: 16 
o James Cook University Hospital, Middlesbrough 17 
Sanjay Rao (principal investigator), Aethele Khunda and the research team, 18 
Hazel Alexander, Sarah Croft, Obstetric Consultants and Anaesthetists, 19 
Speciality Trainees, Labour Ward Midwifery team, Theatre team. 20 
• The Newcastle upon Tyne Hospitals NHS Foundation Trust: 21 
o Royal Victoria Infirmary, Newcastle 22 
Paul Ayuk (principal investigator), Sophia Webster, Jill Sturt, Celia McKee, 23 
Angela Yulia, Andrea Fenn, Michelle Perkins, MaCassie Galeon, Jill Riches, 24 
Cat Rowney, Erica Del Prete, Sue Harbertson, Terri Brosnan, Sharon Chilton, 25 
Victoria Murtha, Jenna Wall, Emma Schultz, Alison Bates, Nicola King. 26 
• Norfolk and Norwich University Hospitals NHS Foundation Trust: 27 
o Norfolk and Norwich University Hospital 28 
Maria del Rocio Ochoa-Ferraro (principal investigator), Elizabeth Turner, 29 
Jonathon Francis, David Thornton, Carole Winstanley, Jeremy Corfe, Rachel 30 
Appleton. 31 
• London North West Healthcare NHS Trust: 32 
o Northwick Park Hospital 33 
Parijat Bhattacharjee (principal investigator). 34 
• Nottingham University Hospitals NHS Trust: 35 
o Queens Medical Centre, Nottingham 36 
o Nottingham City Hospital 37 
Lesley Woods (principal investigator), Jim Thornton, George Bugg, Sujata 38 
Handa, Arani Pillai, Yvette Davis, Yvonne Toomassi, Yvette Gunn, Denise 39 
Lochrie, Carys Smith. 40 
 
 
 
Page 130 of 132 
• Plymouth Hospitals NHS Trust: 1 
o Derriford Hospital, Plymouth 2 
Darryl Thorp-Jones (principal investigator), Heidi Hollands, Jocelyn Watson, 3 
Alison Stolton, Amanda Carney.  4 
• Barking, Havering and Redbridge University Hospitals NHS Trust: 5 
o Queen's Hospital, Romford 6 
Vinod Patil (principal investigator), Annemarie McGregor, Rebecca Murray, 7 
Dorothy Sutton, Theresa McCluskey, Julie Wright, Molly Murwira, Sue 8 
Rogers, Mark Beaufond. 9 
• Sheffield Teaching Hospitals NHS Foundation Trust: 10 
o Royal Hallamshire Hospital, Sheffield 11 
Ian Wrench (principal investigator), Siobhan Gillespie, Carolyn Clark, Emma 12 
Steel, Sarah Senbeto, Paula Woodcock, Tessa Bonnett, Nicola Cawley, 13 
Hannah Yeeles. 14 
• University Hospitals of North Midlands NHS Trust: 15 
o Royal Stoke University Hospital, Stoke-on-Trent 16 
Jules Allt (principal investigator), Charlotte Howell, Siby Sebastian, A 17 
Rajashanker, Angela Rooney, Sara Mountford, Suzanne Jerreat, Amanda 18 
Redford, Anna Fleming, Donna Brayford, Wendy Dudley, Sarah Elson, 19 
Rachel Sparkes, Andrea Vickers, Chris Hollins, N Butler, S Scally, Theresa 20 
Webbon, Susan Bell, Andrea Morgan, Brett Beasley, MJ Newton. 21 
• City Hospitals Sunderland NHS Foundation Trust: 22 
o Sunderland Royal Hospital 23 
Aarti Ullal (principal investigator), Kim Hinshaw, Helen Cameron, Kirsten 24 
Herdman, Eileen Walton, Gill Campbell, Lesley Hewitt, Deborah Bonney, 25 
Kathleen Hubbard, Karen Armstrong, Judith Ormonde, Joanne Knight, 26 
Kathryn Witte,Dawn Edmundson, Sonia Thompson, Denise Mace, Sharon 27 
Morrell, Suzanne Stelling, Marion Collings, Julie Harris, Amanda Bargh, 28 
Judith Holland, Chris Field, Catherine Parkinson. 29 
• Abertawe Bro Morgannwg University Health Board: 30 
o Singleton Hospital, Swansea 31 
Susan Williams (principal investigator), Sue Catling, Sharon Jones, Trudy 32 
Smith, Helen Worrell, Sarah Fox. 33 
• Torbay and South Devon NHS Foundation Trust: 34 
o Torbay Hospital 35 
David Portch (principal investigator), Richard Hughes, Shakila Sudhaker, 36 
Jeremy Ackers, Pauline Fitzell, Janet Palmer. 37 
• St Helens and Knowsley Teaching Hospitals NHS Trust: 38 
Whiston Hospital, Prescot 39 
Peter Yoxall (principal investigator), Zoe Grindley.  40 
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Appendix 2 Recruitment graphs 
Figure 10 Overall recruitment graph 
 
Figure 11 Recruitment graph by caesarean section type 
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